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Virus-like particles (VLP) present a promising platform for antigen delivery in anticancer 
vaccines. Conjugation of rabbit hemorrhagic disease virus (RHDV) VLP and simple 
mannoside components have been shown to increase the immune response generated by 
targeting cross presentation via receptor mediated endocytosis. It has been postulated that 
conjugation to cellular receptors’ ideal ligands will lead to a further increase in immune 
response. A series of oligosaccharides based on the mannose receptor’s ideal biological  
ligands with linkers terminating in an activated ester have been synthesized for 
conjugation to RHDV VLP and further immunological investigations. The synthesis of 
2,6-branched trimannoside 3 was attempted following two routes: a tricyclic orthoester 
intermediate pathway and an ethylidene intermediate pathway (Scheme A). Ultimately, 
the ethylidene synthetic approach proved successful and allowed for 3 to be synthesized 
in a 27% yield over 17 steps. 
 
Scheme A: Synthetic approaches to achieve trimannoside 3. 
Two pathways were also attempted in the synthesis of 3,6-branched trimannoside 5 
(Scheme B). The orthogonally protected pathway using silyl and PMB ethers was 
unsuccessful. 3,6-trimannoside 5 was accessed through di-benzoate 145, which was 
formed using an orthoester protection strategy. Trimannoside 5 was synthesized in a 22% 





Scheme B: Synthetic approaches to give trimannoside 5. 
To investigate the effect of the linker used, the synthesis of 3,6-branched trimannoside 6 
was attempted through the orthogonal protection pathway mentioned above. Compound 
103 was able to be isolated in an 8% yield over 17 steps, although the final palladium 
catalyzed hydrogenolysis reaction required for accessing of trimannoside 6 failed 
(Scheme C).  
 
Scheme C: attempted synthesis of 3,6-trimannoside 6. 
Lastly, the synthesis of Lewis X derivative 11 was attempted to allow for the specific 
targeting of DC-SIGN over the mannose receptor (Scheme D). Disaccharide 188 was 




was not synthesized, however the synthetic pathway followed for compound 188 could 
be applied to achieve 11 in the future. 
 
Scheme D: Synthesis of 188. 
Spectroscopic data of all succinimidyl esters showed that hydrolysis was occurring after 
isolation of the deprotected oligosaccharide over time. Because of this, oligosaccharides 
with activated ester substituents should be stored in their protected forms, and only be 
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The Ward research group at the University of Otago have had considerable success using 
virus-like particles (VLP) to deliver tumour associated antigens to the immune system as 
an anticancer vaccine platform. The Ward group began to collaborate with the Larsen 
group to explore chemical conjugation methods to add additional immunostimulatory 
components to the VLP. The research presented here is a part of the chemistry component 
of this collaboration, aimed to develop synthetic pathways towards a series of 
carbohydrates thought to be optimal ligands for specific cellular receptors that can be 
chemically conjugated to VLP.  
1.1 History of vaccines 
Smallpox, caused by the variola virus (Figure 1.1), is thought to have emerged in humans 
between 3,000 and 4,000 years ago, likely originating in Africa.1 This disease circulated 
through the global population for centuries and caused repeated, large-scale epidemics 
that killed millions and often left survivors severely scarred. Notably, smallpox was 
responsible for the devastation of indigenous populations in the Americas and Australia 
during colonialism. In the 18th century in Europe alone, smallpox caused the deaths of 
more than 400,000 people each year.2   
 
Figure 1.1: electronmicrograph image of smallpox (variola) virus from the 
Centers for Disease Control (CDC), 1975.3 
2 
The first form of vaccination against smallpox, known as variolation, is thought to have 
been developed in China around the 10th century AD.2, 4 Variolation was built on the 
concept that exposure to small amounts of a poison can build a defense to its toxic effects.4 
Dried smallpox scabs were ground into a fine power and introduced to the patient in hope 
of inducing a controlled infection that would not kill or maim the subject.2 Transmission 
of other bloodborne diseases, such as syphilis, could occur during this process.2 
Variolation made its way to Europe in the early 1700s and, while highly successful, was 
considered a controversial practice. A number of smallpox epidemics among the 
unvariolated were traced back to variolated patients during this time.2 
In 1796, after observing that milkmaids infected with cowpox developed an immunity to 
smallpox, Edward Jenner performed the first vaccination by inoculating a young boy with 
cowpox lesions taken from a local milkmaid.2, 4 Vaccination gradually replaced 
variolation and by the mid-1800s it had become the commonplace method for preventing 
smallpox infection.2, 4 Using the foundation laid by Jenner, Louis Pasteur further 
developed vaccines in the 19th century by using killed agents to protect patients against 
anthrax and rabies.4  Maurice Hilleman later developed successful vaccines against 
measles, mumps, hepatitis A, hepatitis B, chickenpox, meningitis, pneumonia, and 
haemophilus influenza.5 A vaccine for polio was introduced in 1955 by Jonas Salk.4 
Table 1.1, adapted from Plotkin,4 outlines the development of human vaccines. Due to 
the development of vaccines, more than a dozen notorious infectious diseases have been 
controlled globally (smallpox, poliomyelitis, rabies, diphtheria, pertussis, haemophilus 
type b, measles, mumps, rubella, etc.).4, 6 Considered one of the most remarkable 
achievements in the history of medicine, smallpox has been declared by the World Health 
Organization (WHO) as completely eradicated in the human population since 1980, with 




Table 1.1: Outline of the development of human vaccines adapted from Plotkin. 4 



















 Century, first half 
Tuberculosis (1927) 





Diphtheria toxoid (1923) 




 Century, second half 









Polio (injected) (1955) 
Rabies (cell culture) (1980) 
Japanese encephalitis (mouse brain) 
(1992) 
Tick-borne encephalitis (1981) 
Hepatitis A (1996) 
Cholera (WC-rBS) (1991) 
 





Haemophilus influenza type B 
polysaccharide (1985) 
H. influenza type b conjugate (1987) 
 
Hepatitis B surface antigen 
recombinant (1986) 
Lyme OspA (1998) 




Rotavirus reassortants (1999) 
Cholera (attenuated) (1994) 
Cold-adapted influenza (1999) 
Meningococcal conjugate (group C) 
(1999) 
Typhoid (Vi) polysaccharide (1994) 
Acellular pertussis (1996) 








Japanese encephalitis (Vero cell) 
(2009) 









Human papillomavirus recombinant 
(quadrivalent) (2006) 
Human papillomavirus recombinant 
(bivalent) (2009) 
Meningococcal group B proteins 
(2013) 
 




Although vaccines have proven successful against a number of infectious diseases, there 
are some, such as malaria, for which no effective vaccines have been licensed.8 Along 
with developing vaccines for these diseases, researchers around the world are also 
interested in using vaccinations to combat cancers and auto-immune disorders.9 Effective 
vaccines are capable of initiating a potent immune response while minimizing possible 
side effects, including development of the disease or hypersensitivity. Today, a majority 
of vaccines used to prevent harmful diseases can be classified as inactivated or live-
attenuated. Attenuated vaccines contain live cells that have either lost their virulent 
properties due to growth conditions or are produced from a closely related nonpathogenic 
organism.4, 10 Inactivated vaccines contain cells of the pathogenic organism that have been 
killed using heat, chemicals, or radiation.4, 11 Jenner’s smallpox vaccine and Pasteur’s 
rabies vaccine could be considered preliminary forms of attenuated and inactivated 
vaccinations, respectively.4 Due to the presence of whole cells, these vaccines provide a 
range of different immunogenic antigens and immunostimulatory factors that allow for 
the generation of long lasting protective immunity.10-11 Whole organism vaccines are not 
completely safe, as some of the components may be harmful and there is a chance of 
incomplete activation or reversion of attenuated vaccines to the active pathogen.11 This 
was seen in the oral polio vaccine where the live-attenuated organism reverted to its 
infectious state, leading to cerebral infection and paralysis of some of those who received 
the vaccine.12 These risks, along with concerns about the inclusion of potentially harmful 
additives, a debunked correlation to autism, and a general lack of understanding 
surrounding vaccines have led to the emergence of a very vocal group termed “anti-
vaxxers”.13 This movement has caused decreased vaccine administration rates that may 
ultimately impact the “herd immunity” that the past 250 years of vaccinations has 
created.13-14 2018 saw an increase in vaccine preventable diseases like measles, mumps, 
and whooping cough across the US and Europe, likely due in part to the prevalence of the 
anti-vaxx movement.13-14 
While effective attenuated vaccines, like RotaTeq® (rotavirus vaccine, Sanofi-Pasteur 
MSD, Lyon, France)15 are still being produced, subunit vaccines are of increasing interest 
and are able to address some of the issues associated with whole-organism vaccines. 
Subunit vaccines contain one or more defined antigenic components including whole 
proteins, peptides, polysaccharides, and nucleic acids.16-17 Because they are only 
composed of specific components, subunit vaccines lack the ability to revert to the active 
7 
pathogen and therefore cannot induce infection.18 Unfortunately, with the loss of a large 
number of cellular components, subunit vaccines tend to require the addition of 
immunostimulatory adjuvants to achieve a comparable level of efficiency.18 Also, some 
of these small subunits cannot aggregate to form stable structures and are instead 
degraded or rapidly cleared by the body upon delivery.16-17 This reduces the ability for a 
specific antigen to be taken in by immune cells and successfully processed. Particulate 
delivery systems, such as virus-like particles (VLP), can help negate these issues by 
enhancing the stability, persistence, and immunogenicity of the desired subunit.16-17, 19  
1.1.1 Vaccinations and cancer treatments 
Vaccines have been extremely successful against a number of diseases, and, when paired 
with the improvements in water and food quality, sanitation, nutrition, and antibiotics that 
have occurred in the past 200 years, have been responsible for the dramatic increase in 
human lifespan worldwide.20 This increase in lifespan has also come with an increase in 
cancer diagnoses. Cancer is one of the leading causes of death and is generally defined 
by rapid cell growth of abnormal cells resulting in a tumor.21 DNA in eukaryotic cells is 
constantly subject to a cycle of synthesis, damage, and repair. Most mistakes that arise 
are caught and corrected, but in tumor cells, the agents responsible for growth 
management are impaired, leading to the accumulation of DNA mutations and ultimately 
uncontrolled cell division.22 Cancer in humans is influenced by internal factors (genetics) 
and external factors (smoking, drinking, diet, chemical exposure, UV light, infectious 
disease, etc.).23-24 Eukaryotic cells have a number of proto-oncogenes that act as positive 
regulators of cells growth. If a mutation alters one of these genes it becomes classified as 
an oncogene and unregulated growth of the cell may occur.25-26 Mutations in tumor 
suppressor genes, negative regulators of cells growth, may also lead to unregulated cell 
division and tumor development.27-28 More than one mutation is typically required to 
cause cancer.27-28  
The immunoediting hypothesis describes the role of the immune system in cancer 
development in three main stages: elimination, equilibrium, and escape.29 The immune 
system is often able to identify and eliminate cancerous cells. An equilibrium balance 
may also develop where the immune system is able to prevent the tumor from growing 
but cannot remove the existing tumor cells. A resistant subpopulation could arise from 
the elimination and equilibrium stages, leading to the escape stage where tumor growth 
8 
becomes beyond the control of the immune system.29 Tumor cells create an 
immunosuppressive microenvironment which can greatly diminish the effectiveness of 
the immune system’s ability to remove cancerous cells.30 By enriching the surrounding 
area with suppressive cytokines, the tumor cells are able to impair dendritic cell (DC) 
function and reduce the ability to recruit regulatory T cells.30  
Current cancer treatments rely heavily on surgical removal as well as radiation and 
chemotherapies. Chemotherapy indiscriminately targets metabolic pathways in rapidly 
dividing cells while radiation therapy induces DNA damage to these cells.31-32 Cancer 
cells are not the only rapidly dividing cell in the human body and the resulting side effects 
of these treatments include hair loss, nausea, anemia, decreased blood clotting, and 
decreased immunity. Further, these treatments cannot be considered “cures” because they 
are not always 100% effective at removing tumor bulk and the patient may experience 
reversion to the disease after treatment is concluded.18 These side effects present the need 
to develop a more effective and less invasive method of treatment for cancer patients.  
Immunotherapies are being investigated to meet this need. These involve manipulating 
the immune system to allow for it to overcome the suppressive tumor microenvironment 
and induce the activation and proliferation of T cells. By doing so, it may be possible to 
eliminate all tumor cells throughout the body and prevent tumor reestablishment. While 
each cancer type is unique, certain antigens associated with cancers like breast and 
melanoma have been identified.33-34 A number of immunotherapies have been developed 
that target these tumor associated antigens (TAA).35 These include cytokine therapies, 
monoclonal antibody therapies, adoptive T cell transfer, and cancer vaccinations. Cancer 
vaccines are intended to induce an in vivo generation of immunity for a targeted TAA, 
although many of the trials for these vaccines have shown limited success.18 This has led 
researchers to consider the use of particulate carrier systems such as VLPs to deliver the 
TAA to antigen presenting cells (APC). 
1.2 Virus-like particles (VLP) 
Virus like particles were first identified in 1968 as a naturally occurring byproduct of 
hepatitis B infection.36 A VLP is a viral capsid mimic that lacks any genetic information 
in the form of RNA or DNA.37 These highly ordered structures are recognized and 
processed by a host organism in a similar fashion as the wild-type virus, but are known 
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to be safe for use due to their inability to replicate or establish infection within a  
host.9, 38-39 These traits make VLPs a good alternative to live-attenuated vaccines. 
Currently, VLP based vaccines are used globally for the prevention of Human 
Papillomavirus (HPV) and Hepatitis B.40-42  
1.2.1 VLP structure and production 
VLPs can vary in size (20-150 nm) and shape (icosahedral, spherical, or rod-like) 
depending on the presentation of the wild-type virus.18 VLPs can be composed of either 
a single capsid protein (HBV) or multiple capsid proteins (rabies, HIV) that can be 
arranged in various ways to form either a single layer or multi-layer viral shell.39 Multi-
protein VLPs can be designed to contain copies of the same proteins derived from 
different viral strains, which can induce immunity against multiple strains of the same 
virus. This is the VLP type used in Gardisil® (Merck) to evoke an immune response to 
multiple strains of HPV.42 Most VLPs can be formed spontaneously in a laboratory 
setting, as viral capsid proteins are known to aggregate when introduced to ideal 
conditions (27°C, 125 rpm). 9, 38 
Viral capsid proteins can be produced by a number of different expression systems, each 
with their own benefits and downsides including ease of expression, scalability, and cost. 
Some expression systems that can be utilized are outlined in Table 1.2.43-44 Post-
translational modifications, such as glycosylation or phosphorylation, can be made to 
viral capsid proteins and can affect the quaternary structure of the protein and in turn lead 
to an altered immune response to the VLP.18 
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Table 1.2: Advantages and disadvantages of various VLP expression systems. This table 
has been adapted from Donaldson et al.43, Rebeaud et al.44, and Al-Barwani.18 
 Advantages Limitations 
Bacteria 
(e.g. Escherichia coli) 
 Rapid cell growth 
 Highest yield 
 Low production cost 
 Scalable  
 No post-translational 
modifications 
 Limited applications for 
mammalian VLPs 
 May form inclusion 
bodies 





 Rapid cell growth 
 High yield 
 Low production cost 
 Scalable 









(e.g. Spodoptera frugiperda) 
 Average cell growth 





 Formation of multi-
protein VLP 
 Requires removal of 
baculovirus proteins 




(e.g. Nicotiana sp.) 
 Rapid production 





 Relatively new system 
Mammalian cells 






 Formulation of multi-
protein VLP 
 Slow growth 
 Low yield 
 Demanding culture 
conditions 
 High production costs 
 Potential infectious 
contamination 
Cell free  Near exclusive 
production of target 
protein 
 Limited cellular 
contaminants 





 Very high production 
cost  
 Limited scalability 





1.2.2 VLP functionalisation 
Depending on the expression system used, various antigens or peptide sequences can be 
recombinantly inserted into the viral structural proteins of the VLP. These can be 
designed to be on the exposed outer surface of the VLP or on the internal face. For 
effective antibody production, it is ideal for antigens to be on the external surface although 
their presence on just the internal surface is usually enough for the induction of cell-
mediated immunity.44 There are a number of advantages and disadvantages associated 
with recombinant insertion. For example, antigen presentation is limited to small peptide 
sequences as larger peptides may disrupt the quaternary structure of the viral proteins and 
in turn interfere with capsid formation; but it is highly advantageous in that every viral 
protein will contain a peptide, making antigen concentrations easily controlled and well 
defined.18 
Chemical insertion is often used to attach non-peptide or synthetic functionalities to the 
VLP. Access points for chemical conjugation can be found in the functional groups of 
amino acid side chains, typically those present on the exposed exterior surface of the VLP. 
Functional groups that are commonly targeted include primary amines (lysine), thiols 
(cysteine), carboxylic acids (glutamic acid, aspartic acid), and phenols (tyrosine) (Figure 
1.2).45 This is often the method of choice for adding immunostimulatory components to 
the VLP. The most common route of chemical conjugation is through cross-linkers 
directed towards either lysine or cysteine residues. Succinimidyl esters and 
isothiocyanates can be used as amine reactive groups to allow for conjugation through 
the primary amine of lysine and maleimide can be used to link to the thiol side chain of 
cysteine. A number of biologically interesting compounds (carbohydrates, fluorophores, 
adjuvants, etc.) with amine or thiol reactive groups are commercially available. Cross-
linkers can be designed to be cleavable as well, allowing for release of the substituent 




Figure 1.2: Chemical conjugation to VLPs. Adapted from Smith et al.45 and 
Al-Barwani.18 Rabbit hemorrhagic disease virus (RHDV) VLP 3D model 




1.2.3 VLP use in licensed vaccinations 
The first VLP-based vaccine made available to the New Zealand public was the Hepatitis 
B vaccine Engerix-B®, released by GlaxoSmithKline in 1988.47 This vaccine uses 
hepatitis B surface antigen (HBsAg) and is produced from genetically engineered yeast 
(S. cerevisiae). After its release, a significant drop in chronic hepatitis B rates was 
observed.48 Engerix-B® paved the way for a number of other VLP-based subunit vaccines 
to be developed and released globally including Epaxal®, Inflexal V, Gardasil®, and 
CervarixTM. Epaxal® (Crucell), used to vaccinate against hepatitis A, uses antigenic 
hepatitis A VLP as an adjuvant to replace aluminium salts.41 This highly immunogenic 
vaccine results in fewer local reactions in patients than its aluminium-adsorbed 
counterpart.41 The influenza VLP vaccine, Inflexal® V (Crucell), is a well-tolerated 
trivalent vaccine that has proven to be highly immunogenic in all age groups.49-50 Perhaps 
the most well-known VLP-vaccines are those that have been used to vaccinate against 
HPV: Gardasil® (Merck) and CervarixTM (GlaxoSmithKline). These two vaccine types 
protect against multiple strains of high-risk HPV, the primary cause of cervical cancer. 
First generation Gardasil® protected against four strains of HPV, while the newer 
generation, Gardasil 9®, affords protection against 9 strains.42, 51-52 CervarixTM, on the 
other hand, is a bivalent vaccine, giving the patient protection against HPV 16 and 18 
associated cancers.51, 53 The successful global use of these vaccines further supports 
investigations into the development of additional VLP-based vaccines. 
1.3 Immune Response to VLP 
The immune system is made up of two branches: the innate immune system and the 
adaptive immune system. The innate immune system primarily prevents pathogens from 
accessing the host organism while the adaptive immune system is far more complex and 
is responsible for reacting when and if these pathogenic invasions occur. There are two 
main pathways for antigen presentation to the immune system: the endogenous pathway 
and the exogenous pathway, illustrated in Figure 1.3.54 As the names suggest, the 
endogenous pathway is generally reserved for antigens produced within somatic cells and 
the exogenous pathway is followed by foreign antigens. The pathway followed dictates 
the immune response to the antigen, with Major Histocompatibility Complex (MHC) I 
stimulating cytotoxic CD8+ T cells while MHC II stimulates CD4+ helper T cells.55 
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Figure 1.3: Pathway a) MHC I molecules present peptides that are primarily 
of endogenous origin. Pathway b) MHC II molecules present peptides of 
exogenous origin. Pathway c) Cross presentation pathways allow peptides to 
be presented by both MHC I and MHC II.54 Used with permission from 
Springer Nature.  
1.3.1 Endogenous Pathway and Major Histocompatibility Complex class I 
The endogenous pathway is the better understood of the two pathways and is used by 
somatic cells to continuously display a sampling of their expressed genes to the immune 
system for review. MHC I complexes are present on the surface of all nucleated  
cells.55-56 Most antigens displayed on MHC class I are fragments of cellular proteins that 
can be ignored, although if the cell is synthesizing foreign proteins (viral infections), 
immune effector cells are stimulated and a response begins. In the endogenous pathway 
the effector cells stimulated are CD8+ cytotoxic T lymphocytes (CTL). 
The major process for degrading the proteins present in the cytosol is ATP-dependent and 
highly conserved throughout the eukaryotic domain. Here, proteins are hydrolysed to give 
oligopeptides by the proteasome. In mammalian cells the cylindrical proteasome is made 
up of outer rings (7 distinct α subunits) for structural support and inner rings (7 distinct β 
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subunits) thought to be the catalytic sites. The resulting peptides are between 5-8 amino 
acids long, likely due to the distance between the proteasome’s active sites. The size range 
is optimal for binding to the MHC class I molecules. Degradation of cellular proteins is 
initiated by the enzyme catalyzed binding of ubiquitin to the lysines through an isopeptide 
bond. The resulting polyubiquitin chain marks the protein for rapid degradation by the 
proteasome. It has been concluded that protein degradation is a rate-limiting step in the 
endogenous presentation pathway. Short chain peptides are rapidly degraded in the 
cytosol; to combat this, oligopeptides commonly associate with chaperone proteins (like 
heat shock proteins) once they exit the proteasome. These chaperone proteins are able to 
protect and guide the oligopeptide to the transporter associated with antigen presentation 
(TAP), for transport from the cytosol into the lumen of the endoplasmic reticulum (ER). 
TAP proteins have 6 transmembrane domains and function as either homodimers or 
heterodimers. TAP mediated transport is ATP-dependent and ATP binding sites have 
been identified near the C-terminus of the TAP subunits, along with Mg2+ binding sites. 
The binding of the peptide to TAP occurs independently of ATP, although transport 
through the membrane is ATP-dependent. Because TAP is responsible for supplying most 
peptides for MHC I presentation, it is thought to have a very large range of specificity. 
TAP is size specific and will only bind to peptides 7 or more amino acids long, with a 
noticeable efficiency decrease with peptides longer than 12 amino acids. Once within the 
ER, it is possible for the oligopeptide to either bind to MHC class I molecules as is or for 
the oligopeptide to be processed further before binding.55-56 
Mature MHC I complexes are composed for three main components; a 45 kDa heavy 
chain, a 12 kDa light chain (β-microglobulin), and the short peptide antigen.55-56 The order 
of assembly is debatable, although the heavy chain and light chain associate first followed 
by the peptide is thought to be the major pathway in most cells. Once all three components 
are assembled to form the mature MHC I complex, MHC I molecules exit the ER and 
transit through the golgi apparatus. Final modifications are made and the complex is 
rapidly shuttled from the golgi to the plasma membrane. Nearly all the MHC I complexes 
displayed on the cell surface contain bound antigens, as the complex becomes highly 
unstable once the antigen dissociates. It is possible for assembly of the complex to occur 
at the cell surface, although it is not common. T lymphocytes and macrophages are able 
to internalize the displayed MHC I complex, while B lymphoblasts are not.55-56  
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1.3.2 Exogenous Pathway and Major Histocompatibility Complex class II 
The exogenous pathway is the lesser understood of the two processes. This pathway can 
be accessed by uptake of antigens from the surrounding environment via receptor 
mediated endocytosis, phagocytosis, and macropinocytosis.9, 57 Antigen presenting cells 
(APC) including macrophages, monocytes, dendritic cells, and B cells are all able to 
express MHC II complexes.9, 57 While uncommon, MHC II complexes can be expressed 
on the surface of other cells in response to stress or injury.55, 57-58 MHC II fragments do 
not induce T-cell mediated cytotoxicity, but instead stimulate the production of cytokines 
that are able to modulate an immune response.55, 57-58 
A simplified outline of the exogenous pathway starts with the assembly of MHC class II 
molecules in the ER.55, 57-58 These are assembled out of an α and a β chain to give a peptide 
binding groove. An invariant chain (Ii) binds to the groove resulting in a trimer. This 
trimer is then associated with three additional class II α-β heterodimers to give yet another 
trimer. The invariant chain is thought to prevent loading of endogenous peptides waiting 
in the ER for MHC I binding, contains signaling regions to allow for the trimer to be 
sorted into endocytic compartments, and helps the complex exit the ER. The trimer is 
then released from the ER into the cytosol and shuffled to various endocytic 
compartments. Most MHC II molecules require HLA-DM, a MHC II-like molecule, to 
allow for binding of an exogenous derived antigen. HLA-DM is usually restricted to 
lysosomal structures and this is where antigen binding is thought to take place. In the 
lysosomal compartment, proteases like cathepsin S degrade Ii until only 8-25 amino acids 
remain, called CLIP (class II associated invariant chain peptide). HLA-DM is then 
responsible for holding the binding cavity of the MHC II molecule open until a peptide 
with high binding affinity attaches to the site. Lysosomal compartments are usually 
considered “dead ends” in terms of intracellular transport, however it is thought that the 
specialized lysosomal compartments which contain MHC II complexes are able to 





1.3.3 Cross presentation and VLP 
Cross presentation is the term often used to refer to instances when internalized antigens 
are displayed on MHC I molecules. Endogenous antigen display by MHC II can also be 
considered a form of cross presentation and occurs when endogenous antigens are 
degraded through autophagy. Display by MHC I is necessary to generate a sufficient 
immune response against viruses, tumours, and after vaccinations.9 This cross-over 
between the endogenous and exogenous pathway is crucial to induce an adaptive immune 
response against antigens that do not directly infect immune cells. While many cells are 
able to present extracellular antigens on MHC I, dendritic cells are thought to be the most 
prominent and relevant of the cross-presenting cells. Because of the broad definition of 
cross-presentation, the mechanisms by which an antigen undergoes cross presentation are 
varied. With that, various VLP access cross presentation pathways in a number of 
different ways depending on the immune response to the wild-type virus they are derived 
from.43 
A study released by Win et al.59 outlines the cross presentation pathway followed by the 
Rabbit Hemorrhagic Disease Virus (RHDV) VLP. The RHDV VLP is predominantly 
taken up by dendritic cells in both murine and human model systems by clathrin-
dependent pinocytosis and phagocytosis. Win was unable to find evidence of uptake by 
receptor-mediated endocytosis although other VLP (i.e. hepatitis C virus VLP and HPV 
VLP) have been shown to access APC via carbohydrate recognition domains present on 
mannose receptors and dendritic cell-specific intracellular adhesion molecules (ICAM)-
3 grabbing non-integrin (DC-SIGN).60-62 Once within the cell, the RHDV VLP is 
degraded into peptides in acidified lysosomal compartments.59 Win concluded that the 
RHDV VLP derived peptides were not shuffled from the lysosomal compartments to the 
cytosol, nor did they enter the ER. With this evidence, they proposed that the VLP-derived 
peptides are instead loaded to MHC I complexes within the lysosomes. The MHC I 
complexes are likely recycled from the cell surface, and upon entering the acidic 
lysosome, dissociate from their currently loaded antigen and are able to be loaded with 
the VLP antigen. From here, the newly complexed MHC I-VLP antigen is delivered back 
to the cell surface leading to the stimulation of CD+8 T cells.59  
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1.4 Enhancing VLP immunogenicity 
While RHDV VLP is effective at initiating an immune response, it could be possible to 
increase that response by accessing a receptor-mediated cross presentation pathway.  
1.4.1 Adjuvants 
Some vaccine types require the use of immunostimulatory adjuvants in order to invoke 
an immune response similar to that caused by infection of the wild-type strains.63 For 70 
years, since its first appearance in human vaccines in 1932, aluminium sulfate salts 
(Alum) were the only adjuvant in use.63 However, as subunit vaccines have become more 
popular and as researchers have begun to target more complex diseases, the need for 
alternative adjuvant systems has become obvious. With the increased popularity of 
subunit vaccines, like VLP, new methods of increasing immune stimulation have been 
implemented. One possibility that is in its infancy of exploration for VLP based vaccines 
is the use of chemical conjugation to alter how the VLP is processed by APC and in turn 
the immune response generated.9, 64  
1.4.2 Receptor mediated 
Cross presentation of an antigen can be established through receptor-mediated 
endocytosis in mammalian macrophages and dendritic cells. Two receptors that have been 
highly researched and whose binding affinities are well documented are mannose receptor 
CD 206 and DC-SIGN. These have been of great interest to the scientific community due 
to the interactions between the receptors and pathogenic glycoproteins during infection.  
1.4.3 Mannose receptor (CD 206) 
The mannose receptor is a 175 kDa transmembrane protein with an internal C-terminus 
and an external N-terminus, illustrated in Figure 1.4.65-66 Eight carbohydrate recognition 
domains (CRDs) are located on the N-terminus and are responsible for the Ca2+ dependent 
binding of sugars with terminal D-mannose or L-fucose residues. The binding properties 
and preferences of this receptor have been studied extensively.65-66 
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Figure 1.4: Visual representation of mannose receptor CD 206. 67 
Inhibitory studies by Kéry et al.66 (Table 1.3) have shown that the human mannose 
receptor (HMR) preferentially binds to monosaccharides in the following order of 
decreasing strength: L-Fuc > D-Man > D-Glc > D-Man-6-P >> D-Gal >> L-Rha >> D-
GalNAc.66 These studies also found that the HMR shows a slight preference for α-linked 
glycosides over β-linked glycosides. Dimannosides were found to be more inhibitory than 
the series of monomannosides. The following dimannosides were studied and the 
inhibitory effects were as follows: Manα1-6Manα1-OMe = Manα1-3Manα1-OMe > 
Manα1-2Manα1-OMe > Manα1-4Manα1-OMe. This showed a preference for 1→6-, 
1→3-, and 1→2-α glycosidic linkages. Extending the mannose oligosaccharide chain 
further led to smaller increases in inhibitory potency. The best inhibitor from the study 
was a 3,6-α-branched trimannoside (in bold, Table 1.3), showing that the HMR favours 
binding to branched mannose-based oligosaccharides. Increasing the number or length of 
branches showed decreased inhibition. One disaccharide, Fucα1-6GlcNAcα1-OMe (in 
bold, Table 1.3), showed similar levels of inhibition as the 3,6-α-branched trimannoside. 
Additionally, the saccharide associated with O-type blood, Fucα1-2Galβ1-OMe (in bold), 
showed a significant level of inhibition.66 These studies can be extrapolated to include 
2,6-α-branched trimannosides in the carbohydrate series with high binding affinities. 
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Table 1.3: Concentrations of HMR inhibitors required to cause 50% inhibition (ID50) of the HMR (0.5 μg/well) binding to the mannan 
Saccharomyces cervisiae (10 μg/well)-coated microplates. Adapted from Kéry et al.66 HMR binding studies. 
Inhibitor ID50 (μM) Inhibitor ID50 (μM) 
D-Man 5,500 Manα1-2Man 300 
α-Man1-OMe 1,000 Manα1-2Manα-1-OMe 3,200 
β-Man1-OMe 2,000  Manα1-2Manα1-2Man (65%) /   
 Manα1-3Manα1-2Man (35%)                    
200 
α-Man1-O(4-methylumbelliferyl) 150 Manα1-3Manα1-6Manβ1-4GlcNAc 170 
D-Man-6-P 13,500 Manα1-3Manα1-OMe 2,000 
L-Rha 35,000 Manα1-3Manα1-2Manα1-2Man 280 
D-Glc 6,000 Manα1-4Manα-1-OMe 4,000 
D-GlcNAc 13,000 Fucα1-6GlcNAcα1-OMe 20 
D-Gal 19,000 Fucα1-2Galβ1-OMe CI(5-500) 
40% 
D-GalNAc 60,000   
L-Fuc 3,200   
Manα1-6Manα-1-OMe 2,000   
Manα1-6 
                Manα1-OMe 
Manα1-3 
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Note from Kéry et al.66: “The binding was performed at 37°C for 1 h in the presence or 
absence of inhibitors. The negative controls (subtracted from all inhibitory curves) were 
wells containing 1 mg/ml yeast mannan and the wells without HMR. The inhibition of 
HMR binding was measured at at least eight different concentrations of serial dilutions 
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Dendritic cell-specific intracellular adhesion molecules (ICAM)-3 grabbing non-integrin 
(DC-SIGN aka CD 209) are another member of the family of c-type lectins that can be 
found on the surface of mammalian cells (Figure 1.5).68-69 DC-SIGN is of special interest 
to the scientific community due to its involvement in a large number of infections. These 
include viral infections such as HIV-1, ebola, hepatitis C, dengue, cytomegalovirus, and 
SARS as well as bacterial infections and some parasitic infections. DC-SIGN is expressed 
mainly on subepithelial dendritic cells (DC) and specialized macrophages in the placenta 
and lung, but can also be found in various DC populations in the blood and other tissues. 
Once DC-SIGN has taken up an antigen, DCs migrate to the lymph nodes and the antigen 
is presented by the appropriate MHC complex.68-69 
 
Figure 1.5: PyMOL rendering of DC SIGN protein (Public domain). 
DC-SIGN, like most membrane bound receptors, is composed of an intracellular domain, 
a trans-membrane domain, and an extracellular domain.68 The intracellular region is the 
N-terminal end and is responsible for signaling. It contains several internalization motifs 
as well, which indicate that DC-SIGN could function as an endocytic receptor. These 
motifs include a dileucine motif critical for internalization and a tri-acidic cluster 
important for targeting proteolytic vacuoles. DC-SIGN has notable dual ligand binding 
properties of adhesion and mediation by endocytosis and releases the bound ligand at 
endosomal pH, making it capable of acting as a recycling endocyclic receptor.68 
DC-SIGN has a tetrameric quarternary structure. The extracellular domain of DC-SIGN 
consists of a neck region with highly conserved tandem 23-amino acid repeats and a CRD 
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region that is believed to complex to mannose rich carbohydrates.68-69 The neck region 
generally contains seven complete repeats and one incomplete repeat of a 23 amino acid 
sequence, which folds into an α-helical conformation interspaced with non-helical regions 
and gives a degree of flexibility to the CRD region. The neck region extends the CRD 
approximately 25Å from the cell membrane. This allows the CRD to interact with 
carbohydrates that are presented with variable spacing on pathogen cell surfaces. Val351 
has been identified to be responsible for van der Waals interactions between the 2 
hydroxyl group on fucose and the CRD region. Additional studies have shown that DC-
SIGN binds preferentially to L-fucose over D-mannose, which allows DC-SIGN to bind 
to blood group antigens (Figure 1.6). 68-69 
 
Figure 1.6: Blood group antigens A, B, H, O, and Lewis X. 
In a study published in 2011 by Holla et al.70, the binding effects of 275 sugars were 
tested for DC-SIGN. These included sulfonated compounds and sialic acid derivatives. 
Holla et al.70 found that DC-SIGN bound strongly to highly branched mannose-type 
structures, showed a weak affinity to linear oligosaccharides, and had no significant 
binding to D-mannose. DC-SIGN showed significant binding to sugars that contained 
Fuc-linked either to GlcNAc or Glc through an α-bond at the 3 or 4 position including 
blood antigens Lewis A, Lewis X, Lewis B, and Lewis Y. Lewis X, is often referred to 
as an ideal natural ligand for DC-SIGN throughout the scientific  
literature.68, 71 Sialyl Lewis A was also recognized, while sialyl Lewis X did not bind 
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significantly. DC-SIGN recognized blood group antigens H, A, and B that do not contain 
a Fuc linked to GlcNAc or Glc.70  
1.5 Rabbit hemorrhagic disease virus (RHDV) VLP  
The Rabbit Hemorrhagic disease virus (RHDV) is highly contagious among rabbits and 
is responsible for a condition that causes hemorrhages and liver necrosis.9 RHDV is of 
the Caliciviridae family and Lagovirus genus; a group of non-enveloped single stranded 
RNA viruses.72 Its viral capsid is composed of 180 copies of 60 kDa major capsid protein 
(VP60) assembled into 90 dimers that form a 40 nm icosahedral structure. VP60 can be 
divided into four domains. The N-terminal domain extends within the capsid and is 
composed of amino acids 1-65, the shell domain forms the icosahedral backbone with 
amino acids 66-229 and is followed by a seven amino acid long hinge domain. Lastly, the 
protruding domain made up of amino acids 237-579 ends with an exposed C-terminus. 
Like other viral capsid proteins, VP60 is able to self-assemble and form VLPs that are 
both structurally and antigenically identical to that of the wild-type  
virus (Figure 1.7).46, 72 
 
Figure 1.7: Visualisation of the RHDV VLP based on structural analyses 
performed by Wang et al.46  
There are a number of amino acids in the protruding domain that carry functional groups, 
like the ones outlined in Figure 1.2. Each VP60 protruding domain contains four lysine 
residues with primary amine side chains available for chemical conjugation. With 180 
copies of VP60 and four potential conjugation sites per copy, there are a total of 720 
locations on RHDV VLP that can act as tethers for various amine reactive substituents.9 
VP60 can be produced using a number of different expression systems including bacteria, 
plants, yeast, and insect cells; making RHDV VLP easily accessible in a lab setting. 
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The Ward group in the Immunology Department at the University of Otago has done a 
great deal of research into the viability of RHDV VLP-based cancer vaccines.9 RHDV 
VLP has been the VLP of choice among the Ward group for a number of reasons. 
Vaccine-grade RHDV VLPs are easily afforded from insect expression systems, the VLP 
is able to support both recombinant insertions of antigens and chemical conjugation of 
various synthetic compounds, and because the wild-type virus is unable to infect humans, 
subjects have no natural immunity to the VLP that may interfere with the vaccine.39, 64 
1.5.1 RHDV VLP as a delivery system for anticancer vaccines 
Over the course of the past decade, the Ward group has used the RHDV VLP as the base 
component of vaccines against a number of cancers, all with significantly positive results 
in mouse model systems. In 2008, Peacey et al.73 provided ground work into the efficacy 
of RHDV VLP as a platform for use in anticancer vaccines. Melanoma, an aggressive 
form of skin cancer which has few non-surgical treatment options, was specifically 
targeted in this study. The RHDV VLP were chemically conjugated to the model tumor 
antigen ovalbumin (OVA) and used to vaccinate mice with an aggressive form of 
melanoma (B16.OVA). Peacey found that the vaccination significantly delayed the 
melanoma growth.73 
Jemon et al.74, also of the Ward group, published work on a RHDV VLP-based vaccine 
designed as an immunotherapy regiment for treatment against HPV16 positive tumors. In 
this system, the universal helper T cell epitope, PADRE, was recombinantly added to the 
N-terminus of VP60. The VLPs were produced, and the peptide from HPV16, E6, was 
added by chemical conjugation via a thiol to the surface of the VLP. Mice with preexisting 
HPV16 positive tumours were vaccinated with the PADRE-RHDV VLP-E6 conjugate 
which led to reduced tumour size and an increased survival time.  
More recently, Donaldson et al.75 published work related to a RHDV VLP-based 
colorectal cancer treatment. Here, three vaccine systems were tested using two antigens: 
topoisomerase IIα (T) and/or survivin (S). The mono-target forms (RHDV VLP-T and 
RHDV VLP-S) and the multi-target form (RHDV-VLP-T-S) all showed significantly 




1.5.2 Carbohydrate conjugation to RHDV VLP for anticancer vaccines 
In 2012, the Ward group expanded their research into glycolipid/glycoside territory when 
they published a paper highlighting the advantages of an α-GalCer-RHDV VLP conjugate 
for use in anti-cancer vaccines.64 α-Galactosylceramide (α-GalCer), Figure 1.8, is a 
highly effective adjuvant and has been shown to stimulate invariant Natural Killer T 
(iNKT) cells. Inclusion of this glycolipid allows for the vaccine to cause a cascade of cell-
cell interactions and in turn leads to a multidimensional immune response.64, 76  
McKee et al.64 used recombinant technology (insect cells) to produce VP60-gp33. These 
were used to make RHDV-gp33 VLP, which were then conjugated to α-GalCer, giving 
the final VLP, α-GalCer-RHDV-gp33. Immunological testing was carried out using 
murine models and they found that the immune response generated to gp-33 was greater 
in the α-GalCer-RHDV-gp33 system than in α-GalCer-gp33 or RHDV-gp33.43 
 
Figure 1.8: α-GalCer, a carbohydrate which McKee et al.64 conjugated to 
RHDV VLP in order to increase immunogenicity of the VLP. 
1.5.3 Carbohydrate conjugation to RHDV VLP for targeting CD 206 
From here, the Ward group joined efforts with the Larsen group to synthesize a series of 
carbohydrates that could be conjugated to RHDV VLP. A mono and dimannoside, 1 and 
2 respectively (Figure 1.9), were synthesised by PhD student Farrah Al-Barwani.18 The 
key design aspect of these mannosides lies in the linker. Al-Barwani aimed to manipulate 
the amine functionalities on the RHDV VLP lysine residues and use them as anchors for 
the synthesized mannosides. To do so, a succinimidyl motif was deemed to be the ideal 
candidate for conjugation to the VLP. Succinimdyl esters are considered amine-reactive 
esters and are able to conjugate at a pH below the dissociation pH of the RHDV VLP and 
form stable amide bonds with the VLP.9 Other motifs were considered, including the 
isothiocyanate derivative, however these are not stable for conjugation under 
physiological conditions.9, 25 
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Figure 1.9: Monomannoside 1 and dimannoside 2 synthesised by Al-Barwani.9 
Al-Barwani generated the RHDV VLP using an insect cell recombinant expression 
system and found that she was able to access four sites per VP60 for conjugation with the 
monomannoside and two sites with the dimannoside. She performed a number of different 
assays using murine cells and human cells to assess the impact of the mono- and 
dimannoside conjugation on the uptake and internalisation of RHDV VLP. Analyses were 
performed on murine APCs included DCs, macrophages, B cells, and T cells in vitro.9 
The cells were pulsed with either the unconjugated VLP, the VLP-monomannoside 
conjugate, or the VLP-dimannoside conjugate and were then incubated for different times 
at 4°C or 37°C. At 4°C, phagocytosis is greatly diminished due to reduced metabolism 
and membrane fluidity, making it an ideal temperature to study the effect of the 
association between the VLP and the surface of the APCs. The healthy body temperature 
of humans, 37°C, was used to analyse the internalisation of the mannosylated VLP.9 
Al-Barwani found that NK and T cells did not demonstrate a significant degree of 
internalisation, an observation supported a number of other times in the literature.9, 59, 77 
DCs and macrophages that were incubated at 4°C displayed increased association with 
both mannoside-VLP conjugates when compared to the non-mannosylated VLP (after 4 
hours or 24 hours incubation). These results indicate that mannosylation of the RHDV 
VLP leads to accelerated uptake by APCs. Interestingly, Al-Barwani observed that the 
monomannoside conjugate was as efficient, if not better than the dimannoside conjugate 
at increasing uptake in murine cells. She did note that this could be due to the highly 
textured surface of the RHDV VLP causing the mannosyl units to protrude at different 
angles. This may in turn allow multiple monomannosides to bind to the same receptor, 
causing the monomannosylated version to mimic a more highly branched mannose 
structure. To confirm that the mannose receptor was indeed the c-type lectin responsible 
for binding to the mannosylated VLPs, Al-Barwani blocked the mannose receptor with 
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mannan, a polymer of mannose. This led to a significant reduction of mannosylated VLP 
uptake.9 
The same studies were performed on human monocyte-derived DCs and macrophages 
and similar results were found. Al-Barwani noted one significant difference between the 
two systems: unlike in the murine model, the human model indicated that the 
dimannoside-VLP was internalised more efficiently than the monomannoide-VLP at all 
time periods examined.9 The variances between the murine APCs and the human APCs 
observed by Al-Barwani are likely due to the 8-24% sequence divergence seen the CRD 
regions between the two species.77-78 These variations may not allow for a single mannose 
receptor to bind to multiple monomannoside protrusions.  
1.5.4 Importance of linker composition 
A study by Yin et al.79, published in 2015, examined the use of various linkers to attach 
the tumour associated carbohydrate antigen, Tn, to VLP. The VLP in this case was that 
belonging to the bacteriophage Qβ. They used a series of triazole and amide based linkers 
(Figure 1.10) and found that triazole based linkers dramatically decreased the diversity 





Figure 1.10: Series of linkers by Yin et al. used to conjugate Tn antigen to 





1.6 Research proposal 
With promising data from the monomannoside and dimannoside RHDV VLP conjugates, 
the proposed research intends to build upon work performed by Al-Barwani9 and the 
Ward group by synthesizing a series of carbohydrates that may be used to target receptor-
mediated uptake of RHDV VLP (Figure 1.11). As discussed previously, the mannose 
receptor has a preference for branched trimannosides, specifically those with (1®2), 
(1®3), and (1®6)-α-linkages.66 Initial synthetic investigations will be directed towards 
the synthesis of the corresponding branched trimannosides 3 and 5 that will allow for 
further studies to be carried out using the mannose receptors’ ideal ligands. These more 
complex mannosides are also essential to determine the effect of the textured surface of 
the VLP on mannose receptor binding. Al-Barwani9 utilised a linker based on 6-methyl 
hexanoate for both the mono and dimannoside, the effect of which can be studied by using 
an alternative succinimidyl-ester for conjugation to the RHDV VLP. A linker derived 
from a 2-azidoethyl handle may be ideal for this (4 or 6). The type-O blood group antigen 
(Fucα1-2Galβ1-OR) and Fucα1-6GlcNAcα1-OR showed significant HMR binding 
abilities in the Kéry et al. study, and their syntheses will be attempted as well (7, 8, 9 
and/or 10). Accessing antigen presenting cells through DC-SIGN could also significantly 
improve the immunogenic properties of RHDV VLP. Synthesis of a natural ligand for 
DC SIGN, like Lewis X derived 11 or 12, that is equipped with an amine reactive linker 











The synthesis of (1→2)-α-(1→6)-α-branched 
trimannoside 3 
2.1 Retrosynthetic analysis of (1→2)-α-(1→6)-α-branched trimannoside 3 
The first synthetic target to be considered was 2,6-α-branched trimannoside 3. Here, a 
central mannopyranosyl unit is O-linked to two mannosyl residues through a (1→2)-α- 
and a (1→6)-α- linkage. This central residue is also bound through an α-O-glycosidic 
linkage to a six-carbon chain terminating in an N-succinimidyl ester. A general approach 
to achieve such a trimannoside can be derived from a retrosynthetic analysis (Scheme 
2.1). 
 
Scheme 2.1: Retrosynthetic analysis of (1→2)-α-(1→6)-α-branched 
trimannoside 3. 
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As outlined in Scheme 2.1, the target 2,6-trimannoside 3 can be obtained from fully 
protected trimannoside 13. This could be efficiently achieved through a bis-glycosylation 
between an appropriately protected glycosyl acceptor such as 14 and glycosyl donor 15. 
A key aspect to the synthetic design is the use of benzyl protecting groups wherever 
possible. Uniform protecting groups will allow for fewer deprotection steps after the bis-
glycosylation reaction. Benzyl ethers are ideal for this purpose due to their high stability 
and ease of removal by palladium catalyzed hydrogenolysis.81-83 The presence of 
protecting groups throughout the manipulation of the linker would allow for more non-
polar compounds, leading to easier purification at each step. Also, hydrogenolysis of 
benzyl ethers is considered a clean reaction with toluene as the byproduct, so purification 
after the final step may be unnecessary. 
2.2 Glycosylation reactions 
It is clear from the retrosynthetic analysis that forming glycosidic linkages will be a 
critical step in the synthesis to achieve any of the target carbohydrates. Glycosylations 
cover a broad range of reactions and reaction conditions which all have the same basic 
components. A glycosylation is generally a nucleophilic substitution reaction of an 
electrophilic glycosyl donor and a nucleophilic glycosyl acceptor to create a glycosidic 
linkage (Figure 2.1).84 The glycosyl donor commonly needs to be activated by some sort 
of promoter, often a Lewis acid. Glycosylations can be used to link two saccharide 
components together or to join a non-saccharide to a given sugar. There are many 
intricacies that need to be considered and controlled to allow for the desired product to be 
formed. These include, but are not limited to, regioselectivity of the acceptor, 
stereochemistry of the glycosidic bond, the participation of the donor O-2 protecting 
group, and the effect of solvent. 
 
Figure 2.1: General outline of a glycosylation reaction resulting in the 
formation of a glycoside. 
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Regioselectivity can be controlled by exploiting protecting group chemistry to allow only 
the desired hydroxyl group(s) of the acceptor to react with the donor. Common protecting 
groups include benzoyl and acetyl esters and the more robust benzyl ethers.81-83 
Additionally, silyl ether protecting groups are often used to selectively protect primary 
hydroxyls over secondary ones. Cyclic acetals and orthoesters may also be used as they 
are able to be opened to reveal specific hydroxyl groups depending on reaction conditions. 
Protecting group chemistry is widely used and well reviewed in the literature.81-83  
2.2.1 Controlling anomeric stereochemistry 
In the aldohexose series, the anomeric configuration is defined by the stereochemistry of 
the C-1 substituent. When the orientation of the C-5 substituent resides on the opposite 
face of the pyranose ring to that of the C-1 substituent, the anomeric configuration is 
deemed α. Conversely, if these two substituents lie on the same face of the pyranose ring, 
the anomeric configuration is β.85-86 Figure 2.2 illustrates the four anomeric linkage types 
that are found in the D-series of aldohexo-pyranosides: 1,2-trans-α, 1,2-trans-β, 1,2-cis-
α, and 1,2-cis-β.  
 
Figure 2.2: Possible anomeric configurations (left to right); 1,2-trans-α, 1,2-
trans-β, 1,2-cis-α, and 1,2-cis-β. Substituents are only shown at C-1 and C-2 
for clarity. 
Of these, the relevant linkages to this project are that of 1,2-trans-α and 1,2-trans-β. These 
can be formed with ease by utilising a participating group at the O-2 position of the chosen 
glycosyl donor.87 
2.2.2 Glycosyl donors with O-2 substituent participation 
Some protecting groups, predominantly esters, are able to participate in glycosylation 
reactions and result in the formation of only one anomer.87 Acetyl, benzoyl, and 
levulinoyl esters are the most commonly used hydroxyl protecting groups that are able to 
participate in glycosylations.88-89 When a participating group is present at the O-2 
position, it is capable of forming acyloxonium ion B which is much more stable than 













the acceptor, resulting in only 1,2-trans linkages. Unfortunately, while esters are excellent 
for ensuring 1,2-trans stereochemistry, they are also electron withdrawing and can slow 
down the glycosylation reaction.90 Electron withdrawing groups at C-2 can affect the rate 
at which the leaving group leaves, while those located at C-4 and C-6 can destabilise the 
oxocarbenium ion.90-91 Often the guarantee of only the 1,2-trans product makes these 
obstacles worth overcoming, and alteration of the reaction conditions can minimise these 
effects. While less frequently utilised, long range participation effects of protecting 
groups have also been observed, particularly those located at C-3 and C-6.91-93 An 
interesting example of long range participation can be seen in galactosides, where an ester 
group at the axial C-4 position can act as a remote participating group during 
glycosylation, giving the α-glycoside in excess.91, 94  
 
Scheme 2.2: Generic mechanism for blocking the cis face using participating 
group chemistry. 
2.2.3 Leaving groups on glycosyl donors 
The course of the glycosylation reaction is also affected by the choice of leaving group at 
the anomeric position and in turn the choice of promoter. The Koenigs-Knorr 
glycosylation, one of the first glycosylation methods, was developed in 1901 and utilises 
an anomeric halide as a leaving group.95 Scheme 2.3 outlines the reaction mechanism, 
where the halogen (commonly Br or Cl) is enticed to leave by the promoter, a silver salt. 
This results in the formation of an oxocarbenium ion. If a participating group is present, 
the acyloxonium ion forms, directing for only 1,2-trans linkages. Many different 
variations of the Koenigs-Knorr method have been developed in the past century, 
including the Helferich method, where the silver salt is replaced with a mercuric salt.96 
Although well explored, Koenigs-Knorr glycosylations are not the most practical in all 
applications due to the instability of glycosyl halides and the need for stoichiometric 
amounts of expensive (Ag) and toxic (Hg) metal salts.  
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Scheme 2.3: General mechanism of Koenigs-Knorr glycosylation using a 
glycosyl bromide donor with a participating group at O-2 to achieve a 1,2-
trans-α-linkage. 
More recently, a number of alternative leaving group-promoter combinations have 
emerged. Two examples are thioaryl/thioalkyl and trichloroacetimidate donors. 
Thiophenyl donors are considered to be very versatile and are able to be installed early in 
reaction pathways due to their remarkable stability in a wide range of reaction conditions. 
Although they are highly stable, the soft nature of the sulfur atom allows for the use of a 
soft electrophile when activation is required.84 Early work with thioglycosides used 
promoters like mercury, copper, or silver salts. Activation of thioglycoside donors with 
thiophilic halonium ions has become the method of choice for many research groups.84 
The most common soft electrophile used is the iodonium cation which can be generated 
in situ from N-iodosuccinimide (NIS) and iodonium di-sym-collidine perchlorate (IDCP), 
among others.97-98 Scheme 2.4 highlights an example of the use of a thioglycoside and 
NIS/trimethylsilyl trifluoromethanesulfonate (TMSOTf) promoter system to create a 
glycosidic bond by Ali et al.99 
 
Scheme 2.4: Thiophenyl donor glycosylation using NIS/TMSOTf promoter 
system by Ali et al.99 
Scheme 2.5 outlines work by Zhu and Boons 100 which demonstrates the versatility of 






























































be selectively activated by varying the reaction conditions. This makes thioglycosides 
good candidates for one-pot syntheses. 
 
Scheme 2.5: (top) Thioethyl donor and IDCP promoter glycosylation; 
(bottom) Thiophenyl donor and NIS promoter glycosylation. Both performed 
by Zhu and Boons. 100 
The use of trichloroacetimidate (TCA) donors in glycosidic reactions was implemented 
in the 1980s by Richard Schmidt 101 to overcome some of the difficulties associated with 
the Koenigs-Knorr method. Here, the TCA is able to be activated with a catalytic amount 
of a strong Lewis acid, and in the presence of a nucleophilic acceptor, a glycosidic bond 
can be formed.101 TCA donors are readily generated through the base-promoted addition 
of the anomeric hydroxyl group to trichloroacetonitrile.102 They are highly moisture 
sensitive and are unstable when left at room temperature for prolonged periods of time. 
Because of this, it is common to use them in glycosylation reactions quickly after their 
formation and isolation. These donor types are also highly reliable and readily 
synthesized so are often the leaving group of choice in the synthesis of oligosaccharides. 
Al-Barwani used TCA donor 24 in two glycosylation reactions in her synthesis of mono 
and dimannosides 1 and 2 (Scheme 2.6).9 The first glycosylation was between 24 and the 
primary alcohol of methyl 6-hydroxyhexanoate (25) to give 26 in an 82% yield. The 
second, between 24 and the secondary 2-OH of mannoside 27 gave dimannoside 28 in an 





































































and provides a good donor option for the bis-glycosylation to achieve 2,6-branched 
trimannoside 3.  
 
Scheme 2.6: General reaction pathway followed by Al-Barwani et al.9 to 
achieve both the mono and dimannosides 26 and 28. 
2.3 Synthesis of glycosyl acceptor 14 
The retrosynthetic analysis presented at the start of this chapter can be further broken 
down to reveal a number of synthetic approaches to diol 14 (Scheme 2.7). To secure the 
chosen linker chain, a glycosylation reaction is required between some donor (generically 
represented by 29) and the acceptor, methyl 6-hydroxyhexanoate (25). 
 
Scheme 2.7: Retrosynthetic analysis of bis-acceptor 14. 
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2.3.1 Synthesis of methyl 6-hydroxyhexanoate (25) 
Methyl 6-hydroxyhexanoate (25) is a well-known compound that began to appear in the 
literature in the early 1980s.103 The most common method for synthesis of alkyl esters 
like 25 is via lactone ring opening reactions. This procedure, followed by many, including 
Al-Barwani,9 and Duffy and Grayson,104 involves refluxing ε-caprolactone in methanol 
(MeOH) with sulfuric acid. 
To synthesize methyl 6-hydroxyhexanoate (25) in the current work, ε-caprolactone was 
stirred under acidic conditions in methanol for 30 minutes, resulting in quantitative yields 
of the desired product as a clear, colourless liquid (Scheme 2.8). This reaction was 
performed at reflux and also at room temperature, both giving 25 in high yields. 
 
Scheme 2.8: Reaction of ε-caprolactone to give methyl 6-hydroxyhexanoate (25).  
Due to the reaction conditions and the nucleophilic product, it is possible to form a 
polymeric by-product that can be difficult to detect. Distillation of the crude reaction 
material by Kugelrohr apparatus (2 mBar, 150°C) was used to ensure purity of the 
acceptor 25 prior to use in glycosylation.9 All qualitative data were consistent with those 
published in the literature.9, 104 
2.4 Synthetic approaches towards glycosyl donor 29 
Again, an additional retrosynthetic analysis must be performed to determine a viable 
pathway to achieve glycosyl donor 29. Scheme 2.9 identifies two possible options that 
could conceivably result in the formation of diol 14. The first pathway uses a tricyclic 
orthoester intermediate, 30, and presents an elegant method to give a protected 
preliminary product 31. Removal of the benzoyl protecting group at C-2 would reveal 
diol 14. Alternatively, a pathway involving 1,2-ethylidene intermediate 32 to give the 
diacetylated trichloroacetimidate 33, could be used. 
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Scheme 2.9: Retrosynthetic analysis of bis-acceptor 14 to reveal two possible 
synthetic pathways, a tricyclic orthoester pathway and a 1,2-ethylidene 
intermediate pathway. 
2.4.1 Tricyclic orthoester pathway  
2,6-Branched trimannoside 3 has been a long time synthetic target of the Larsen 
 lab.105-107 Former members of the lab group have laid the foundation for the tricyclic 
orthoester based pathway to form diol 14.105-106 Mannosyl tricyclic orthoesters are well 
known to open when in the presence of a Lewis acid and a nucleophile  
(Scheme 2.10).108-110 This occurrence has been specifically noted in 1,2,6-tricyclic 
orthoesters previously by Hiranuma et al.108 This concept was further developed by 
Seeberger and coworkers109 concept in 2008 and provided an efficient synthetic approach 





Scheme 2.10: General tricyclic orthoester opening conditions as reported by 
Seeberger and coworkers.109 
A member of the Larsen lab, honours student Rebecca Jelley, found that methyl 6-
hydroxyhexanoate (25), was not sufficiently nucleophilic to participate in the dissociation 
of the tricyclic orthoester 34 and give any significant yield of the target product 35.105 An 
alternative tricyclic orthoester containing a phenyl ring was synthesized by summer 
student Étienne Decaudin, in hopes that more aromatic tricyclic orthoester 30 would be 
more susceptible to nucleophilic attack by 25 than the methyl variation.106 Unfortunately, 
this alteration did not produce desired product 36 in any significant quantities either. Both 
of these attempts are outlined in Scheme 2.11.105-106 
 
Scheme 2.11: Attempts by both Jelley (unpublished) and Deaudin 
(unpublished) to open tricyclic orthoesters with 25.105-106  
This led the group to consider an alternative nucleophile. Previous work done by PhD 
student Greg Rankin showed that allyl alcohol participated in the dissociation of tricyclic 
orthoester 30 to give 37 in quantitative yields (Scheme 2.12).110 There are a number of 
different reactions that would utilize the double bond of the allyl group to potentially give 
a functional linker structure, and it could also be removed and replaced with an alternative 




Scheme 2.12: Work by Rankin opening tricyclic orthoester 30.110 
 As an Honours project by myself, methods into functionalizing the anomeric allyl handle 
were explored using model systems (Scheme 2.13).107 A cross metathesis reaction on 38 
to achieve carboxylic acid 39 failed using multiple generations of Grubbs’ catalyst. 
Promising results indicated that a hydroboration reaction of 40 with 9-
borabicyclo(3.3.1)nonane (9-BBN) could achieve 41 with an alcohol functionality on the 
linker which in turn could be expanded to give 42 with an oxygenated linker, similar in 
length to that used by Al-Barwani et al.9, 107 
 
Scheme 2.13: Linker exploration from an allylated mannoside by Hall 
(unpublished) 107 in 2015.  
While this work was not completed, valuable information on the nature and yield of the 
bis-glycosylation reaction was obtained. Notably, it was found that the bis-glycosylation 
of 38 with TCA donor 24 was able to be carried out under comparable conditions as the 
Al-Barwani glycosylations to consistently give 43 in yields between 60% and 70% 
(Scheme 2.14).9, 107 
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Reagents and conditions: a) BF3OEt2, AllOH, CH2Cl2, 0°C; b) NaOMe, MeOH/CH2Cl2; c) 24, 
TMSOTf, 4Å molecular sieves (MS), 0°C, toluene (tol). 
Scheme 2.14: Previous work by Hall (unpublished)107 demonstrating the 
success of a bis-glycosylation with acceptor 38 and donor 24. 
With the background work laid out, this pathway was undertaken first. Using the synthetic 
pathway published by Seeberger and coworkers and followed in the work by Rankin, 
Jelly, Decaudin, and Hall, synthesis of tricyclic orthoester 30 was attempted. 105-107, 109-110 
This pathway could conceivably achieve a suitable acceptor required for a bis-
glycosylation in 7 steps, depending on what nucleophile is used in step (g) when the 
orthoester is opened (Scheme 2.15).  
 
Reagents and conditions: a) BzCl, pyridine (py), 0°C → rt; b) HBr/AcOH, CH2Cl2; c) KF, 
CH3CN, MeOH, 40°C, d) NaOMe, MeOH/CH2Cl2; e) CSA, 3Å MS, CH3CN; f) BnBr, NaH, 
DMF, 0°C → rt; g) HO-R’, BF3OEt2, CH2Cl2, 0°C; h) NaOMe, MeOH/CH2Cl2. 
 
Scheme 2.15: Tricyclic orthoester pathway attempted towards bis-acceptor 14.107, 109-110 
 
D-Mannose was globally benzoylated under basic conditions, followed by the formation 
of mannosyl bromide 45, in a 93% yield over the two steps. This material was then reacted 
with KF and MeOH to achieve 1,2-orthoester 46. A debenzoylation step followed, 
resulting in the formation of 47 in an 87% yield over the two steps. All data collected for 
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the products described in this reaction pathway matched those outlined in the literature 
and the unpublished previous work of the Larsen group.107, 109-110  
The formation of the tricyclic orthoester 48 was unable to be carried out although this 
compound has been synthesized numerous times in the Larsen lab, and a number of times 
by myself in 2015 as part of an Honours project. Investigations into the issue indicated 
that the acetonitrile was contaminated with methanol. Outlined in Scheme 2.16, the 
methoxyl group of the orthoester is initially protonated and leaves as methanol, resulting 
in the formation of a carbcation. 3Å molecular sieves are used to remove the methanol 
generated in the reaction, however an impurity in the solvent or a large quantity of 
methanol may render the sieves useless. This reaction was tested with freshly activated 
3Å sieves, 4Å sieves, and 4Å powdered sieves, all resulting in the unwanted methyl 
glycoside 51. Acetonitirile was taken from the PURE-SOLV MD-6 purification system, 
then dried over 4Å molecular sieves for anywhere from three hours to overnight, all of 
which also resulted in byproduct 51. When the reaction was performed with HPLC grade 
acetonitrile dried over 4Å molecular sieves overnight low yields of orthoester 48 were 
obtained. As a result, the Seeberger 109 synthetic method to achieve tricyclic orthoester 
30 was set aside in favour of the pursuit of an alternate way to synthesize a suitable 
mannosyl acceptor for bis-glycosylation. 
 
Scheme 2.16: Mechanism of tricyclic orthoester formation and possible 
results of MeOH interference in the reaction.  
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A paper by Yongyat et al.,111 published in 2010, offered an alternative route to tricyclic 
orthoester 30. Here they used an allylated 1,2-orthoester, 52, whose synthetic approach 
can be found in Scheme 2.17.111 The addition of an allyl group allowed for the cyclisation 
reaction required to form 48 to be performed in dichloromethane instead of acetonitrile. 
It was decided to try to synthesize tricyclic orthoester 30 by following this pathway. 
Preliminary trials towards the synthesis of allylated orthoesters 52 and 53 were easily 
accomplished following this method. Although upon formation of the tricyclic orthoester, 
the acidic conditions caused the tricyclic orthoester to open unpredictably, often before a 
work up was able to be carried out.  
 
Reagents and conditions: BzCl, py, 0°C → rt; b) HBr in AcOH (33%), Ac2O; c) 
CH2=CH2CH2OH, lutidine; d) KOH, H2O, MeOH, THF; e) CSA, CH2Cl2; f) BnBr, NaH, DMF, 
0°C → rt. 
Scheme 2.17: Method followed by Yongyat et al.111 to achieve tricyclic 
orthoester 30. 
Given the inherent difficulties with the tricyclic orthoester synthesis, it was decided to 
move on to an alternative approach to form the desired diol acceptor 14. 
2.4.2 Ethylidene intermediate pathway 
After moving away from the tricyclic orthoester based pathway, an approach using a 1,2-
ethylidene protected mannoside derivative was followed. The general plan, in Scheme 
2.18, was to use an ethylidene group to protect the anomeric position and O-2. The 
primary hydroxyl at C-6 could then be selectively protected with a silyl protecting group, 
leaving only O-3 and O-4 available for benzylation. The silyl group and the ethylidene 
could then be removed and replaced with acetyl groups. The anomeric ester could be 
selectively esterified and functionalised as a trichloroacetimidate. Mannosyl donor 33 
could then be used in a glycosylation reaction with methyl 6-hydroxyhexanoate (25) to 




Reagents and conditions: a) Ac2O, py, 0°C → rt; b) HBr/AcOH, CH2Cl2; c) NaBH4, anhyd. 
CH3CN; d) IRA-400 (OH
-), MeOH/ CH2Cl2; e) TBSCl, 4-DMAP, TEA, CH2Cl2; f) BnBr, NaH, 
DMF, 0°C → rt; g) TBAF, THF; h) (i) HCl, dioxane, (ii) Ac2O, py, 0°C → rt; i) NH3(g), THF, 
MeOH, 0°C ; j) Cl3CCN, NaH, CH2Cl2, 0°C. 
 
Scheme 2.18: Synthetic pathway for TCA donor 33 via a series of ethylidene 
intermediates.  
 
First, D-mannose was fully acetylated under basic conditions to give 54. The anomeric 
acetate was replaced with a bromine, giving mannosyl bromide 55. Both of these steps 
were carried out in quantitative yields. The use of a 1,2-ethylidene protecting group on 
mannosides is relatively rare in the literature, with only Giordano and Iandonisi 112 
reporting the synthesis and characterisation of derivative 56 as a mixture of stereoisomers 
(5:1) in a 58% yield (Scheme 2.19).  
 
Scheme 2.19: Ethylidene formation as reported by Giordano and Iandonisi.112 
Mechanistically, the Lewis base NaBH4 may act as an effective hydride source, and is 
thought to attack the carbonyl carbon, resulting in the formation of a negatively charged 
oxygen species. This is then able to attack the anomeric carbon in an intramolecular 
nucleophilic substitution manner, resulting the in the formation of the desired ethylidene 
product (Scheme 2.20).  
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Scheme 2.20: Proposed reaction mechanism for the formation of the 
acetylated ethylidene intermediate 56.  
While Giordano and Iandonisi 112 chose to use mannosyl iodide 62 as the starting material, 
using mannosyl bromide 55 proved to be much more effective and resulted in a 94% yield 
of 56 as a 7:1 mixture of endo/exo isomers‡ (Scheme 2.18). 1H NMR and 13C NMR 
spectroscopy were used to confirm the formation of acetylated ethylidene acetal 56. For 
the major stereoisomer, the 1H NMR spectrum showed a quartet at 5.30 ppm, typical of 
the ethylidene acetal proton as well as a doublet that integrated for three protons at 1.54 
ppm attributed to the attached methyl group. Corresponding signals for the minor 
stereoisomer were also seen. The presence of three singlets between 2.00 and 2.15 ppm 
that each integrated to three protons confirmed that the three acetyl protecting groups at 
O-3, O-4, and O-6 had remained in place. Additionally, the 13C NMR spectrum had three 
resonances between 169 and 171 ppm, indicative of three carbonyl carbons of the three 
acetyl protecting groups. A signal at 104.9 ppm was assigned to the ethylidene acetal 
carbon while the anomeric carbon resonated slightly upfield at 96.7 ppm. These 
assignments were in agreement with those published by Giordano and Iandonisi.112 
Removal of the acetyl protecting groups, performed by either reaction with sodium 
methoxide or IRA-400 (OH-) basic exchange resin in methanol, resulted in the formation 
of triol 57 in quantitative yields. Spectroscopic data for deacetylated mannoside 57 were 
consistent with literature data.112-113 Next, selective protection of the primary alcohol 
using a tert-butyldimethylsilyl (TBS) protecting group gave the novel compound 58 in a 
92% yield.114-115 The 1H NMR spectrum collected for 58 showed a quartet at 5.30 ppm 
and a three-proton doublet at 1.47 ppm, confirming that the 1,2-ethylidene functionality 
remained intact. The anomeric proton resonated as a doublet at 5.23 ppm which showed 
a strong correlation to a double doublet at 4.16 ppm assigned to H-2. A nine-proton singlet 
was apparent at 0.90 ppm along with two three-proton singlets at 0.10 and 0.09 ppm, as 
 
‡Aribituary assignment of the major product as endo and the minor product as exo. No further studies 
were carried out to determine the true configuration of the major stereoisomer. 
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expected from the tert-butyl group and the two methyls of the TBS protecting group. The 
13C NMR spectrum was consistent with the structure of 58. Additional information from 
high resolution mass spectrometry (HRMS) supported the molecular formula as 
C14H28O6Si. Attachment of the TBS group to the primary hydroxyl was confirmed by 
spectroscopic data collected for compounds later in the synthetic pathway (see below). 
The next step was the benzylation of O-3 and O-4 using a Williamson ether synthesis. 
Reaction of 58 with benzyl bromide and sodium hydride in DMF gave novel dibenzyl 
ether 59 in a quantitative yield after purification (Scheme 2.21). Signals corresponding 
to the 1,2-ethylidene group were retained in the 1H NMR spectrum. Two overlapping AB 
proton splitting systems could be seen between 4.77 and 4.94 ppm along with a large 
multiplet in the aromatic region that integrated for ten protons, indicative of the addition 
of two benzyl protecting groups. 13C NMR data and HRMS also supported the conclusion 
that this reaction resulted in the successful addition of the benzyl groups.   
 
Scheme 2.21: Synthesis of 59 from 58. 
Both ethylidene and silyl protecting groups are acid sensitive, and given that, it should be 
possible to remove them in the same reaction.81 Unfortunately, treatment of 59 with HCl 
in dioxane gave a low yield (<20%) of the 1,2,6-triol 63 and purification proved to be 
difficult at this stage. Instead, a two-step deprotection was carried out. First, treatment 
with TBAF gave 32 in a 95% yield after purification. Subsequent reaction with HCl in 
dioxane gave triol 63, which upon acetylation of the crude reaction material under basic 
conditions, resulted in the formation of 60 as a mixture of anomers (7:1 α/β) in an 89% 
yield over the two steps (Scheme 2.22).  
50 
 
Scheme 2.22: Synthesis of 60 in 89% yield over two steps from 32. 
Triacetate 60 has also been reported in the literature by Ogawa et al.116, Verduyn et al.117, 
and Zhao et al.118, although alternative synthetic pathways were followed (Scheme 2.23). 
All three groups used a 1,2-orthoester intermediate as opposed to the 1,2-ethylidene 
utilized in this project. The ethylidene intermediate pathway used in the current work 
gave higher yields of 60 than those followed in the existing literature. Spectroscopic data 
collected for 60 were consistent with those presented by these groups.116, 118 The anomeric 
proton resonance for the major anomer of 60 was apparent at 6.07 ppm, while three, three-
proton singlets were present at 2.17, 2.09, and 2.06 ppm. HRMS confirmed the compound 






Reagents and conditions: (top) a) Ac2O, AcOH, H2SO4, -10°C. 
116-117 (bottom) DIPEA, TrCl, 
DMF; b) BnBr, NaH, DMF; c) Ac2O, AcOH, H2SO4.
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Scheme 2.23: Synthetic pathways published in the literature to achieve 
triacetylated mannoside 60. 
2.5 Synthesis of trichloroacetimidate donor 33 
In order to achieve TCA donor 33 (Scheme 2.18), the anomeric acetyl protecting group 
must be removed. Anomeric acetyl protecting groups are able to be removed selectively 
due to their proximity to the ring oxygen. There are a number of different ways to perform 
this reaction type, two of which stand out as particularly popular in the literature. The first 
involves the use of ammonia and was developed by Fiandor et al.119 in 1985. As shown 
in Scheme 2.24, Fiandor et al.119 experimented with a series of glycosides containing an 
anomeric ester protecting group and found that this group was easily removed in the 
presence of ammonia in methanol at 0°C.  
 
Scheme 2.24: Summary of studies removing anomeric ester protecting 
groups adapted from that published by Fiandor et al.119 
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Hydrazine acetate in DMF is another popular method for selective removal of the 
anomeric acetate in the literature. Greatrex et al.120 published the use of this method in 
2009, applied to 68 to give 69, outlined in Scheme 2.25.  
 
Scheme 2.25: Removal of the anomeric acetyl protecting group using 
hydrazine acetate and DMF by Greatrex et al.120 
Treatment of 60 at 0°C in a 7:3 THF/MeOH solvent system saturated with ammonia gave 
bis-acetylated glycoside 61 as a mixture of anomers (10:1 α/β) in a 95% yield (Scheme 
2.26). 1H NMR, 13C NMR, and HRMS data were consistent with the successful outcome 
of the reaction. The signal of the anomeric proton in the 1H NMR spectrum had shifted 
upfield from 6.07 ppm in 60 to 5.17 ppm in 61. Two three-proton singlets at 2.12 and 2.02 
ppm attributed to the major product remained. All data were in agreement with those 
published in the literature. 118, 121 
 
Scheme 2.26: Synthesis of trichloroacetimidate donor 33 from 60. 
Upon successful removal of the anomeric acetyl group, the trichloroacetimidate 
functionality was installed. As mentioned previously, a TCA leaving group is commonly 
put in place by reaction of an anomeric hydroxyl group with a base and 
trichloroacetonitrile. The choice of base dictates the stereochemistry of the product, with 
NaH giving predominantly the thermodynamic α-product and K2CO3 resulting in more 
of the kinetic β-product (Scheme 2.27).101-102  
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Scheme 2.27: Selective formation of trichloroacetimidates. 
Trichloroacetimidate donor 33, was consistently produced in quantitative or near 
quantitative yields using catalytic amounts of NaH.9 Ultimately, donor 33 was 
synthesized in a 68% yield over 11 steps from D-mannose. The crude material was 
deemed to be of sufficiently high purity without undergoing additional purification. The 
structure of TCA donor 33 was confirmed by analysis of NMR spectroscopic data which 
was in agreement to those published in the literature.118, 122 In the 1H NMR spectrum, two 
three-proton resonances between 2.20 and 2.04 ppm were attributed to the acetyl 
protecting groups at O-2 and O-6 (Figure 2.3). Two one-proton doublets at 4.92 and 4.75 
ppm with coupling constants of 10.7 Hz and 11.2 Hz were assigned to one benzylic proton 
from each of the benzyl groups while a two-proton doublet at 4.59 ppm (3JH-H = 11.0 Hz) 
was assigned to the remaining benzylic protons. The imidate proton was apparent as a 
deshielded singlet at 8.70 ppm.  
 
Figure 2.3: 400 MHz 1H NMR spectrum of 33 in CDCl3. 9.1 to 1.5 ppm shown. 
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2.6 Glycosylation reaction between donor 33 and acceptor 25 
With the successful synthesis of glycosyl donor 33, attachment of the linker was 
attempted following the experimental strategy presented by Al-Barwani and previously 
described (Scheme 2.6, p 39).9 Reaction of TCA donor 33 and methyl 6-
hydroxyhexanoate (25) promoted by TMSOTf at 0°C gave the target glycoside 70 as well 
as two other products; one arising from the loss of an acetyl protecting group the other 
hydrolysed TCA glycoside material. Efforts to overcome the side reactions included 
lowering the temperature from 0°C to -20°C (Scheme 2.28). This minimized the 
hydrolysis of the donor although the product related to the loss of an acetyl protecting 
group was still present. To increase the efficiency of the process, the crude product 
underwent methanolysis mediated by IRA-400 (OH-) exchange resin resulting in the 
formation of diol 14 in an 87% yield over the two steps. Acetylated glycoside 70 was 
isolated in low yields (<35%) a number of times in the initial stages of optimizing this 
reaction sequence.  
 
Scheme 2.28: Glycosylation between TCA donor and methyl 6-
hydroxyhexanoate to give 70, which was then deacetylated yielding 14. 
As an aside, a general labelling method is used for all of the atoms of the mannosides and 
branched trimannosides presented in this project (Figure 2.4). The anomeric carbon and 
proton of the central mannosyl fragment are given the label of C-1 and H-1. All 
assignments for the mannosyl residue connected through the (1→6)-α- glycosidic linkage 
are designated as “A” and those connected through the (1→2)-α- or (1→3)-α- linkage are 
designated “B”, when present. The linker, as it is an extension of the central mannosyl 
residue, will be labelled as shown. All other assignments follow the traditional 
conventions used for carbohydrates throughout the literature.  
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Figure 2.4: Outline of the numbering convention used for the branched 
trimannosides presented in the current research. 
Examination of the 1H NMR spectrum collected for 70 showed the successful attachment 
of the linker (Figure 2.5). In methyl 6-hydroxyhexanoate (25), the protons assigned as 
H-6 resonate as a two-proton triplet at 3.63 ppm. When the linker is attached at the 
anomeric position, as in 70, these two protons (H-7) become diastereotopic and are seen 
as two one-proton double triplets between 3.65 and 3.30 ppm. The isolated position of the 
more upfield H-7 double triplet makes it a good diagnostic tool for determining the 
presence of an attached linker. The H-11 protons are also distinct and appear as an isolated 
two-proton triplet at 2.30 ppm. The acetyl protecting groups remained in place and were 
present as two, three-proton singlets at 2.13 and 2.05 ppm. A large singlet at 3.64 ppm, 
integrating for three protons, was indicative of the methyl ester of the linker. The ring 
protons closest to the acetyl protecting groups, H-2 and H-6, appeared relatively 
downfield at 5.34, 4.33, and 4.29 ppm, respectively. One anomer was present in the 
purified reaction product, with the anomeric proton appearing as a doublet at 4.77 ppm. 
The assignment of the anomeric configuration was made based on the literature precedent 
of reactions of mannosyl donors with O-2 participating groups being α-selective.9, 82, 89, 
123 The 13C NMR spectrum further confirmed that a single anomer was formed, with the 
anomeric carbon resonating at 97.9 ppm. Three carbonyl carbon signals were apparent at 
174.1, 170.9, and 170.5 ppm, arising from the two acetyl protecting groups and the methyl 
ester of the linker. 
The deacetylated glycoside 14, in comparison, showed the resonances for H-2 and both 
H-6 shifting upfield to 4.02, 3.85, and 3.78 ppm (Figure 2.5). The two acetyl methyl 
singlets were replaced with one broad two-proton singlet at 2.20 ppm, assigned to the 
newly revealed hydroxyl groups at C-2 and C-6. The linker appeared unaffected, with the 
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double triplets from H-7 remaining in place as well as the three-proton singlet between 
3.68 and 3.60 ppm, assigned to the methyl ester present at the tail end of the linker. HRMS 
was used to further confirm the successful removal of the acetyl protecting groups by 
showing that the reaction product had the molecular formula C27H36O8. 
 
Figure 2.5: (top) 500 MHz 1H NMR spectrum of 70 in CDCl3; (bottom) 500 
MHz 1H NMR of 14 in CDCl3. 5.7 to 1.1 ppm shown. 
2.7 Synthesis of trichloroacetimidate donor 24 
The synthetic pathway used by Al-Barwani to form donor 24 was followed in the current 
work with minor alterations (Scheme 2.29). This reaction pathway has been used a 
number of times in the Larsen lab to achieve a glycosyl donor with a C-2 participating 
group. 9, 124-125 Peracetylated orthoester 71 was synthesized from D-mannose in three 
steps. The material was then deacetylated using either IRA-400 (OH-) exchange resin or 
sodium methoxide in methanol to give 72. Benzylation of the three hydroxyl groups gave 
orthoester 73 in an 86% yield over five steps. 73 was subsequently hydrolysed under 
acidic conditions to give mannopyranose 74 in a 91% yield. Orthoester glycosides 
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reliably open under acidic conditions to give an axial ester protecting group, a trait that 
was utilized in this synthesis.126-127 
 
Reagents and conditions: Ac2O, py, 0°C → rt; b) HBr in AcOH, CH2Cl2; c) collidine, TBAB, 
EtOH, CHCl3; d) IRA-400 (OH
-), MeOH/CH2Cl2; e) BnBr, NaH, DMF, 0°C → rt; f) 60% acetic 
acid(aq); g) Cl3CCN, NaH, CH2Cl2, 0°C. 
Scheme 2.29: Synthetic scheme followed for the formation of glycosyl donor 
24, synthesized in a 78% yield over seven steps.   
While there are a number of ways outlined in the literature that may be used to 
functionalise the anomeric hydroxyl as a trichloroacetimidate, the use of a catalytic 
amount of NaH proved to be the best option to achieve TCA donor 24 from 74 in a 
quantitative yield. The overall yield of TCA donor 24 was 78% over seven steps from D-
mannose. Various analytical tools were used to ascertain the purity and formation of 
donor 24 before it was used in the bis-glycosylation reaction. Examination of the 1H NMR 
spectrum (Figure 2.6) of 24 showed a distinctive downfield singlet at 8.68 ppm, 
characteristic of an imidate proton. Additionally, the resonances associated with the 
anomeric proton and H-2 at 6.30 ppm and 5.49 ppm respectively, were deshielded due to 
the electron withdrawing substituents at both these positions. The benzylic protons 
(PhCH2) appear as a series of overlapping AB splitting systems between 4.87 and 4.51 
ppm. Lastly, the acetyl group located at C-2 was confirmed due to the presence of a three-
proton singlet at 2.19 ppm. The 13C NMR spectrum notably contained two signals at about 
170.1 and 160.2 ppm, the former of which was from the acetyl carbonyl carbon and the 
latter could be attributed to the imidate carbon. The HRMS also supported the formation 




Figure 2.6: 400 MHz 1H NMR spectrum of 24 in CDCl3. 9.0 to 1.2 ppm shown. 
The related methyl orthoester was also synthesized a number of times following the same 
reaction pathway, although in step (c) ethanol was substituted with methanol. This 
alteration proved to be ideal as it eliminated the possibility for transesterification to occur 
between the orthoester and the solvent in step (d) and did not drastically affect the overall 












2.8 Bis-glycosylation reaction between donor 24 and acceptor 14 
Bis-glycosylations between mannosyl donors and acceptors can be found throughout the 
literature, often used to form 3,6-branched trimannosides.118, 123, 128-130 Reina et al.123 
explored bis-glycosylation reactions in a paper published in 2008, where the group 
synthesized both a 2,6-α-branched trimannoside and a related 3,6-α-branched 
trimannoside using a convergent synthetic strategy. The synthesis of the 3,6-branched 
trimannoside will be discussed in the next chapter.123 Reina et al.123 used thiophenyl donor 
75 and diol acceptor 76 to achieve 2,6-branched trimannoside 77 (Scheme 2.30).  
 
Scheme 2.30: Synthetic scheme followed by Reina et al.123 to form trimannoside 77. 
In the current work, bis-acceptor 14 was stirred over 4Å molecular sieves in freshly 
distilled toluene with 2.4 equivalents of TCA donor 24 at room temperature for 45 
minutes to ensure dryness. Initial bis-glycosylation reactions utilized the glycosylation 
conditions used by Al-Barwani. The reaction mixture was cooled to 0°C before the 
addition of a catalytic amount of TMSOTf. These attempts resulted in low yields (<35%) 
of 2,6-trimannoside product 78. Adjustment of the temperature from 0°C to -20°C 
allowed for more consistent glycosylation yields of about 65% after purification and 
decreased the amount of hydrolysed donor present in the crude reaction product (Scheme 
2.31).  
 
Scheme 2.31: Bis-glycosylation between TCA donor 24 and mannosyl 
acceptor 14 to give 78. 
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The 1H NMR spectrum recorded for 78 showed two, one-proton double doublets at 5.57 
and 5.41 ppm which were attributed to H-2 protons of mannosyl residues A and B, which 
were located downfield due to the deshielding effect of the acetyl groups (Figure 2.7). 
Two downfield anomeric proton signals at 5.09 and 4.93 ppm were also attributed to 
residues A and B, respectively. The anomeric resonance of the central mannosyl 
component, H-1, was more upfield as a doublet at 4.79 ppm while the associated H-2 
resonance was part of a 15 proton multiplet between 4.05 and 3.68 ppm. The two three-
proton singlets expected for the acetyl groups were close in chemical shift at 2.12 ppm. 
The continued presence of the linker was confirmed by the two one-proton double triplets 
at 3.55 and 3.24 ppm as well as the methyl ester singlet visible in the 5 proton mutliplet 
between 3.67 and 3.59 ppm.  
The 13C NMR spectrum showed three resonances in the region in which acetal carbons 
resonate (85 ppm – 110 ppm), indicative of three anomeric carbons. Three carbonyl 
carbon signals could be seen between 177 and 172 ppm, two from the acetyl protecting 
groups and one from the ester of the linker. HRMS further confirmed the product’s 







Figure 2.7: (top) 500 MHz 1H NMR spectrum of 2,6-branched trimannoside 
78 in CDCl3 (5.9 to 1.1 ppm shown). (bottom) 125 MHz 13C NMR spectrum 







In mannosides, 3J1,2 coupling constants retrieved from the 1H NMR spectrum are not 
sufficiently different between α- and β-anomers to be able to be used to confirm the 
anomeric stereochemistry (Figure 2.8).131 Instead, the 1JC-H coupling constant is used for 
this purpose. Investigations on the empirical relationship between the anomeric 
configuration and the 1JC-H coupling constant were carried out by Podlasek et al.,132 who 
found that α-configurations gave coupling constants of approximately 170 Hz while β-
configurations gave coupling constants of around 160 Hz.  
 
Figure 2.8: 1H NMR 3J1,2 coupling constants for α- and β-mannosides, 
showing that the difference between the two are low. The 3J1,2 coupling 
constants for α- and β-glucosides shown for comparison.131 
Proton-coupled 13C NMR is often used to determine the 1JC-H coupling constant, however 
it is also possible to retrieve this information from a coupled HSQC spectrum. The 
coupled HSQC experiment is a more time efficient method than acquiring coupled 13C 
NMR spectrum and was therefore the method of choice for this project. The 1JC-H value 
for the anomeric carbons present in the protected 2,6-branched trimannoside 78 were 174 
Hz, 170 Hz, and 173 Hz, all indicative of the α-configuration at each anomeric position 





Figure 2.9: Coupled HSQC spectrum of the anomeric region of 78 used to 
determine only the α-anomeric configuration was present.  
The synthetic design implemented to achieve bis-acceptor 14 was expected to give only 
one trimannoside product from the bis-glycosyation, in this case one with (1→2)-α and 
(1→6)-α glycosidic linkages. This glycosylation pattern was further confirmed by 
analysis of the 2D NMR spectroscopic data. The HMBC and HSQC spectra allowed for 
the assignment of the anomeric protons and their associated carbons. The methylene 
protons, H-7, of the linker group correlated strongly to a carbon resonance at 98.7 ppm, 
which was assigned as C-1. The HSQC spectrum showed a correlation between the signal 
for C-1 and the doublet at 4.79 ppm, assigned as H-1. Further, HMBC and HSQC 
correlations allowed for the assignment of the key resonances in the 1H NMR and the 13C 
NMR spectra (Figure 2.10). This analysis supported the connectivity of the product as a 
2,6-branched trimannoside. 
 




1JC-H = 174 Hz 
1JC-H = 170 Hz 
1JC-H = 173 Hz 
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Figure 2.10: HMBC correlations (purple) and HSQC correlations (orange) 
for the anomeric protons and carbons of 2,6-branched trimannoside 78. 
2.9 Functionalisation of the linker to achieve N-succinimidyl ester 79 
With the bis-glycosylation of 14 optimized to produce protected 2,6-trimannoside 78, 
focus shifted to the establishment of an amine-reactive ester at the tail-end of the linker. 
This was achieved in a similar fashion to that used by Al-Barwani for the synthesis of the 
related mono and dimannosides mentioned previously (Scheme 2.32).9  
 
Reagents and conditions: a) NaOMe, MeOH/CH2Cl2; b) NaOH, THF, 60°C; c) DCC, NHS, THF; 
d) Pd(OH)2/C, H2, THF. 
Scheme 2.32: Functionalisation of 28 to N-succinimidyl ester 82 as 
performed by Al-Barwani to achieve dimannoside 2. The same pathway was 
followed for the related monomannoside 1.9 
Al-Barwani deacetylated the mannosyl residues using methoxide in methanol, followed 
by hydrolysis of the methyl ester to give a carboxylic acid, which was then be able to be 
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coupled to N-hydroxysuccinimide (NHS), resulting in the formation of an N-succinimidyl 
ester.9 N,N’-dicyclohexylcarbodiimide (DCC) was used as the coupling agent and the 
general coupling mechanism can be found in Scheme 2.33.9 In these reaction types, urea 
byproducts are formed. N,N’-dicyclohexylurea (DCU), the urea byproduct from DCC 
coupling, is organic soluble and is often very difficult to remove from the intended 
product. Al-Barwani found that DCU co-eluded with her protected succinimidyl ester 
mannosides and could only get a purified sample after palladium catalyzed hydrogenation 
of the benzyl protecting groups.9  
 
Scheme 2.33: Coupling of a carboxylic acid to NHS using DCC. 
As the linker is well separated from the sugar region, the process followed by Al-Barwani 
should be able to be applied to corresponding 2,6-branched trimannoside 78. 9 Scheme 
2.34, below, outlines the synthetic route pursued in this project to produce the protected 
precursor trimannoside 79. 
 
Reagents and conditions: a) 2 M NaOH(aq), THF, 75°C; b) NHS, EDCI, CH2Cl2. 
Scheme 2.34: Synthetic pathway followed from protected 2,6-branched 
trimannoside 78 to achieve succinimidyl ester 79. 
Initially, both the acetyl protecting groups and the methyl ester were hydrolyzed with 
sodium hydroxide to give the carboxylic acid 83. Increasing the temperature from 60°C 
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to 75°C and increasing the time of the hydrolysis performed by Al-Barwani allowed for 
these deprotections to be carried out in one step.9 Ultimately, these changes gave 83 in a 
94% yield after purification by column chromatography. 1H NMR spectroscopy was 
sufficient in determining the success of the hydrolysis reaction, although 13C NMR and 
HRMS were collected as well and supported the conclusions drawn from the 1H NMR 
spectrum (Figure 2.11). The two three-proton singlets at 2.12 ppm in acetylated 
trimannoside 78 were no longer apparent. Additionally, the double doublets attributed to 
H-2 of mannosyl residues A and B shifted upfield into the large multiplet of ring protons, 
with only one in an isolated position at 3.98 ppm. The singlet assigned to the methyl ester 
that had been present in the five-proton multiplet from 3.67 to 3.59 ppm was also absent 
from the spectrum. 
Esterification of the trimannoside 83 with NHS was attempted using DCC a number of 
times, however, the reaction was low yielding. DCU was difficult to remove and appeared 
to interfere with the hydrogenolysis of the benzyl ethers required to achieve 2,6-branched 
trimannoside 3. Because of this, other coupling agents were considered. 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI), can be used as a replacement for DCC, and 
forms a water soluble urea byproduct, 1-ethyl-3-(3-dimethylaminopropyl)carbourea 
(EDCU).  
EDCI is often sold as the hydrochloride salt, and there were initial concerns surrounding 
an appropriate solvent system for EDCI.HCl and the protected trimannoside 83 starting 
material. A search of the literature found a publication by van den Berg et al.133 that gave 
a general procedure for the synthesis of succinimidyl esters from carboxylic acids using 
EDCI in dichloromethane. This procedure proved to be ideal for the reaction of 83 with 
NHS, resulting in the formation of the activated ester glycoside 79 in an 84% yield. No 
trace of EDCU contamination was evident in the spectroscopic data collected. 1H NMR 
spectroscopy was again the primary data used to confirm the successful synthesis of the 
succinimidyl trimannoside 79 (Figure 2.11). A broad singlet at 2.70 ppm integrating for 
four protons along with the H-11 triplet shifting from 2.29 ppm in 83 to 2.56 ppm 
confirmed the addition of the succinimidyl component. The 13C NMR spectrum showed 
an additional carbonyl carbon signal, arising from the two equivalent carbonyls of the 




Figure 2.11: (top) 500 MHz 1H NMR spectrum in CDCl3 of trimannoside 78. 
(middle) 500 MHz 1H NMR spectrum in CDCl3 of trimannoside 83. (bottom) 
500 MHz 1H NMR spectrum in CDCl3 of trimannoside 79. Region from 5.7 
to 1.1 ppm shown.  
2.10 Synthesis of 2,6-branched trimannoside 3 
The final step, palladium catalyzed hydrogenolysis of the benzyl ether protecting groups, 
presented a number of issues. Deprotected 2,6-branched trimannoside 3 was expected to 
be highly polar and therefore the solvent system for the hydrogenation must be polar 
enough for the partially protected intermediates and the product to remain dissolved. 
Looking to the literature, Al-Barwani used ethyl acetate as a solvent in the debenzylation 
step required for the monomannoside 1, with the NMR spectroscopic data for 1 collected 
in deuterated acetone.9 The hydrogenolysis required for the dimannoside 2 was carried 
out in tetrahydrofuran (THF) and spectroscopic data were collected in CD3OD. 9 Given 
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this information, the first solvent system trialed for the hydrogenolysis of 3 was 
MeOH/THF (1:1). Upon work-up, it was found that all benzyl groups had been removed, 
however methyl ester 84 was isolated instead of the desired succinimidyl ester 3 (Scheme 
2.35).  
 
Scheme 2.35: Nucleophilic attack of succinimidyl ester 3 observed following 
hydrogenolysis conditions (Pd/C, H2) with (a) MeOH and (b) CD3OD. 
Initially, these results were thought to be anomalies. Succinimidyl esters were chosen due 
to their stability in the presence of weak nucleophiles and their reactivity with amines. 
Furneaux and coworkers 128-129 had previously reported the formation of a series of 
mannosides and 3,6-trimannosides which were able to be coupled to NHS using DCC 
(Scheme 2.36). Their solvent systems in these reactions contained methanol. 128-129 This 
work suggested that products similar to 2,6-branched trimannoside 3 are stable under 
these conditions. 
 
Scheme 2.36: Furneaux and coworkers coupling of NHS to mannosides to 
achieve N-succinimidyl functionalities.128-129 
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Unfortunately, subsequent trials of the hydrogenolysis with various solvent systems and 
work-up conditions continued to show that when the succinimidyl ester 3 was exposed to 
methanol during the reaction or work up, the corresponding ester was formed by 
tranesterification (Scheme 2.35).  
Interestingly, Al-Barwani did not note reactivity between the succinimidyl ester and weak 
nucleophiles like methanol and was able to collect NMR data for dimannoside 2 in 
deuterated methanol.9, 128-129 At present, no reasonable explanations can be presented for 
why the nucleophilic attack was seen for 2,6-branched trimannoside 3 but not in the 
related publications. Presumably, the side reaction was catalyzed by acid or base, but no 
sources of these have been identified. 
Less nucleophilic alcohols, like ethanol, were considered as a replacement for methanol 
and proved to be the solution to the transesterification issue. Hydrogenolysis reactions 
taking place in 1:1 THF/EtOH with an EtOH work up showed no trace of the ethyl 
glycoside and gave 3 in a 98% yield after freeze drying (Scheme 2.37).  
 
Reagents and conditions: Pd/C, H2, EtOH/THF, work up in EtOH. 
Scheme 2.37: Conditions that resulted in the formation of deprotected 2,6-
branched trimannoside 3. 
The 1H NMR spectrum of 3, collected in DMSO-d6, showed a series of doublets and 
triplets between 4.90 and 4.30 ppm, attributed to the hydroxyl protons and the three 
anomeric protons. To confirm the assignment of the hydroxyl resonances, D2O was added 
to the NMR tube and the resonances caused by the hydroxyl groups disappeared, leaving 
only the anomeric signals in this region (Figure 2.12). HSQC and HMBC spectra were 
utilized in the assignments of the anomeric resonances. The N-succinimidyl ester was 
present in the 1H NMR as a broad four-proton singlet at 2.81 ppm. The H-11 two-proton 
triplet continued to be slightly deshielded at 2.67 ppm. No resonances were visible in the 
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aromatic region (between 6-8 ppm) and it was concluded that all benzyl ethers had 
undergone hydrogenolysis. There was also no evidence of benzylic protons, further 
supporting this conclusion. All linker resonances were present as upfield multiplets 
between 1.35 and 1.60 ppm. 
 
Figure 2.12: (top) 500 MHz 1H NMR spectrum in DMSO-d6. (bottom) 500 
MHz 1H NMR spectrum of the same sample following the addition of D2O. 
Region from 5.0 to 1.0 ppm shown 
The 13C NMR spectrum showed three anomeric resonances at 102.3, 99.4 and 98.2 ppm 
(Figure 2.13). Two carbonyl carbon signals, at 170.2 and 168.9 ppm, correlated to the 
linker carbonyl and the identical succinimidyl carbonyls respectively. All additional 
linker carbons and ring carbons were accounted for in the spectrum. No evidence of 
aromatic carbons could be seen. HRMS indicated that the compound formed was one 
with the molecular formula of C28H45NO20, further confirming the successful removal of 
all benzyl ethers and the retainment of the succinimidyl ester.  
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Figure 2.13: 125 MHz 13C NMR spectrum of 3 in DMSO-d6 (190 to 10 ppm 
shown). NMR has been edited to remove the solvent peak (35 ppm-42 ppm) 
for clarity. No other resonances were visible in this region. 
Ultimately, fully deprotected 2,6-branched trimannoside 3 was synthesized following the 




Reagents and conditions: a) Ac2O, py, 0°C → rt; b) HBr in AcOH, CH2Cl2; c) NaBH4, CH3CN; 
d) IRA-400 (OH-), MeOH/CH2Cl2; e) TBSCl, 4-DMAP, TEA, CH2Cl2; f) BnBr, NaH, DMF, 0°C 
→ rt; g) TBAF, THF; h) HCl, dioxane, i) Ac2O, py, 0°C → rt; j) NH3(g), THF, MeOH, 0°C ; k) 
Cl3CCN, NaH, CH2Cl2, 0°C; l) 25, TMSOTf, 4Å MS, tol, -20°C; m) IRA-400 (OH-), 
MeOH/CH2Cl2; n) 24, TMSOTf, 4Å MS, tol, -20°C → -10°C; o) 2 M NaOH(aq), THF, 75°C; p) 
NHS, EDCI, CH2Cl2; q) Pd/C, H2, EtOH/THF. 
 
Scheme 2.38: Ethylidene intermediate pathway used to synthesize 3 in a 27% 




The synthesis of (1→3)-α-(1→6)-α-branched 
trimannosides 5 and 6 
3.1 (1→3)-α-(1→6)-α-branched trimannosides 5 and 6 
Given the successful synthesis of 2,6-branched trimannoside 3, attention turned towards 
trimannosides with other glycosylation patterns. In the binding study carried out by  
Kéry et al.,66 discussed in full in Chapter 1, the 3,6-branched trimannoside moiety was 
identified as a ligand with high binding affinity to the human mannose receptor. Because 
of this, synthesis of a 3,6-branched trimannoside with an amine reactive ester at the 
reducing end was attempted (Figure 3.1). 
 
Figure 3.1: General structure of 3,6-branched trimannoside 86. 
3.1.1 Previous synthesis of 3,6-branched trimannoside 87 by Reina et al. 123 
Reina et al.,123 previously reported the synthesis of 3,6-branched trimannoside 87 as part 
of a study investigating the binding of various oligosaccharides to DC-SIGN (Figure 3.2). 
 
Figure 3.2: 3,6-branched trimannoside 87 as synthesized by Reina et al.123 
Analysis of their synthetic strategy suggested that modifications could be made to give a 
viable pathway towards a 3,6-branched trimannoside for conjugation to RHDV VLP. The 
key glycosylation reaction in the Reina synthesis was the bis-glycosylation between 
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thiophenyl donor 75 and bis-acceptor 88 giving trimannoside 89 in a 78% yield 
(Scheme 3.1).123 
 
Scheme 3.1: Bis-glycosylation reaction between 75 and 88 performed by 
Reina et al.123 to give 3,6-branched trimannoside 89. 
Removal of ester protecting groups (Ac and Lev) was carried out via methanolysis using 
NaOMe in methanol to give 90 (Scheme 3.2). Palladium catalyzed hydrogenolysis of the 
benzyl ether protecting groups with simultaneous reduction of the azide to an amino group 
gave deprotected 3,6-branched trimannoside 87.123 
 
Reagents and conditions: a) NaOMe, MeOH; b) Pd/C, H2, MeOH. 
Scheme 3.2: Deprotection of 89 to give 87 as published by Reina et al.123 
Amino groups can be easily extended upon reaction with cyclic anhydrides to give 
compounds with a terminal carboxylic acid group.134 This could then be coupled with 
NHS using EDCI to give an amine reactive ester (Scheme 3.3).  
 
Scheme 3.3: General reaction conditions to form succinimidyl esters from 
primary amines. 
75 
As discussed for the synthetic design of 2,6-branched trimannoside 3, a sufficiently 
protected trimannoside component would be ideal for the reactions required to achieve a 
linker with a terminal succinimidyl ester. Benzyl ether protecting groups are the obvious 
choice due to their successful use in the synthesis followed to achieve 2,6-branched 
trimannoside 3. The non-polar nature of these protecting groups would allow for normal-
phase column chromatography of all intermediates. 
3.2 Synthesis of glycosyl acceptor 91 
With an understanding of how an appropriate linker could be formed from a 2-azidoethyl 
derivative, it was decided to synthesize 3,6-branched trimannoside 6 following the 
procedures of Reina et al.123 to form bis-acceptor 91, with minor alterations (see  
Scheme 3.6, p 77). First, 2-azidoethyl mannose (94) was synthesized in an 86% yield 
over four steps from D-mannose (Scheme 3.4). Anomeric stereochemistry was assigned 
as α due to literature precedent.123, 135-136 All data collected on these compounds were 
consistent with those published in the literature. 135-136 
 
Reagents and conditions: a) Ac2O, py, 0°C → rt; b) HOCH2CH2Br, BF3OEt2, CH2Cl2; c) NaN3, 
DMF, 60°C; d) IRA-400 (OH-), MeOH/CH2Cl2. 
Scheme 3.4: Synthesis of 94 following literature procedures. 
The method described by Reina et al.123 was then followed to achieve mannoside 95 in a 
47% yield over 5 steps from 94 (Scheme 3.5). Data collected for each step were consistent 
with those reported.123 After protection of the primary hydroxyl group of 94 as a TBDPS 
ether, reaction with 2,2-dimethoxypropane gave isopropylidene 96. Benzylation of 96, 
acidic hydrolysis of the isopropylidene group, and dibutyltin oxide mediated alkylation 
of the equatorial hydroxyl group with PMBCl resulted in the formation of 95. The PMB 
group was evident from the 1H NMR spectrum of 95, which showed a three-proton singlet 
at 3.80 ppm due to the methoxyl group. The benzylic protons of the PMB group were 
apparent as a two-proton singlet at 4.63 ppm. The aromatic region also increased in 
integration from 15 protons to 19 protons. Furthermore, the 13C NMR spectrum showed 
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a distinct quaternary carbon signal at 159.6 ppm, attributed to the ipso-aromatic carbon 
substituted with the methoxyl group of the PMB.  
 
Reagents and conditions: a) TBDPSCl, imidazole (Im), DMF; b) (CH3)2C(OCH3)2, p-TSA, 
acetone; c) BnBr, NaH, DMF, 0°C → rt; d) TFA, CH2Cl2; e) (i) Bu2SnO, tol., Δ; (ii) PMBCl, 
Bu4NI, DMF, Δ. 
Scheme 3.5: Synthesis of 95 following the Reina et al.123 method.  
At this stage the synthesis diverged from that published by Reina et al.123 Instead of 
protecting the C-2 hydroxyl group with Lev, a benzyl ether would be more advantageous 
for the current work. The anomeric configuration of the azidoethyl group had been 
established from the earlier Fischer glycosylation making a participating group at O-2 
unnecessary. The benzylation of 95 to give 100 was achieved in a quantitative yield 
following a standard Williamson ether synthesis (Scheme 3.6). The 1H NMR spectrum 
for 100 showed two AB splitting systems between 4.89 and 4.55 ppm for the benzylic 
protons as well as a singlet at 4.58 ppm arising from the benzylic protons of the PMB 
group. A 24-proton multiplet between 7.75 and 6.82 ppm accounted for all the aromatic 
protons. All other resonances were consistent with 100. Following this, the silyl ether was 
cleaved using TBAF to give 101 in a quantitative yield (Scheme 3.6). The spectroscopic 
data reflected the successful removal of the TBDPS protecting group.  
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Scheme 3.6: Synthesis of 91 from 100. 
Next, the PMB ether was hydrolysed under acidic conditions using TFA at -20°C to give 
bis-acceptor 91 in a 69% yield after purification. Ultimately, 91 was synthesized in a 28% 
yield over 12 steps from D-mannose. Analysis of the spectroscopic data of 91 supported 
the protecting group pattern.  
The 1H NMR spectrum of 91 contained no signals that would indicate the presence of the 
PMB group (Figure 3.3). Two overlapping AB splitting systems were apparent between 
4.91 and 4.65 ppm as a result of the benzylic protons from two benzyl protecting groups. 
The aromatic region contained a ten-proton multiplet, further supporting the presence of 
two aromatic protecting groups. The anomeric proton resonance appeared as a doublet at 
4.89 ppm and H-3, more deshielded from the loss of an electron donating protecting 
group, was a distinct double doublet at 4.03 ppm. The azidoethyl linker resonances were 
present as well, with H-8 resonating as two one-proton double double doublets at 3.38 
and 3.31 ppm.  
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Figure 3.3: 500 MHz 1H NMR spectrum of 91 in CDCl3. Section from 7.5 
ppm to 3.1 ppm shown. 
The 13C NMR spectrum of 91 contained two ipso-aromatic carbon resonances at 138.4 
and 137.7 ppm from the benzyl ethers. C-1 resonated at 97.6 ppm and the signal assigned 
as C-8 was distinct at 50.5 ppm. Both the 13C and 1H NMR spectra were fully assigned 
with the aid of HSQC and HMBC data. Importantly, the HMBC spectrum showed 
correlations between the benzylic protons and carbons and the protons and carbons 
assigned to position 2 and position 4 of the mannoside ring (Figure 3.4). This information 
supported the positions of the benzyl ether protecting groups. 
 
Figure 3.4: Relevant HMBC correlations (purple) and HSQC correlations 
(orange) of bis-acceptor 91. 
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Infrared spectrometry (IR) was used to confirm the presence of the azido functionality, 
with a distinct strong band seen at 2101 cm-1.  
3.3 Bis-glycosylation reaction between donor 24 and acceptor 91  
Although the Reina et al.123 synthesis used thiophenyl mannosyl donor 75 for the bis-
glycosylation, the previous success with trichloroacetimidate donor 24 indicated that it 
could be an appropriate alternative. The bis-glycosylation between acceptor 91 and TCA 
24 was carried out under the same conditions as the previous bis-glycosylation in this 
work. 2.4 equivalents of donor and a catalytic amount of TMSOTf at -20°C proved to be 
the most successful reaction conditions, giving the intended 3,6-branched trimannoside 
102 in a 74% yield (Scheme 3.7).  
 
Scheme 3.7: Bis-glycosylation between acceptor 91 and TCA donor 24. 
A full suite of NMR spectra were collected for the purified bis-glycosylation product. 
Assignments of anomeric signals to corresponding mannosyl residues were made using 
the 2D spectra (Figure 3.5). The HMBC spectrum was used to determine that the 
glycosidic linkages were in fact (1→3) and (1→6). The anomeric proton resonating as a 
doublet at 4.80 ppm showed a strong correlation to the methylene carbon signal belonging 
to C-7 at 69.2 ppm. This carbon signal was also correlated to the distinct resonances of 
H-8. The anomeric proton and carbon of mannosyl residue A and B were assigned in the 
same fashion.  
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Figure 3.5: Select HMBC correlations (purple), HSQC correlations (orange), 
and COSY (teal) for the anomeric protons and carbons of 3,6-branched 
trimannoside 102. Truncated for clarity. 
The 1H NMR spectrum also showed two downfield double doublet resonances at 5.51 
and 5.45 ppm which were assigned as H-2 of mannosyl components B and A, respectively 
(Figure 3.6). Two three-proton singlets at 2.15 and 2.09 ppm were indicative of the acetyl 
protecting groups of mannosyl A and B. The azidoethyl linker protons continued to 
persist, with two one-proton double double doublets at 3.26 and 3.16 ppm.  
The 13C NMR spectrum further agreed that a trimannoside had been formed (Figure 3.6). 
Three carbon signals could be seen in the acetal region; C-1A at 98.0, C-1B at 99.8, and 
C-1 at 97.6 ppm. C-8 resonated in an isolated region of the spectrum at 50.4 ppm. Lastly, 
the two methyl carbons from the acetyl protecting groups were apparent at 21.3 and 21.1 
ppm, the related carbonyl resonances were seen at 170.5 and 170.3 ppm. HRMS showed 





Figure 3.6: (top) 500 MHz 1H NMR spectrum of 102 in CDCl3 (5.75 to 1.7 
ppm shown). (bottom) 125 MHz 13C NMR spectrum of 102 in CDCl3 (185 to 
10 ppm shown).  
Anomeric stereochemistry was assigned as α for all three glycosidic linkages. 1JC-H 
coupling constants for C-1B, C-1A, and C-1 were collected from the coupled HSQC 
spectrum and gave values of 173, 173, and 172 Hz, respectively. The IR spectrum showed 
the continued presence of the strong band at 2103 cm-1 arising from the azido 
functionality. 
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3.4 Linker expansion and functionalisation to achieve N-succinimidyl ester 
103 
Expansion of the linker to give a terminal succinimidyl ester was carried out over four 
steps (Scheme 3.8). 
 
Reagents and conditions: a) IRA-400 (OH-), MeOH/CH2Cl2; b) Me3P, THF, 0°C → rt, then 
NaOH; c) succinic anhydride, dioxane, 80°C; d) NHS, EDCI, CH2Cl2. 
Scheme 3.8: Extension of the linker handle to give succinimidyl ester 103. 
First, acetyl protecting groups were removed with IRA-400(OH-) exchange resin in 
methanol to give 104. Next, a Staudinger reduction was required to achieve a primary 
amine for reaction with a cyclic anhydride.  
Staudinger reductions using triphenylphosphine are highly reliable, however the 
byproduct, triphenylphosphine oxide, is often difficult to remove (Scheme 3.9).137 To 
avoid any issues with triphenylphosphine oxide contamination at this stage of the 
synthesis, other reducing agents had to be considered. Trimethylphosphine can be used 
in place of triphenylphosphine and is beneficial in that the byproduct, trimethylphosphine 




Scheme 3.9: Mechanism for Staudinger reduction of an azide to an amine 
using triphenyl and trimethylphosphine.137 
The reduction of 104 was performed using trimethylphosphine (Me3P) in THF and gave 
105. The success of the Staudinger, as well as the acetyl removal, was confirmed with 
HRMS with the molecular ion of each matching that expected for the sodiated products 
104 and 105 respectively. Carboxylic acid 106 was achieved upon reaction of the amine 
intermediate and succinic anhydride in a 51% yield over three steps from 102. Succinic 
anhydride was the cyclic anhydride of choice because it would extend the linker to be 
comparable to that of previously described 2,6-trimannoside 3.  
Spectroscopic data collected for carboxylic acid 106 were used to confirm the structure. 
The 1H NMR spectrum showed three one-proton doublets with 3J1,2 coupling constants of 
approximately 1.7 Hz at 5.34, 5.06, and 4.80 ppm which were assigned as the anomeric 
protons (Figure 3.7). No singlets were apparent in the region in which acetyl methyl 
protons resonate, confirming their removal in the previous step. Further, two two-proton 
multiplets could be seen upfield and were assigned to the newly added H-11 and H-12 of 
the linker.  
The 13C NMR spectrum showed two carbonyl carbon resonances at 174.8 and 172.7 ppm, 
expected from the expanded linker. Three anomeric carbon signals were visible between 
101.5 and 99.0 ppm. The isolated resonance of the carbon neighboring the azide, near 50 
ppm in previous compounds, had shifted to 39.3 ppm due the newly formed amide.  
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Figure 3.7: (top) 500 MHz 1H NMR of 106 in CDCl3 (6.0 to 2.2 ppm shown). 
(bottom) 125 MHz 13C NMR of 106 in CDCl3 (190 to 20 ppm shown).  
Carboxylic acid 106 was able to be coupled to NHS giving succinimidyl ester 103 in an 
88% yield following the procedures used for the 2,6-branched trimannoside NHS 








Reagents and conditions: NHS, EDCI, CH2Cl2. 
Scheme 3.10: Coupling of NHS to 3,6-branched trimannoside 106 using 
EDCI giving 103. 
One major difference was evident upon the comparison of the 1H NMR spectrum of 
carboxylic acid 106 to that of succinimidyl ester 103 (Figure 3.8). The spectrum of 103 
contained a broad four-proton singlet at 2.69 ppm which was absent in the 1H NMR 





Figure 3.8: (top) 500 MHz 1H NMR of 106 in CDCl3. (bottom) 500 MHz 1H 
NMR of 103 in CDCl3. Region between 5.7 and 2.0 ppm shown. 
The 13C NMR spectrum showed three carbonyl resonsances at 170.2, 169.2, and 168.3 
ppm, two from the linker and one from the equivalent carbonyls of the succinimidyl ester 
(Figure 3.9). Three anomeric carbon signals could be seen as expected. A carbon 
resonance at 25.6 ppm was assigned to the equivalent succinimidyl carbons.  
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Figure 3.9: 125 MHz 13CNMR spectrum in CDCl3 for 103 (185 to 7 ppm 
shown). Solvent peak between 77.6 and 76.4 ppm has been removed for 
clarity.  
More conclusive evidence of the presence of newly formed succinimidyl ester 103 was 
found in the HRMS. A peak of m/z 1487.6113 corresponded to a sodiated molecular ion 
was consistent with the molecular formula of 103 (C84H92O21N2). 
3.5 Attempted formation of deprotected 3,6-branched trimannoside 6 
Armed with the knowledge that methanol could cause problems with deprotected 
succinimidyl ester trimannoside 6, palladium catalyzed hydrogenolysis of the benzyl 
ethers of 103 was carried out using an EtOH/THF solvent system (Scheme 3.11).  
 
Scheme 3.11: Hydrogenolysis of 103 to afford the deprotected 3,6-trimannoside 6.  
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Unfortunately, the NMR data could not be used to confirm the success of this reaction. 
The 1H NMR spectrum of the reaction product, shown in Figure 3.10, clearly indicated 
that the product was impure. Although the 13C NMR spectrum initially appeared to have 
three signals for anomeric carbons, closer analysis indicated that other carbohydrate 
products were also present. Due to the nature of 6, purification of the reaction product 
could not be carried out. 
 
Figure 3.10: (top) 500 MHz 1H NMR spectrum of the reaction product for 
the hydogenolysis reaction preformed on 103. (bottom) 125 MHz 13C NMR 
spectrum for the reaction product. Section from 38.5 to 40 ppm (solvent peak) 
was removed for clarity. 
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The HRMS spectrum of the reaction product (Figure 3.11) showed an ion at m/z 
767.2314, consistent with the sodiated molecular ion of 6.  
 
 
Figure 3.11: Truncated HRMS spectrum (m/z 665 – 680 shown) of reaction 
product from the hydrogenolysis of 103. Molecular ions corresponding to 
107, 108, and 6 are labelled. 
Additional ions at m/z 670.2046 and m/z 698.2353 were evident of the presence of the 























Figure 3.12: Compound 107, the product of hydrolysis of 3,6-trimannoside 
6. 108 is the product of nucleophilic attack of the hydrogenolysis solvent. 
Ultimately, protected 3,6-trimannoside 103 was synthesized in an 8% yield over 17 steps, 
following the synthetic pathway outlined in Scheme 3.12. Because of the intensive 
process required to form 103, it was not feasible to repeat the synthesis to optimize 
reaction conditions for the hydrogenolysis reaction and the synthesis of deprotected 6 was 
deemed unsuccessful. A synthetic pathway with fewer steps would be ideal to raise the 
overall percentage yield and allow for the preparation of the target 3,6-trimannoside 









Reagents and conditions: a) Ac2O, py, 0°C → rt; b) HOCH2CH2Br, BF3OEt2, CH2Cl2; c) NaN3, 
DMF, 60°C; d) IRA-400(OH-), MeOH/CH2Cl2; e) TBDPSCl, Im, DMF; f) (CH3)2C(OCH3)2, p-
TSA, acetone; g) BnBr, NaH, DMF, 0°C → rt; h) TFA, CH2Cl2; i) (i) Bu2SnO, tol, Δ; (ii) PMBCl, 
Bu4NI, DMF, Δ; j) BnBr, NaH, DMF, 0°C → rt; k) TBAF, THF; l) TFA, CH2Cl2, -20°C; m) 24, 
TMSOTf, 4Å MS, tol, -20°C; n) IRA-400(OH-), MeOH/CH2Cl2; o) Me3P, THF, NaOH; p) 
succinic anhydride, dioxane, 80°C; q) NHS, EDCI, CH2Cl2; r) Pd/C, H2, EtOH/THF. 
Scheme 3.12: Reaction pathway followed to give protected 3,6-branched 
trimannoside 103. 
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3.6 Previous reported synthesis of (1→3)-α-(1→6)-α-branched trimannoside 
5 
Given the success of the methylhexanoate linker in the synthesis of 2,6-branched 
trimannoside 3, focus shifted towards the synthesis of 3,6-branched trimannoside 5 
(Figure 3.13). 3,6-Branched trimannoside 5 has been synthesized previously by 
Furneaux et al.129 in 2002, although Furneaux failed to report spectroscopic data for this 
compound.  
 
Figure 3.13: Target 3,6-branched trimannoside 5. 
Bernd et al.128 from the Ferneaux research group, first synthesized related 3,6-branched 
trimannoside 109 in 1999, using an 8-(methoxycarbonyl)octanol based linker (Scheme 
3.13). It is well known that the primary hydroxyl of α-mannosides is the most reactive, 
while the axial O-2 and the sterically hindered O-4 are the least reactive.128, 138 Bernd 
utilized the reactivity of hydroxyl functionalities to achieve trimannoside 109, as opposed 
to using protecting group chemistry to isolate the O-3 and O-6 positions for glycosylation. 
The bis-glycosylation was performed on the deprotected mannoside 110 using two 
equivalents of benzoyl protected trichloroacetimidate 111 and TMSOTf. 128  
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Reagents and conditions: a) 8-(methoxycarbonyl)octanol, TMSOTf, 4Å MS, CH2Cl2, rt; b) 
K2CO3, MeOH; c) 111, 4Å MS, TMSOTf, CH2Cl2, -40°C ® -18°C; d) py, Ac2O; e) K2CO3, 
MeOH; f) NaOH, THF/H2O, rt, 3 d; g) DCC, NHS, THF/CHCl3/MeOH. 
 
Scheme 3.13: Synthetic route to trimannoside 109 by Bernd et al.128  
Three years later, Furneaux et al.129 published the synthesis for two corresponding 3,6-α-
trimannosides; One with a four-carbon linker and the other with a six-carbon linker. The 
synthetic approach used to achieve the 6-carbon linker can be found in Scheme 3.14. 
Again, the bis-glycosylations were performed on deprotected mannosides and no 
biological studies were reported for either compound. 
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Reagents and conditions: a) 25, TMSOTf, 4Å MS, CH2Cl2, rt; b) K2CO3, MeOH; c) 111, 4Å MS, 
TMSOTf, CH2Cl2, -40°C ® -18°C; d) py, Ac2O; e) K2CO3, MeOH; f) NaOH, THF/H2O, rt, 3 d; 
g) DCC, NHS, THF/CHCl3/MeOH. 
 
Scheme 3.14: Synthesis of branched trimannoside 5 by Furaneaux et al.129 
There are a number of reasons to design an alternative synthesis towards 3,6-branched 
trimannoside 5. Furneaux et al.129 did not report data on the deprotected succinimidyl 
ester and used it immediately to couple to amines. In the current research, it is essential 
to obtain well characterised oligosaccharides for eventual use by the immunological 
collaborators of the Ward research group. Secondly, Furneaux performed the bis-
glycosylation on deprotected mannoside 118, and relied only on the reactivity differences 
between the hydroxyl groups to achieve the correct product.129 They noted that an 
inseparable tetrasaccharide was also produced from the bis-glycosylation and required 
acetylation of the reaction mixture in order to get a purified glycosylation product.129 This 
could be avoided by using protecting group chemistry to allow for only the O-3 and O-6 
to act as glycosyl acceptors. Lastly, the use of tetra-benzoylated donor 111 meant that 
Furneaux had to remove all protecting groups before being able to activate the linker as 
a succinimidyl ester. This gave Furneaux a series of very polar compounds to purify 
through a number of steps.129 It would be better if the protecting groups on the mannosyl 
residues could remain mostly in place throughout the activation of the linker, only to be 
removed at the last step.  
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3.7 Retrosynthetic analysis of 3,6-branched trimannoside 5 
A retrosynthetic analysis of trimannoside 5 is required to develop a synthetic approach, 
and can be found in Scheme 3.15. Protected 3,6-branched trimannoside 123 can be 
achieved through a bis-glycosylation of TCA donor 24 and acceptor 124. With the 
glycosyl donor already in hand, the primary focus was on the synthesis of glycosyl 
acceptor 124. This could be produced from thiomannoside 125 with the orthogonal 
protection pattern used previously in the synthesis of 3,6-trimannoside 103. 
 





3.8 Attempted synthesis of thiomannoside 125 
While the modified Reina approach ultimately failed to give deprotected 3,6-
trimannoside 6, the protecting group strategy was successful in forming an appropriate 
bis-acceptor, mannoside 91.123 This could be used to give other intermediates that may 
ultimately provide a 3,6-trimannoside with a linking group at the reducing end. One 
possibility would be to synthesize a glycosyl donor with this protecting group pattern to 
which a variety of linker groups could be attached. With this in mind, the synthesis of 
thiophenyl mannoside 125 was attempted (Scheme 3.16).  
 
Reagents and conditions: a) Ac2O, py, 0°C → rt; b) HSPh, BF3OEt2, CH2Cl2, 0°C → rt; c) IRA-
400 (OH-), MeOH, CH2Cl2; d) TBDPSCl, Im, DMF; e) 2,2’-dimethoxypropane, p-TSA, acetone; 
f) BnBr, NaH, DMF, 0°C → rt; g) TFA, CH2Cl2; h) Bu2SnO, tol, Δ, then PMBCl, Bu4NI, DMF, 
Δ; i) BzCl, py, 0°C → rt. 
Scheme 3.16: Synthetic pathway to achieve 125. 
Thiophenyl D-mannoside (127) was synthesized in a 94% yield over three steps from D-
mannose, following the reaction pathway outlined above in Scheme 3.16. 127 was then 
reacted with TBDPSCl and imidazole to give 128 in a 60% yield.139 The 2,3-acetonide 
was installed, and a benzyl protecting group was affixed at the 4-position, allowing the 
anomers to be separated by column chromatography, to give compound 130. The 1H 
NMR spectrum obtained for 130 showed a two-proton AB signal, indicative of a single 
set of benzylic protons. The aromatic region contained a series of multiplets integrating 
for a total of 20 protons; five from the thiophenyl, ten from the TBDPS protecting group, 
and an additional five from the benzyl protecting group. The acetonide was still apparent 
from the two, three-proton singlets at 1.57 and 1.42 ppm. The 13C NMR spectrum also 
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supported the conclusion that a single benzyl group was added and the rest of the 
protecting groups remained intact.  
Treatment of 130 with TFA gave 131 in a 62% yield over three steps from 128. The loss 
of the acetonide proton resonances was evident in both the 1H NMR and the 13C NMR 
spectra. HRMS showed a molecular ion with the formula C35H40O5SSiNa+, consistent 
with sodiated molecular ion of 131. 
While O-3 of 2-azidoethyl glycoside 99 (see Chapter 3, p 75) was able to be selectively 
protected with a PMB group, difficulties were encountered in the related reaction using 
thiophenyl glycoside 131. Reflux of 131 with dibutyltin oxide under Dean-Stark 
conditions followed by the addition of PMBCl, tetra-butylammonium iodide, and DMF 
was expected to give only 132. Instead, an inseparable 5:1 (approx.) mixture of 132 and 
133 was isolated (Scheme 3.17 and Figure 3.14).  
 
 
Reagents and conditions: Bu2SnO, tol, Δ, then PMBCl, Bu4NI, DMF, Δ. 





Figure 3.14: 1H NMR spectrum in CDCl3 from 7 to 5.5 ppm showing two 
PMB aromatics and the anomeric resonances for 132 and 133. 
This material was carried on through additional steps with the hope that there would be 
an opportunity for separation at a later stage (Scheme 3.18). Benzoylation of the mixture 
of 132 and 133 resulted in an inseparable mixture of 125 and 134. This was used in a 
NIS/TMSOTf promoted glycosylation reaction with methyl 6-hydroxyhexanoate (25), 
giving a mixture of four products: 135, 136, 137 and 138 with 136 and 138 arising from 
the loss of the para-methoxybenzyl group. A small portion of each of 132, 125, 135 and 
136 were able to be isolated and characterized.  
 
Reagents and conditions: a) BzCl, py, 0°C → rt; b) 25, NIS, TMSOTf, 4Å MS, CH2Cl2, -30°C. 
Scheme 3.18: TMSOTf promoted glycosylation of 125 and 134 with 25 gave 
a mixture of products. 
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Clearly, the lack of complete selectivity in the installation of the PMB ether made this 
approach unviable. However, silyl protecting groups could provide an alternative to the 
PMB ether. Bulky silyl chlorides would be expected to react preferentially with the more 
reactive C-3 hydroxyl group of 131 over that at C-2. Subseqent benzoylation of O-2 
followed by treatment with TBAF buffered with acetic acid could provide thiophenyl 
mannoside 139 (Scheme 3.19). 
 
Reagents and conditions: a) TBSCl, TEA, 4-DMAP, CH2Cl2; b) BzCl, py, 0°C → rt, c) AcOH, 
0°C → rt, TBAF, THF. 
Scheme 3.19: Proposed protecting group based synthesis towards an acceptor 
for the desired bis-glycosylation reaction. 
Two different methods were pursued to install a TBS protecting group at the 3-position 
of mannoside 131 (Scheme 3.20). First, 131 was reacted with TBSCl and 4-DMAP in 
dichloromethane under basic conditions. The 1H NMR spectrum collected for the crude 
material showed that no reaction had occurred. Similarly, reaction of 131 with TBSCl and 
imidazole in DMF was also unsuccessful. 
 
Reagents and conditions: (attempt 1) 4 eq. TEA, .15 eq. 4-DMAP, 1.05 eq TBSCl, anhyd. CH2Cl2, 
rt; (attempt 2) 1.1 eq Im, 1 eq TBSCl, rt, anhyd. CH2Cl2. 
Scheme 3.20: Unsuccessful attempts to selectively silylate O-3 of 131. 
With the TBS protection options explored and deemed unusable, this synthetic pathway 






3.9 Previous synthesis of 3,6-trimannoside 87 by Dowlut et al.140 
The synthesis of 3,6-branched trimannosides can be found throughout the literature, some 
of which were formed through bis-glycosylation reactions. 128-129, 140 A paper published 
by Dowlut et al.140 presented a very simple technique to achieve a mannoside platform 
with O-2 and O-4 protected and the anomeric position α-linked to a 2-azidoethyl group 
(Scheme 3.21).  Here, they formed two orthoesters in situ that were able to be opened 
under acidic conditions to give 142 with benzoyl protection on O-2 and O-4, leaving  
O-3 and O-6 available as hydroxyl groups. Dowlut et al.140 used a Koenigs-Knorr 
glycosylation method for their bis-glycosylation with mannosyl bromide donor 143 and 
silver triflate as a promoter.140  
 
Reagents and conditions: a) C6H5C(OCH2CH3)3, CSA, TFA, rt; b) AgOTf, CH2Cl2, 0°C; c) (i) 
NaOMe, MeOH, rt, (ii) H2/Pd, rt. 
 
Scheme 3.21: Synthetic strategy followed by Dowlut et al.140 to form 
branched trimannoside 87. 
Although the 2-azidoethyl group in trimannoside 144 could be useful in the current work, 
the earlier experience synthesizing 3,6-trimannoside 6 with a linker derived from this 
handle proved to be unsuccessful (see p 87). Instead, this protection pattern could be 
applied to achieve trimannoside 5 with a hexanoate linker.  
3.10 Synthesis of bis-acceptors 145 and 146 
There are two possible approaches to synthesize protected trimannoside 147 using the 
methodology outlined by Dowlut et al.140 (Scheme 3.22). First, glycosylation of 
mannoside 145, with the linker installed and benzoyl protection at O-2 and O-4, and TCA 
donor 24 could provide protected trimannoside 147. Alternatively, the thiophenyl 







































trimannoside 148. A NIS/TMSOTf promoted glycosylation could be carried out between 
148 and methyl 6-hydroxyhexanoate (25) to give the target 3,6-trimannoside 147. 
 
Reagents and conditions: a) 24, TMSOTf, 4Å MS, tol, -20°C;  b) 25, NIS, TMSOTf, CH2Cl2, -
40°C. 
Scheme 3.22: Proposed synthesis to achieve trimannoside 145 from 
mannoside 146 or 147. 
The first option pursued was that using the bis-acceptor with a preinstalled methyl ester 
linker. Di-benzoate 145 could be made by reaction of 118 using the experimental protocol 
outlined by Dowlut et al.140 (Scheme 3.23). An efficient synthesis to achieve mannoside 
118 from TCA 111 was previously provided by Furneaux et al.129 in their 2002 
publication of 3,6-branched trimannoside 5.  
 
Scheme 3.23: Mannoside 118 may provide a platform for the formation of 
dibenzoate 145. 
The synthesis of TCA 111 was effected using the pathway outlined in Scheme 3.24. First, 
D-mannose was globally benzoylated under standard basic conditions to give 44 which 
was then converted into 45. Mannosyl bromide 45 was hydrolysed with water and silver 
carbonate to give hemiacetal 149 in a 92% yield over three steps from D-mannose. Data 
collected for 149 matched those presented in the literature.141-142 Reaction of 149 with 
trichloroacetonitirile catalyzed by sodium hydride provided TCA 111 in a quantitative 
yield after purification. 
102 
 
Reagents and conditions: a) Ac2O, py, 0°C → rt; b) HBr in AcOH, CH2Cl2; c) Ag2CO3, H2O, 
acetone; d) Cl3CCN, NaH, CH2Cl2, 0°C. 
Scheme 3.24: Synthesis of 111 from D-mannose. 
TCA donor 111 was used in a TMSOTf promoted glycosylation reaction with methyl 6-
hydroxyhexanoate (25) following the procedure outlined by Furneaux et al.129 to give 117 
in a 76% yield (Scheme 3.25). Debenzoylation of 117 using NaOMe/MeOH gave 118 in 
an 89% yield. The spectroscopic data collected for 117 and 118 matched those published 
in the literature.129 
 
Scheme 3.25: Glycosylation reaction between donor 111 and methyl 6-
hydroxyhexanoate (25) followed by NaOMe catalyzed removal of ester 
protecting groups. 
Reaction of mannoside 118 with excess triethyl orthobenzoate under acidic conditions 
provided bis-orthoester 150, which was not isolated (Scheme 3.26). Treatment with 
aqueous TFA gave a 1:1 mixture of the two di-benzoates 145 and 151 which were 
separated by column chromatography, both in a 42% yield. This 1:1 ratio was consistent 
with literature results from similar di-orthoester reactions.140, 143 
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Reagents and conditions: a) p-TSA, TFA, C6H5C(OCH2CH3)3, MeCN, 15 min; b) 90% TFA(aq), 
MeCN, 10 min.  
Scheme 3.26: Formation of dibenzoylated 145 and 151 from 118. 
The structures of 145 and 151 were evident from the NMR data. A summary of key 
chemical shifts of each can be found in Figure 3.15, below.  
 
Figure 3.15: Chemical shifts and 3JH-H coupling constants of ring protons 
from the 1H NMR spectra of 145 and 151. 
The 1H NMR spectrum of 145 showed three of the mannoside ring protons with relatively 
downfield chemical shifts: H-4 as a triplet at 5.49 ppm, H-2 as a double doublet at 5.40 
ppm, and H-1 as a multiplet from 5.07 - 5.02 ppm (Figure 3.16). The other ring protons 
were apparent as more upfield signals. The distinct double triplet at 3.50 ppm from one 
H-7 along with the methoxyl three-proton singlet at 3.68 ppm signified that the linker was 
present. In comparison, the 1H NMR spectrum of 151 showed signals arising from H-1, 
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H-2 and both H-6 as more downfield while the remaining ring proton shifts were visible 
upfield. 
 
Figure 3.16: (top) 500 MHz 1H NMR spectrum of di-benzoate 145 in CDCl3. 
(bottom) 500 MHz 1H NMR spectrum of di-benzoate 151. Region between 
5.65 and 3.25 ppm shown. 
For the alternative pathway, thiophenyl di-benzoates 146 and 152 were prepared from 
127 in a similar manner to give a near 1:1 mixture in yields of 42% and 41%, respectively, 
after purification by column chromatography (Scheme 3.27).  
 
Reagents and conditions: a) p-TSA, TFA, C6H5C(OCH2CH3)3, MeCN, 15 min; b) 90% TFA(aq), 
MeCN, 10 min.  
Scheme 3.27: Formation of dibenzoylated 146 and 152 in a 1:1 ratio from 127. 
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The 1H NMR spectrum for 146 showed resonances associated with H-2 and H-4 as a one 
proton double doublet at 5.69 ppm and a one-proton triplet at 5.58 ppm, respectively 
(Figure 3.17). The other ring protons were seen as more upfield signals due to their lack 
of electron withdrawing protecting groups. For 152, the triplet from H-4 was more upfield 
than that of 146. Proton signals associated with H-6 were deshielded compared to those 
of 146 and were apparent as a one proton double doublet at 4.82 ppm and a one proton 
double double doublet at 4.59 ppm.  
 
Figure 3.17: Chemical shifts and 3JH-H coupling constants for 146 (left) and 
152 (right) from 1H NMR spectrum. 
As an aside, the di-othoester reaction was also performed on 2-azidoethyl mannoside 94, 
the same compound used by Dowlut et al.140 (Scheme 3.28). Literature precedent on this 
reaction reported that the two benzoate products, 142 and 154, were difficult to separate 
completely by column chromatography.140, 143 In a two solvent column system, the 
products co-eluded to some extent. However, in the current work, a three solvent system 
using an EtOAc/CH2Cl2/PE gradient allowed for complete separation, giving 142 in a 
50% yield and 154 in a 45% yield. Although not pursued in full, 142 presents an acceptor 
that could be used in a bis-glycosylation to achieve previously attempted 3,6-branched 
trimannoside 6. This pathway would allow for protected trimannoside 103 to be 
synthesized in fewer steps than the Reina synthetic pathway, and would allow for the final 





Reagents and conditions: a) p-TSA, TFA, C6H5C(OCH2CH3)3, MeCN, 15 min; b) 90% TFA(aq), 
MeCN, 10 min.  
Scheme 3.28: Di-orthoester formation to achieve 142 and 154. 
3.11 Bis-glycosylation between donor 24 and acceptor 145 
The bis-glycosylation reaction required to form protected 3,6-branched trimannoside 147 
was carried out using TCA donor 24, acceptor 145, and TMSOTf over 4Å molecular 
sieves in toluene (Scheme 3.29). The glycosylation was trialed at a range of different 
temperatures and it was found that -40°C to -20°C for three hours gave the best results. 
These attempts initially gave a mixture of 3,6-trimannoside 147 and dimannoside 156. 
The crude material was then resubjected to the glycosylation conditions as stated above 





Scheme 3.29: TMSOTf promoted bis-glycosylation reaction between TCA 
donor 24 and mannosyl acceptor 145 to give 3,6-trimannoside 147. 
The 1H NMR spectrum of 147 showed a distinct one-proton triplet at 5.73 ppm assigned 
to be H-4 of the central mannosyl residue (Figure 3.18). This signal was downfield due 
to the electron withdrawing effect of the attached benzoyl protecting group. Three 
anomeric protons were identified, H-1B and H-1 resonated at 5.04 and 4.86 ppm, 
respectively, while H-1A had the same chemical shift as H-2 and was part of a two-proton 
multiplet at 4.99 ppm. The linker was apparent, although H-7 double triplets were buried 
within multiplets. The two-proton triplet arising from H-11 was visible at 2.33 ppm. Two 
three-proton singlets at 2.10 and 1.91 ppm were indicative of the acetyl protecting groups 
from mannosyl residues A and B.  
Carbon resonances from the 13C NMR spectrum also corroborated with the conclusions 
drawn from the 1H NMR spectrum. Five carbonyl resonances were apparent at 174.1, 
170.3, 170.0, 165.9, and 165.5 ppm, arising from the linker, the two acetyl groups, and 
the two benzoyl protecting groups.  Three signals at 99.9, 98.0, and 97.3 ppm were 





Figure 3.18: (top) 1H NMR spectrum of 147 in CDCl3 (6.3 to 1.1 ppm 








The HMBC spectrum was used to substantiate the linkage pattern as (1→3) and (1→6) 
(Figure 3.19). The anomeric proton resonating as a doublet at 4.99 ppm showed a strong 
correlation to the methylene carbon resonance that had been assigned to C-7. The 
anomeric proton and carbon of mannosyl residue A and B were assigned in the same 
fashion, with H-1B corresponding to C-3 and H-1A showing a correlation to the methylene 
carbon C-6 of the central mannosyl unit.  
 
Figure 3.19: Select HMBC correlations (purple), HSQC correlations 
(orange), and COSY (teal) for the anomeric protons and carbons of 3,6-
branched trimannoside 147. 
The coupled HSQC spectrum for 147 showed that all glycosidic linkages were α with 1JC-
H values of 172, 173, and 176 Hz for C-1B, C-1A, and C-1.  
Thiophenyl di-benzoate 146 was also used in a bis-glycosylation reaction with TCA 
donor 24, however the reaction was low yielding and the intended trimannoside product 
was unable to be purified (Scheme 3.30). An NIS/TMSOTf promoted glycosylation 
reaction was attempted using the impure reaction product and methyl 6-
hydroxyhexanoate (25), however the resulting glycosylation product was also unable to 
be purified and this pathway was not pursued further.  
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Reagents and conditions: a) TMSOTf, 24, 4Å MS, tol, -40°C → -20°C; b) 25, NIS, TMSOTf, 4Å 
MS, CH2Cl2, -30°C. 
Scheme 3.30: Attempted synthesis of 147 from thiophenyl dibenzoate 146. 
3.12 Functionalisation of the linker to achiever N-succinimidyl ester 157 
As with the 2,6-branched trimannoside synthesis, the methyl ester of the linker must be 
converted into an amine-reactive ester for conjugation to the RHDV VLP. The main 
difference in the two syntheses is that while 2,6-trimannoside 78 had acetyl protecting 
groups, 3,6-trimannoside 147 has two benzoyl protecting groups and two acetyl 
protecting groups. Benzoyl groups are generally much more stable than their acetyl 
counterparts and may persist, in part, through the NaOH hydrolysis. Because of this, it 
was decided to remove these in a separate step from the hydrolysis of the methyl ester of 
the linker. 
147 was treated with one equivalent of NaOMe to catalyze methanolysis of the ester 
protecting groups. Upon purification, carboxylic acid 158 was isolated instead of the 
expected methyl ester 159 (Scheme 3.31). Due to the polarity of 159 and the amount of 
sodium salts present, the crude material was dry loaded onto the column for purification, 
and it is postulated that the presence of trace amounts of water in the silica caused the 
hydrolysis of the methyl ester. On repeated attempts under the same conditions, 





Scheme 3.31: Reaction of 147 with NaOMe in methanol reliably yielded 158 
over the expected product, 159. 
Comparison of the 1H NMR spectrum of 158 to that of 147 showed an upfield shift of all 
H-2 resonances and the distinct H-4 triplet at 5.73 ppm in 147 had shifted upfield as well 
(Figure 3.20). No methyl singlets were apparent, indicative of successful removal of the 
ester protecting groups. The strong singlet arising from the methoxyl protons that had 
been a part of the multiplet from 3.92 to 3.60 ppm in 147 was not present in 158.  
The 13C NMR spectrum showed three anomeric carbon resonances at 100.8, 100.5 and 
99.4 ppm. One carbonyl carbon resonated at 176.5 ppm, as expected for the newly formed 
carboxylic acid. The HRMS spectrum showed the major ion at m/z 1181.5080 of the 
purified reaction product, consistent with a formula of C66H78O18Na+ for the sodiated 
molecular ion of 158. 
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Figure 3.20: (top) 500 MHz 1H NMR 147 collected in CDCl3. (bottom) 500 
MHz 1H NMR 158 collected in CDCl3, a small amount of ethyl acetate 
(EtOAc) is present in the sample. 9.0 to 0.4 ppm shown. 
The reaction was repeated with K2CO3 instead of NaOMe and the linker methyl ester 
remained intact under these conditions, giving 159 in a 63% yield (Scheme 3.32). The 
serendipitous two-step in one reaction appeared to be much higher yielding and 






Scheme 3.32: Methanolysis of ester protecting groups of 147 using K2CO3 to 
give 159. 
Carboxylic acid 158 was then esterified with N-hydroxysuccinimide using EDCI as a 
coupling agent resulting in 157 in an 87% yield (Scheme 3.33).133 
 
Scheme 3.33: Synthesis of 157 from 158 using EDCI as a coupling agent. 
As with the other succinimidyl esters synthesized in the current work, a full suite of 
spectroscopic data was obtained. The 1H NMR spectrum of 157 displayed a broad four-
proton singlet at 2.75 ppm, arising from the succinimidyl-ester protons (Figure 3.21). 
The successful attachment was confirmed by the two-proton triplet from H-11 shifting 
downfield to 2.60 ppm in 157 from 2.32 ppm in 158. The 13C NMR spectrum showed two 
carbonyl carbon resonances at 170.0 and 168.7 ppm, one from the linker carbonyl and the 
other from the two equivalent carbonyls of the succinimidyl group. The other 
succinimidyl carbons were apparent as a single resonance at 29.0 ppm. Three anomeric 
resonances at 100.7, 100.6 and 99.5 ppm resulted from C-1B, C-1 and C-1A of 
trimannoside 157. Lastly, HRMS supported the formation of 157 with an ion at m/z 
1278.5217, consistent with C70H81O20NNa+. 
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Figure 3.21: (top) 500 MHz 1H NMR of 147 in CDCl3. (middle) 500 MHz 
1H NMR of 158 in CDCl3. (bottom) 500 MHz 1H NMR of 157 in CDCl3. 










3.13 Synthesis of 3,6-branched trimannoside 5 
Palladium catalyzed hydrogenolysis was used to remove the benzyl protecting groups of 
157 to achieve final 3,6-branched trimannoside 5 (Scheme 3.34).  
 
Scheme 3.34: Palladium catalyzed hydrogenolysis of 5 giving deprotected 
3,6-branched trimannoside 157. 
The 1H NMR spectrum collected for the hydrogenolysis product appeared to be a complex 
mixture of various products (Figure 3.22). Upon closer inspection, HSQC data were used 
to identify three anomeric protons visible at 4.83, 4.63, and 4.56 ppm, among a number 
of broadened signals attributed to the hydroxyl protons. Importantly, a broad, four-proton 
singlet was apparent at 2.81 ppm from the succinimidyl protons. The two-proton triplet 






Figure 3.22: 500 MHz 1H NMR spectrum of 5 in DMSO-d6. Region between 
5.5 and 1.1 ppm shown. 
A number of unexpected signals were apparent in the 1H NMR spectrum as well. A broad 
singlet could be seen at 2.55 ppm and a double triplet at 2.29 ppm. The broad singlet 
showed a correlation to a methylene carbon at 25.3 ppm in the HSQC spectrum (Figure 
3.23). The HMBC spectrum showed both the singlet and the double triplet correlating to 
an unidentified carbonyl carbon not assigned to 5 that only became apparent after freeze 
drying. This indicated that the succinimidyl ester was undergoing hydrolysis. 
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Figure 3.23: HSQC spectrum for 5. Methine resonances in red, methylene 
resonances in orange. 
The 13C NMR spectrum of 5 obtained immediately after workup showed the expected 
two carbonyl carbon resonances and three anomeric resonances (Figure 3.24). An 
additional 13C NMR spectrum was also collected for the material after freeze drying. 
Here, a third carbonyl resonance and additional anomeric carbon became significant, 




Figure 3.24: (top) 125 MHz 13C NMR spectrum of 5 in DMSO-d6 
immediately after formation. (bottom) 125 MHz 13C NMR spectrum of 5 in 
DMSO-d6 after freeze drying, Region from 165 to 110 ppm removed for 
clarity. 
A HRMS was obtained quickly after the reaction work up had been carried out and before 
the reaction product was put on the freeze dryer. This showed no molecular ion associated 
with any expected decomposition products (methyl ester, ethyl ester, or carboxylic acid). 
The major molecular ion was visible at m/z 738.2426, consistent with the sodiated 
molecular ion of 5.  
It was determined from the analysis of the spectra over time that 5 was the major product 
of the hydrogenolysis and that the decomposition visible by NMR occurred during or 
after freeze drying or upon solvation with NMR solvents. Ultimately, deprotected 3,6-
branched trimannoside 5 was synthesized in a 22% yield over eleven steps from D-
mannose, although a data set of the pure compound was unable to be obtained. The 




Reagents and conditions: a) BzCl, py, 0°C → rt; b) HBr in AcOH, CH2Cl2; c) Ag2CO3, H2O, 
acetone; d) Cl3CCN, NaH, 0°C; e) 25, TMSOTf, 4Å MS, CH2Cl2, 0°C; f) NaOMe, MeOH, 
CH2Cl2; g) (i) p-TSA, TFA, C6H5C(OCH2CH3)3, MeCN, (ii) 90% TFA(aq), MeCN; h) 24, 
TMSOTf, 4Å MS, tol, -40°C → -20°C; i) NaOMe, MeOH, CH2Cl2; j) NHS, EDCI, CH2Cl2; k) 
Pd/C, H2, EtOH/THF. 
Scheme 3.35: Efficient synthetic pathway followed to achieve deprotected 






Synthetic approaches towards blood group 
antigen derivatives  
4.1 Blood antigen derivatives 
With the synthesis of the trimannoside series near completion, it was time to move on to 
the blood group antigen derivatives such as 7, 8, 9, 10, 11, and 12 which were previously 
mentioned in Chapter 1 (Figure 4.1). For these compounds, it was decided the synthesis 
of only one linker type was required per saccharide component. The Lewis X moiety is 
known to have a high binding affinity to DC-SIGN and Lewis X derivative 11 was the 
first blood group antigen derivative to be considered in the current work. 
 
Figure 4.1: Proposed synthetic targets 7, 8, 9, 10, 11, and 12. 
4.1.1 Previous syntheses of Lewis X 
The synthesis of Lewis X, sialyl Lewis X, and their derivatives has received a great deal 
of attention throughout the literature (Figure 4.2).144-146 Sialyl Lewis X is often the target 
of synthetic studies due to its role in cellular adhesion.147-148 It has been identified as an 
ideal ligand for selectins, carbohydrate recognizing receptors that are found on the surface 
of endothelial cells. Sialyl Lewis X has also been identified as a tumor associated antigen 
in carcinoma cell lines.147-148 As related structures to sialyl Lewis X, Lewis X and 
protected variations of Lewis X are frequently isolated intermediates during the synthesis 
of sialyl Lewis X.144 
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Figure 4.2: Blood group antigens Lewis X and sialyl Lewis X. 
With the focus of the current work on Lewis X derivative 11, syntheses of related 
compounds were examined. The α-L-fucosyl linkage is known to be acid sensitive, and 
when designing a synthesis of Lewis X, the L-fucosyl residue is preferably installed in 
the later stages.149 In 2015, Munneke et al.145 published a paper outlining a highly 
convergent synthesis of Lewis X in a 38% overall yield (Scheme 4.1). The key step in 
their synthetic approach was the selective glycosylation of acceptor 160 and galactosyl 
donor 161. They found that if the reaction was carried out with stoichiometric amounts 
of donor 161 at -50°C, the NIS/TfOH promoted reaction gave only 162 in a 78% yield. 
This left the 3-hydroxyl group available to act as an acceptor in a glycosylation reaction 
with L-fucosyl donor 163 using copper(II) bromide promotion to give 164 in a 92% yield. 
Removal of protecting groups gave the target compound, Lewis X.145 
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Scheme 4.1: Glycosylation reactions performed by Munneke et al.145 in the 
convergent synthesis to achieve Lewis X. 
An alternative approach using a benzylidene protected D-N-acetyl glucosamine (GlcNAc) 
glycoside was reported by Pérez et al.146 for the synthesis of Lewis X derivative 165. The 
key step in this synthesis was the regioselective reduction of benzylidene acetal 166 to 
provide acceptor 167 (Scheme 4.2). This intermediate was taken forward to Lewis X 
derivative 165 by glycosylation of O-4 with galactosyl donor 168, subsequent removal of 
the PMB ether, and an additional glycosylation between 169 and L-fucosyl donor 170.146 
124 
 
Reagents and conditions: a) (i) NaOMe, MeOH, (ii) ZnCl, PhCHO; b) BaO, Ba(OH)2.8H2O, 
PMBBr, DMF; c) NaBH3CN, 3Å MS, THF; d) 168, AgOTf, 4Å MS, CH2Cl2; e) DDQ, 
CH2Cl2/H2O; f) 170, TEAB, CH2Cl2. 
Scheme 4.2: Synthesis of protected Lewis X derivative 165 from 171 as 
carried out by Perez et al.146  
4.2 Retrosynthetic approach to Lewis X derivative 11 
Lewis X derivative 11 can be broken down retrosynthetically to reveal a number of key 
glycosyl donors and acceptors (Scheme 4.3). A glycosylation between GlcNAc donor 
174 and methyl 6-hydroxyhexanoate (25) followed by a series of protection and 
deprotection steps could result in acceptor 175. A galactose derivative with a participating 
group at C-2, shown generically as 176, could be used as a glycosyl donor in a 
glycosylation reaction with 175. Selective removal of the O-3 protecting group would 
give 177 that could be fucosylated with commercially available donor 163. 
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4.3 Synthesis of glycosyl donor 174 
Formation of glycosyl chloride 174 from GlcNAc has been published a number of times 
in the literature.150-151 Treatment of GlcNAc with acetyl chloride gave the expected 
glycosyl chloride 174 as well as peracetate 178 (Scheme 4.4). Spectroscopic data 
collected for both 174 and 178 matched those presented in the literature.150-153  
 
Scheme 4.4: Reaction of GlcNAc with acetyl chloride to give 174 and 178. 
Anomeric stereochemistry for aldopyranosides with O-2 in the equatorial position can be 
assigned using 3J1,2 coupling constants retrieved from the 1H NMR spectrum. α-anomers 
are expected to have coupling constants of approximately 2-4 Hz while their β-
counterparts will have coupling constants of around 8 Hz.131-132 The 1H NMR spectrum 
for 174 showed a downfield one-proton doublet at 6.18 ppm (3J1,2 = 3.7 Hz) that was 
assigned as the α-anomeric proton. The amide proton could be seen as a doublet at 5.86 
ppm. Four, three-proton singlets, two of which were overlapping, were assigned to the 
methyl protons of the four acetyl protecting groups.  
4.4 Glycosylation reaction between donor 174 and acceptor 25 
174 could act as a viable donor in a Koenigs Knorr or Helferich-type glycosylation 
reaction with methyl 6-hydroxyhexanoate (25) with an appropriate metal salt promoter 
system (Scheme 4.5).  
 
Scheme 4.5: General glycosylation method to form 179. 
A publication by Amvam-Zollo and Sinaÿ 154 used 174 in a mercuric cyanide promoted 
Helferich glycosylation with 180 giving 181 containing a linker with a terminal methyl 
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ester (Scheme 4.6). Initial glycosylation reactions between 174 and 25 in the current 
research utilized the reaction conditions outlined by Amvam-Zollo and Sinaÿ.154 
 
Scheme 4.6: Mercury(II) promoted glycosylation reaction between 174 and 
180 to give 181 as reported by Amvam-Zollo and Sinaÿ.154 
The glycosylation was trialed with Hg(CN)2, Ag2CO3, and AgOTf  (Table 4.1). It was 
found that AgOTf was the best promoter for this particular reaction. By using two 
equivalents of  methyl 6-hydroxyhexanoate (25) the glycosylation gave 179 in a 97% 
yield (entry 6). 
Table 4.1: Summary of investigations into the metal salt promoted 
glycosylation reaction between 174 and 25. 








1 Hg(CN)2 1.7 1 1.2 19% 
2 Ag2CO3 1.7 1 1.2 30% 
3 Ag2CO3 1.7 1 1.2 27% 
4 AgOTf 1.3 1 1.2 52% 
5 AgOTf 1.3 1 1.2 36% 
6 AgOTf 1.1 1 2.0 97% 
 
NMR spectroscopy was used to determine that the glycosylation reaction was successful 
(Figure 4.3). The 1H NMR spectrum showed the anomeric proton as a doublet at 4.66 
ppm with a 3J1,2 value of 8.3 Hz, confirming that only the β-anomer was formed. The 
amide proton was visible as a double doublet downfield at 5.91 ppm. The successful 
attachment of the hexanoate linker was clear due to the characteristic one-proton double 
triplet at 3.45 ppm arising from one of the two H-7. H-11 were visible as a two-proton 
triplet at 2.27 ppm and the three-proton singlet at 3.63 ppm was assigned to the protons 
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of the methyl ester. Four three-proton singlets upfield between 2.04 and 1.90 ppm were 
attributed to the methyl protons of the four acetyl protecting groups. 
The 13C NMR spectrum supported the conclusions made from the 1H NMR spectrum. A 
single carbon resonance in the anomeric region at 100.8 ppm further indicated that only 
one anomer was formed. Five carbonyl carbon resonances could be seen downfield 
between 174.3 and 169.5 ppm, one from the linker and four from the acetyl protecting 
groups. The signal at 51.6 ppm was assigned to the methyl carbon of the methyl ester and 
the one at 33.9 ppm was assigned to C-11 of the linker. Four methyl carbon resonances 
were also visible, three from the O-linked acetyl groups and one from the N-linked acetyl 
group. HRMS showed a molecular ion at m/z 498.1946, corresponding to the sodiated 





Figure 4.3: 500 MHz 1H NMR (6.3 to 1.1 ppm) and 125 MHz 13C NMR (195 









4.5 Synthesis of acceptor 182 
The O-acetyl ester protecting groups of 179 were removed using IRA-400 basic 
exchange resin in methanol giving 183 in a 93% yield (Scheme 4.7).  
 
Scheme 4.7: Methanolysis of 179 using IRA-400 (OH-) exchange resin to give 183. 
The 1H NMR spectrum of 183 showed no trace of the O-acetyl protecting groups, 
although one methyl singlet remained at 2.04 ppm, attributed to the remaining N-acetyl 
group. The linker resonances remained, and the presence of the methoxyl three-proton 
singlet assured that the methyl ester was intact. The 13C NMR spectrum and HRMS data 
were in agreement with the conclusion that this reaction was successful. 
Triol 183 was then reacted with benzaldehyde dimethyl acetal in DMF under acidic 
conditions at 70°C, following a procedure described by Emmerson et al.,155 to give 182 
in an 80% yield after purification (Scheme 4.8).  
 
Scheme 4.8: Reaction of 183 to form benzylidene 182. 
NMR spectroscopic data showed that O-4 and O-6 had been successfully protected with 
a benzylidene group (Figure 4.4). The 1H NMR spectrum showed the benzylidene proton 
as a one-proton singlet at 5.54 ppm. Two multiplets were visible in the aromatic region, 
integrating for a total of five protons from the phenyl of the newly added protecting group. 
The amide proton was apparent as a one-proton doublet at 6.03 ppm while the anomeric 
proton appeared as a doublet at 4.70 ppm (3J1,2 = 8.3 Hz). Linker proton resonances were 
present including the three-proton singlet from the methyl ester at 3.67 ppm. The 13C 
NMR spectrum showed one ipso-carbon resonance at 137.2 ppm consistent with one 
phenyl group. Two carbon signals were visible in the acetal region, one at 102.0 ppm due 
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to the benzylidene carbon the other at 100.8 ppm arising from the anomeric carbon. 
HRMS found an ion with m/z 460.1942, consistent with the [M+Na+] for a compound 
with a molecular formula of C22H31O8N. 
 
Figure 4.4: (top) 500 MHz 1H NMR spectrum of 182 in CDCl3 (8.0 to 0.5 
ppm shown). (bottom) 125 MHz 13C NMR spectrum of 182 in CDCl3, solvent 






4.6 Glycosylation reaction between donor 163 and acceptor 182 
The successful synthesis of 182 provided an acceptor that could be used to trial a 
glycosylation with commercially available L-fucosyl donor 163. Further, the 
comprehensive binding study by Holla et al.,70 discussed previously in Chapter 1, 
indicated that carbohydrates containing fucosylated GlcNAc residues demonstrate a 
binding affinity to DC-SIGN. 
Munneke et al.145 successfully glycosylated acceptor 162 with thiophenyl fucoside 163 
(Scheme 4.1, p 123). Additionally, Zierke et al.156 carried out a similar glycosylation 
between thiophenyl fucoside 163 and acceptor, 184, giving 185 in a 77% yield  
(Scheme 4.9). 
 
Scheme 4.9: Formation of disaccharide 185 via a copper(II) bromide 
promoted glycosylation reaction between 184 and 163, as described by 
Zierke et al. 156 
The glycosylation reaction between 182 and 163 was carried out using TBAB and 
copper(II) bromide following the procedure of the latter group which resulted in the 
formation of 186 in an 81% yield after purification by column chromatography  
(Scheme 4.10).156  
 
Scheme 4.10: Glycosylation reaction between acceptor 182 and donor 163. 
Resonances from the 1H NMR and 13C NMR spectra were assigned with the help of 2D 




Figure 4.5: Selected HMBC correlations (purple) and HSQC correlations 
(orange) of protected disaccharide 186.  
The 1H NMR spectrum indicated the presence of the benzylidene protecting group with 
a one-proton singlet at 5.49 ppm (Figure 4.6). The anomeric proton of the L-fucosyl 
residue was visible as a doublet at 5.06 ppm, and was assigned α-stereochemistry due to 
the 3J1,2 constant (J= 3.7 Hz). The anomeric proton resonance from the GlcNAc residue 
was part of a three-proton multiplet between 4.93 and 4.87 ppm, along with two benzylic 
proton resonances. The remaining four benzylic protons were seen as a series of 
overlapping AB systems between 4.74 and 4.58 ppm. Ring protons of both saccharide 
components were assigned using 2D NMR spectra. The hexanoate linker appeared to be 
intact, with the two H-7 double triplets at 3.88 and 3.45 ppm and the methyl ester protons 
as a singlet at 3.66 ppm. 
The 13C NMR spectrum revealed two carbon resonances in the carbonyl region; with the 
one at 174.3 ppm arising from the ester and the one at 170.6 ppm from the amide. Four 
ipso-carbon signals slightly downfield from the aromatic region between 138.9 and 137.5 
ppm accounted for the benzylidene group and the three benzyl ethers from the L-fucosyl 
residue. Three resonances were visible in the anomeric region at 101.7, 100.9, and 98.3 
ppm and were assigned to the benzylidene acetal carbon and C-1 of the GlcNAc and L-
fucosyl residues respectively. The upfield carbon signal at 16.4 ppm was assigned to the 
C-5 methyl of the L-fucosyl component.  
HRMS suggested that the molecular ion present was due to a compound with the 
molecular formula of C49H59O12N, consistent with the expected glycosylation reaction 
product.   
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Figure 4.6: (top) 500 MHz 1H NMR spectrum of 186 in CDCl3 (6.1 to 0.4 
ppm shown). (bottom) 100 MHz 13C NMR spectrum of 186 in CDCl3. Region 









4.7 Functionalisation of the linker to achieve N-succinimidyl ester 187 
The Holla et al.70 binding study of DC-SIGN indicated that fucosylated GlcNAc residues 
may have some binding affinity to the receptor, and due to this, it was decided to carry 
on the synthesis of deprotected Lewis X derivative 188 (Scheme 4.11). This reaction 
series could be applied to the latter steps of the Lewis X derivative 11 synthesis and would 
allow for each step to be optimised before being attempted on intermediates to give 11.  
 
Scheme 4.11: Lewis X derivative 188 could be synthesised via protected 
disaccharide 186. 
To achieve Lewis X derivative 188 from protected disaccharide 186, the linker must be 
activated as an N-succinimidyl ester (Scheme 4.12). 
 
Reagents and conditions: a) 2 M NaOH(aq), THF, 70°C; b) NHS, EDCI, CH2Cl2. 
Scheme 4.12: Functionalisation of the linker of 186 to give succinimidyl ester 
187. 
Following the linker activation method previously optimized in the synthesis of 2,6-
trimannoside 5, disaccharide 186 was hydrolysed using aqueous sodium hydroxide and 
THF at 70°C. The resulting crude material was examined using 1H NMR and mass 
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spectroscopy, the latter of which showed a sodiated molecular ion of m/z 862.3787, 
supporting the success of the reaction.  
Carboxylic acid 189 was coupled with NHS using EDCI to give 187 in an 80% yield over 
two steps after purification by column chromatography. The 1H NMR spectrum showed 
a broad, four-proton singlet at 2.75 ppm, arising from the newly added succinimidyl 
protons (Figure 4.7). The successful synthesis of 187 was apparent from the two-proton 
H-11 triplet at 2.60 ppm, downfield from that at 2.29 ppm in the 1H NMR spectrum of 
methyl ester 186. All other proton resonances were assigned using 2D NMR spectra.  
 
Figure 4.7: (top) 500 MHz 1H NMR spectrum of 186 in CDCl3. (bottom) 400 
MHz 1H NMR spectrum of 187 in CDCl3. Region from 6.1 to 0.2 ppm shown. 
The 13C NMR spectrum contained three carbonyl carbon resonances at 170.7, 169.4, and 
168.7 ppm assigned to the amide, the equivalent succinimidyl carbonyls, and the linker 
ester respectively (Figure 4.8). Three acetal carbon resonances were also observed, 
assigned to the benzylidene carbon and the two anomeric carbons. The equivalent 
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succinimidyl carbons could be seen as a resonance at 25.7 ppm. The HRMS spectrum 
identified a molecular ion at m/z 959.3937, consistent with the sodiated molecular ion of 
succinimidyl ester 187. 
 
Figure 4.8: 100 MHz 13C NMR spectrum of 187 in CDCl3. Region from 185 












4.8 Synthesis of Lewis X derivative 188 
As with the trimannoside series, the benzyl ether protecting groups of 187 were removed 
using palladium catalyzed hydrogenolysis following the procedure previously described 
for the other deprotected final oligosaccharides in the current work (Scheme 4.13). 
Toluene is the byproduct of hydrogenolysis of benzyl ethers and benzylidene acetals, and 
as such, this reaction type is known to give clean reaction products with little need for 
further purification. Filtration of the reaction mixture containing 188 to remove the 
catalyst gave a quantitative recovery of material after evaporation of the solvent.  
 
 
Scheme 4.13: Palladium catalyzed hydrogenolysis of 187 to give 188. The 
hydrolysis of 188 to give 190 and NHS is also included. 
The 1H NMR spectrum of 188 obtained after freeze drying showed some degradation 
compared to that collected immediately after synthesis (Figure 4.9). The evidence of this 
deterioration lies in the appearance of a singlet at 2.55 ppm and a multiplet at 2.29 ppm. 
This broad singlet is believed to arise from N-hydroxysuccinimide as it showed a strong 
correlation to carbon signals in the 2D NMR spectra that match those of NHS. This was 
likely the result of a small amount of hydrolysis of the succinimidyl ester to give 190. 
The multiplet is thought to arise from H-11 of hydrolysed disaccharide material 190.  
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Figure 4.9: (top) 1H NMR spectrum for 188, immediately after synthesis and 
work up. (bottom) 1H NMR spectrum for 188 after freeze drying. Both in 
DMSO-d6, 8.5 to 0.4 ppm shown. 
The 13C NMR spectrum obtained after freeze drying showed a carbonyl carbon resonance 
at 173.0 ppm belonging to NHS (Figure 4.10). Additionally, a signal was seen at 25.1 
ppm and was shown to correlate to the methylene proton resonance at 2.55 ppm on the 
HSQC spectrum. All other carbon resonances that were apparent were found to be 




Figure 4.10: 13C NMR spectrum for 188 after freeze drying. 180 to 10 ppm 













The HRMS showed an ion at m/z 601.2231, consistent with the sodiated molecular ion of 
188 (Figure 4.11). There was also an ion present at m/z 504.2041, which was determined 
to be from the sodiated molecular ion of carboxylic acid decomposition product 190.  
 
Figure 4.11: Truncated HRMS spectrum of the hydrogenolysis reaction 
product after freeze-drying, from m/z 500 to 610. Sodiated molecular ions of 
190 and 188 are labelled. 
This information supported the conclusions drawn from the trimannoside series that the 
succinimidyl esters are susceptible to hydrolysis and that deprotected succinimidyl esters 
should be used immediately after their preparation, as storage leads to deterioration.  
Although there were signs of deterioration of 188 after freeze drying, it can be said that 
188 was synthesized in eight steps from GlcNAc in a 22% yield overall. The reaction 

















Reagents and conditions: a) AcCl; b) 25, AgOTf, 4Å MS, CH2Cl2, 0°C → rt; c) IRA-400 (OH-), 
MeOH, CH2Cl2; d) PhCH(OMe)2, p-TSA, DMF, 70°C; e) 163, CuBr2, TBAB, 4Å MS, CH2Cl2, 
DMF; f) 2 M NaOH(aq), THF, 70°C; g) NHS, EDCI, CH2Cl2; h) Pd/C, H2, EtOH/THF. 
Scheme 4.14: Synthetic pathway followed to give disaccharide 188 in eight 
steps from GlcNAc. 
First, glycosyl chloride 174 was obtained in a 48% yield from the reaction of GlcNAc 
with acetyl chloride. A Koenigs Knorr glycosylation was performed on 174 with AgOTf 
as a promoter and methyl 6-hydroxyhexanoate (25) as an acceptor giving 179 in a 97% 
yield. IRA-400 (OH-) mediated methanolysis of 179 gave triol 183 in a 93% yield. 183 
was converted into 4,6-benzylidene 182 in an 80% yield, leaving O-3 available to act as 
a glycosyl acceptor. A copper(II) bromide promoted glycosylation reaction was 
performed between acceptor 182 and L-fucosyl donor 163 giving protected disaccharide 
186 in an 81% yield. The methyl ester of the linker was hydrolysed and coupled with 
NHS resulting in the formation of succinimidyl ester 187 in an 80% yield over two steps. 
Lastly, palladium catalyzed hydrogenolysis of 187 gave the Lewis X derivative 188 in a 





4.9 Progress towards Lewis X derivative 11 
As previously mentioned, the (1→3) glycosidic linkage between the L-fucosyl residue 
and the GlcNAc residue is known to be acid labile, due to the electron donating methyl 
group at C-5 of the fucosyl component. Hendel et al.149 demonstrated this when they 
attempted the BF3OEt2 mediated glycosylation of 191 and 192 and found the resulting 
reaction product contained a significant portion of fucose derivative 193 (Scheme 4.15). 
 
Scheme 4.15: Reaction of 191 with 192 and BF3OEt2 gave 194 and 
hydrolysed fucoside 193 reported by Hendel et al.149  
With this evidence, it is likely that the conditions required to selectively reduce the 
benzylidene group and affix the D-galactosyl residue could cause hydrolysis of the 
fucosyl residue from the D-GlcNAc moiety. Therefore, glycosylation with thiophenyl 
fucoside 163 should be the last glycosylation reaction preformed in the synthesis of Lewis 
X derivative 11. 
4.10 Synthesis of glycosyl acceptor 195 
To synthesize an appropriate glycosyl acceptor necessary to install the galactose residue 
first, O-3 of 182 must be protected. The protecting group would have to be orthogonal to 
a benzyl ether group and stable enough to survive the regioselective reduction of the 
benzylidene acetal. Two candidates that are commonly used in the Larsen group are allyl 
and PMB ethers. The latter is known to be acid sensitive and so was discounted. Allyl 
ethers are easily formed in high yields, stable in a wide range of reaction conditions, and 
are able to be selectively removed by palladium(0) or iridium(I) isomerization to a vinyl 




Scheme 4.16: Conditions commonly used to achieve and remove an allyl 
ether. 
Iridium(I) isomerization is the common method in the Larsen group used to remove allyl 
ethers and will likely be the method applied in the current work. Ainge et al.,125 
demonstrated the selectivity of the iridium isomerisation in the synthesis of PIM6 
(Scheme 4.17). The highly benzylated material, 196, was isolated in a 91% yield and 
showed no disturbance of the benzyl groups from the reaction. 
 
Reagents and conditions: a) (1,5-Cyclooctadiene)bis- (methyldiphenyl-phosphine)iridium(I) 
hexafluorophosphate, H2, THF, then AcCl, CH2Cl2/MeOH. 
Scheme 4.17: Selective iridium catalyzed isomerisation of 197, published by 
Ainge et al.125 
The allylation of 182 is shown in Scheme 4.18. The first attempt gave the desired allyl 
ether 198 in a 65% yield along with allyl ester 199 (7%). Presumably, the presence of 
trace amounts of water was resulting in the formation of some allyl alcohol which was 
then undergoing a transesterification reaction with the methyl ester. To overcome this, 
the workup procedure was modified. After TLC indicated the reaction was complete, a 
small amount of sodium hydride followed by methanol was added to effect a 
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transesterification of any allyl ester 199 with methoxide. This proved successful, giving 
allyl ether 198 in an 89% yield after column chromatography. 
 
Scheme 4.18: Allyl protection of 183. 
The spectroscopic data confirmed the structure of 198 with the 1H NMR spectrum 
showing signals typical of an allyl ether (Figure 4.12 and Figure 4.13). All other signals 
in the 1H NMR spectrum and also those in the 13C NMR spectrum were consistent with 
the structure of the product 198.  
 
Figure 4.12: Chemical shifts of allyl protons for 198. Truncated for clarity. 
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Figure 4.13: (top) 500 MHz 1H NMR spectrum of 198 in CDCl3 (6.1 to 1.1 
ppm). (bottom) 125 MHz 13C NMR spectrum of 198 in CDCl3 (190 to 12 
ppm). 
With O-3 orthogonally protected, investigations into the regioselective reduction of the 
benzylidene acetal were carried out. Benzylidene acetal protecting groups are commonly 
used for selective protection of O-4 and O-6 of aldohexoses and can be partially reduced 
to reveal a free hydroxyl group at either C-4 or C-6 depending on the reaction conditions 
used. 
A publication by Ghosh et al.158 in 2000 demonstrated the versatility of this regioselective 
reduction (Scheme 4.19). They found that BH3.NMe3 and Me2BBr at -78°C selectively 
gave 4-O-benzyl glycoside 200 from 201. LiAlH4 and AlCl3 at reflux resulted in the 
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formation of 202, although the reaction was low yielding. NaBH3CN gave the 6-O-benzyl 
glycoside 203 in a 76% yield. 158 
 
Scheme 4.19: Ghosh et al.158 reaction of benzylidene acetal 201 to give 200, 
202, and 203. 
The goal in the current work is to selectively achieve a 6-O-benzyl glycoside, and 
therefore searching the literature for precedent on similar reactions was required.  
A common method to selectively reveal the hydroxyl group at O-4 from a benzylidene 
acetal group is through the use of sodium cyanoborohydride. For example,  
Visansirikul et al. 159 used NaBH3CN and hydrogen chloride to selectively achieve 204 
from 205 in a 97% yield (Scheme 4.20). While this method is promising, the need to 
generate anhydrous hydrogen chloride makes it undesirable for the current work. 
 
Scheme 4.20: Reduction of benzylidene acetal 205 to give 204 by Visansirikul et al. 159 
Alternatively, triethylsilane may be used to replace NaBH3CN and allows for the use of 
different acid sources such as TFA,160 BF3OEt2,161 TfOH and TMSOTf.162   
DeNinno et al.160 used Et3SiH and TFA for a number of benzylidene protected 
carbohydrates. This series included GlcNAc derivative 206, which was able to be 





Scheme 4.21: Reduction of benzylidene acetal 206 to give 207, published by 
DeNinno et al.160 
It was decided to reduce the benzylidene acetal 198 of the current work following the 
procedure developed by Hargreaves et al.162 (Scheme 4.22). 195 was purified using 
column chromatography in a 68% yield.  
 
Scheme 4.22: Regioselective reduction of 198 with triethylsilane to give 195. 
The loss of the benzylidene proton and carbon signals in the NMR spectra from 198 to 
195 were indicative of the success of the reaction (Figure 4.14). The 1H NMR spectrum 
showed an AB splitting system as a multiplet between 4.63 and 4.52 ppm, signifying the 
addition of a single benzyl ether. All signals corresponding to the other protecting groups 
and the linker remained as expected. 
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Figure 4.14: (top) 500 MHz 1H NMR spectrum of 198 in CDCl3. (bottom) 
500 MHz 1H NMR spectrum of 195 in CDCl3. 6.1 to 1.0 ppm shown. 
Only one glycoside was apparent from the spectroscopic data of the purified reaction 
product with the anomeric proton resonating at 4.88 ppm in the 1H NMR spectrum and 
the anomeric carbon at 99.8 ppm in the 13C NMR spectrum (Figure 4.15). The product 
was concluded to be the 6-O-benzyl glycoside 195 from the strong correlation between 



















4.11 Progress towards galactosyl donor 208 
The ideal galactoside donor required for glycosylation with 195 should have a 
participating group at the O-2 position, a leaving group at anomeric position, and the 
remaining hydroxyl groups should be robustly protected. These requirements could be 
met by galactoside 208.  
By comparing galactoside 208 to the mannosyl trichloroacetimide donor 24 used in the 
trimannoside syntheses, it became apparent that the synthetic pathway to make 24 could 
be applied to 208 (Scheme 4.23). 
 
Reagents and conditions: Ac2O, py, 0°C → rt; b) HBr in AcOH, CH2Cl2; c) collidine, 
TBAB, EtOH, CHCl3; d) IRA-400 (OH-), MeOH/CH2Cl2; e) BnBr, NaH, DMF, 0°C → 
rt; f) glacial AcOH; g) NH3(g), THF, MeOH; h) Cl3CCN, NaH, CH2Cl2, 0°C. 
Scheme 4.23: Synthesis of 208 from D-galactose. 
D-galactose was acetylated under basic conditions, following the same preparation as 
described for the related mannose reaction (Scheme 2.29, p 56). Next, 209 was stirred in 
HBr and acetic acid to give galactosyl bromide 210 in a 99% yield over two steps. Methyl 
orthoester 211 was formed from the reaction of mannosyl bromide 210 with collidine, 
TBAB, and methanol heated to reflux in chloroform. The acetyl protecting groups were 
removed via methanolysis utilising IRA-400 basic exchange resin and the resulting crude 
oil was benzylated using NaH and benzyl bromide to give 213 in an 86% yield over five 
steps from D-galactose. The success of each step was confirmed by HRMS and 1H NMR 
spectra, all of which were consistent those published in the literature.163 
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With the mannoside ethyl orthoester equivalent 73, 60% acetic acid(aq) was used to open 
the orthoester to give an acetyl protecting group at the axial O-2 position and a hydroxyl 
at the anomeric, which was subsequently converted into the trichloroacetimidate.9 
Because the O-2 of galactoside derivatives is equatorial, using 60% acetic acid(aq) will 
most likely give the acetate at the anomeric position and the hydroxyl at O-2 or some 
combination of both. Instead, using glacial acetic acid would be expected to give acetates 
at both positions.163 
Orthoester 213 was stirred in glacial acetic acid overnight resulting in the formation of 
214 in 32% yield after purification, and the data collected were consistent with those 
published in the literature.163 The 1H NMR spectrum collected for 214 showed a single 
anomeric proton at 5.58 ppm with a 3J1,2 coupling constant of 8.2 Hz, allowing for the 
product to be assigned as the β-anomer (Figure 4.16). Three overlapping AB splitting 
systems could be seen between 4.93 and 4.48 ppm, indicative of the three sets of benzylic 
protons. Two three-proton singlets at 2.06 and 2.00 ppm were assigned to the methyl 
protons of the acetyl protecting groups. The 13C NMR spectrum agreed with the 
conclusion that one anomer was formed with only one anomeric carbon present at 92.8 
ppm. Two carbonyl carbon resonances at 169.7 and 169.6 ppm and two methyl carbon 
resonances at 21.1 and 21.0 ppm were consistent with two acetyl protecting groups. Three 
ipso-carbon signals could be seen downfield from the other aromatic carbon resonances, 




Figure 4.16: (top) 400 MHz 1H NMR spectrum obtained in CDCl3 of 
acetylated galactoside 214 (6.1 to 1.8 ppm shown). (bottom) 100 MHz 13C 
NMR spectrum of 214. Solvent resonances (78 to 76 ppm) removed, spectrum 
cropped to show 185 to 12 ppm. 
At this stage, time did not permit the completion of galactosyl TCA donor 208 for 
glycosylation with 195, and the synthesis of Lewis X derivative 11 was halted. Had this 
synthesis been carried out, it would have followed the general experimental protocol 
outlined in Scheme 4.24. First, a glycosylation reaction between 195 and D-galactosyl 
donor 208 is expected to give disaccharide 216. Iridium(I) catalysed removal of the allyl 
ether would reveal the hydroxyl group at C-3 of the GlcNAc residue for glycosylation 
with L-fucosyl donor 163. From here, all ester protecting groups could be hydrolysed to 
give carboxylic acid 217. Coupling to NHS with EDCI is expected to result in the 
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formation of succinimidyl ester 218. Lastly, hydrogenolysis of benzyl ether protecting 
groups should give Lewis X derivative 11. 
 
Reagents and conditions: a) 25, TMSOTf, 4Å MS, tol, -20°C; b) iridium(I) catalyst, H2, THF, 
then AcCl, CH2Cl2/MeOH; c) 163, CuBr2, TBAB, 4Å MS, CH2Cl2, DMF; d) 2 M NaOH(aq), THF, 
70°C; e) NHS, EDCI, CH2Cl2; f) Pd/C, H2, EtOH/THF. 
Scheme 4.24: Possible synthetic pathway from 195 to achieve Lewis X 




Conclusions and future work 
5.1 Conclusions 
In summary, three oligosaccharides, trimannosides 3 and 5, and fucoside 188 have been 
synthesized for attachment to RHDV VLP (Figure 5.1). Furthermore, protected 3,6-
trimannoside 103, with an alternative linker, was also synthesized. 
 
Figure 5.1: Oligosaccharides synthesized in the current work. 
2,6-branched trimannoside 3 was synthesized in 17 steps from D-mannose in a 27% 
overall yield. The most effective synthetic pathway to 3 is shown in Scheme 5.1. D-
mannose was first acetylated and the anomeric acetate was replaced with a bromide to 
give mannosyl bromide 55 in a 98% yield over two steps. This compound was then 
reacted with NaBH4 to give the acetylated ethylidene 56 in a 94% yield. The ester 
protecting groups were removed via methanolysis and the resulting material was reacted 
with TBSCl to selectively protect the primary hydroxyl group, forming 58 in a 92% yield 
over two steps. 58 was benzylated using BnBr and NaH which resulted in the formation 
of 59 in a quantitative yield. At this stage, the silyl protecting group was removed using 
TBAF to give 32. The ethylidene was then opened under acidic conditions using HCl and 
dioxane. The crude material was acetylated under basic conditions to give triacetatylated 
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mannoside 60 in an 89% yield over two steps. The anomeric acetate was selectively 
transesterified with methanol and then converted into trichloroacetimidate 33 in a 
quantitative yield. 33 was used as a glycosyl donor in a TMSOTf promoted glycosylation 
reaction with methyl 6-hydroxyhexanoate (25) and the crude reaction material was 
deacetylated to give diol 14 in an 87% yield over two steps. A bis-glycosylation was 
performed between donor 24 and acceptor 14 to give the protected branched trimannoside 
78 in a 65% yield. The acetyl protecting groups and the methyl ester were hydrolysed and 
the resulting carboxylic acid 83 was coupled with NHS using EDCI. Lastly, global 
debenzylation of succinimidyl ester 79 using palladium catalyzed hydrogenolysis gave 







Reagents and conditions: a) Ac2O, py, 0°C → rt; b) HBr in AcOH, CH2Cl2; c) NaBH4, CH3CN; 
d) IRA-400 (OH-), MeOH/CH2Cl2; e) TBSCl, 4-DMAP, TEA, CH2Cl2; f) BnBr, NaH, DMF, 0°C 
→ rt; g) TBAF, THF; h) HCl, dioxane, i) Ac2O, py, 0°C → rt; j) NH3(g), THF, MeOH, 0°C ; k) 
Cl3CCN, NaH, CH2Cl2, 0°C; l) 25, TMSOTf, 4Å MS, tol, -20°C; m) IRA-400 (OH-), MeOH/ 
CH2Cl2; n) 24, TMSOTf, 4Å MS, tol, -20°C → -10°C; o) 2 M NaOH(aq), THF, 75°C; p) NHS, 
EDCI, CH2Cl2; q) Pd/C, H2, EtOH/THF. 
 







To explore the effect of the linker composition, the synthesis of 3,6-trimannoside 6 was 
attempted. Protected 3,6-branched trimannoside 103 was synthesized in an 8% yield over 
17 steps from D-mannose (Scheme 5.2). First, D-mannose was globally acetylated to give 
54, which was then used in a Fischer glycosylation with BF3OEt2 and 2-bromoethanol. 
Substitution of the bromine of mannoside 92 was achieved by treatment with sodium 
azide to give 93. The acetyl protecting groups were then removed to give 94 in an 88% 
yield over two steps. The primary hydroxyl was protected with TBDPS and a 2,3-
acetonide group was installed, leaving only the C-4 hydroxyl unprotected in 96. O-4 was 
protected as a benzyl ether and the acetonide was removed under acidic conditions to give 
99 in a 68% yield over four steps. Dibutyltin oxide mediated alkylation of the equatorial 
hydroxyl group with PMBCl resulted in the formation of 95 in a 69% yield. The O-2 
position was protected as a benzyl ether and the silyl protecting group was hydrolysed 
with TBAF to give 101 in a quantitative yield over two steps. Next, the PMB ether was 
hydrolysed under acidic conditions which resulted in the formation of mannosyl acceptor 
91 in a 69% yield. A TMSOTf promoted glycosylation between TCA donor 24 and 91 
gave the protected trimannoside 102 in a 74% yield. 102 was deacetylated using IRA-400 
basic exchange resin and methanol. The azide function of the linker was extended to give 
carboxylic acid 106 by first undergoing a Staudinger reduction with trimethylphosphine 
and then reaction with succinic anhydride. Carboxylic acid 106 was coupled to NHS with 
EDCI to give the protected succinimidyl ester 103 in a 45% yield over four steps. 
Unfortunately, global debenzylation of 103 proved problematic. Mass spectrometry 




Reagents and conditions: a) Ac2O, py, 0°C → rt; b) HOCH2CH2Br, BF3OEt2, CH2Cl2; c) NaN3, 
DMF, 60°C; d) IRA-400 (OH-), MeOH/CH2Cl2; e) TBDPSCl, Im, DMF; f) (CH3)2C(OCH3)2, p-
TSA, acetone; g) BnBr, NaH, DMF, 0°C → rt; h) TFA, CH2Cl2; i) (i) Bu2SnO, tol, Δ; (ii) PMBCl, 
Bu4NI, DMF, Δ; j) BnBr, NaH, DMF, 0°C → rt; k) TBAF, THF; l) TFA, CH2Cl2, -20°C; m) 24, 
TMSOTf, 4Å MS, tol, -20°C; n) IRA-400 (OH-), MeOH/CH2Cl2; o) Me3P, THF, NaOH; p) 
succinic anhydride, dioxane, 80°C; q) NHS, EDCI, CH2Cl2; r) Pd/C, H2, EtOH/THF. 
Scheme 5.2: Reaction pathway followed to give protected 3,6-branched 
trimannoside 103. 
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The synthesis of 3,6-branched trimannoside 5 was able to be efficiently carried out in a 
22% yield over 11 steps from D-mannose (Scheme 5.3). D-mannose was benzoylated and 
the anomeric benzoate was substituted with bromide to give 45. This was then substituted 
for a hydroxyl group by silver carbonate mediated hydrolysis. A trichloroacetimidate was 
then installed at this position to give the glycosyl donor 111 in an 86% yield over four 
steps. 111 was used in a TMSOTf promoted glycosylation with methyl 6-
hydroxyhexanoate (25) to resulting in the formation of 117 in a 76% yield. The benzoyl 
ester groups were removed with methoxide mediated methanolysis to give 118, which 
was used to achieve di-benzoate 145 via a di-orthoester intermediate. A bis-glycosylation 
reaction between 145 and donor 24 gave protected 3,6-trimannoside 147 in a 71% yield. 
Ester protecting groups and the methyl ester were hydrolysed to give 158 in a 70% yield. 
Succinimidyl ester 157 was formed by reaction of 158 and NHS with EDCI. Lastly, 







Reagents and conditions: a) BzCl, py, 0°C → rt; b) HBr in AcOH, CH2Cl2; c) Ag2CO3, H2O, 
acetone; d) Cl3CCN, NaH, 0°C; e) 25, TMSOTf, 4Å MS, CH2Cl2, 0°C; f) NaOMe, MeOH, 
CH2Cl2; g) (i) p-TSA, TFA, C6H5C(OCH2CH3)3, MeCN, (ii) 90% TFA(aq), MeCN; h) 24, 
TMSOTf, 4Å MS, tol, -40°C → -20°C; i) NaOMe, MeOH, CH2Cl2; j) NHS, EDCI, CH2Cl2; k) 
Pd/C, H2, EtOH/THF. 
Scheme 5.3: Efficient synthetic pathway followed to achieve deprotected 3,6-









Fucoside 188 was synthesized in a 22% yield in an eight step synthesis from GlcNAc 
(Scheme 5.4). Reaction of GlcNAc with acetyl chloride gave glycosyl chloride 174 in a 
48% yield. Koenigs-Knorr glycosylation between donor 174 and methyl 6-
hydroxyhexanoate (25) using AgOTf resulted in the formation of methyl ester 179 in a 
97% yield. 179 was deacetylated using IRA-400 (OH-) exchange resin and the resulting 
material, 183, was reacted with benzaldehyde dimethyl acetal under acidic conditions to 
give glycosyl acceptor 182 in an 80% yield. A copper(II) bromide promoted glycosylation 
between L-fucosyl donor 163 and 182 resulted in disaccharide 186 in an 81% yield. The 
methyl ester of 186 was hydrolysed using NaOH to give carboxylic acid 189, which was 
then coupled with NHS using EDCI to give the succinimidyl ester 187 in an 80% yield 
over two steps. Disaccharide 188 was achieved via hydrogenolysis to remove the 
benzylidene and benzyl ether protecting groups.  
 
Reagents and conditions: a) AcCl; b) 25, AgOTf, 4Å MS, CH2Cl2, 0°C → rt; c) IRA-400 (OH-), 
MeOH, CH2Cl2; d) PhCH(OMe)2, p-TSA, DMF, 70°C; e) 163, CuBr2, TBAB, 4Å MS, CH2Cl2, 
DMF; f) NaOH, THF, 70°C; g) NHS, EDCI, CH2Cl2; h) Pd/C, H2, EtOH/THF. 
Scheme 5.4: Synthetic pathway followed to give disaccharide 188 in eight 
steps from GlcNAc. 
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It was clear that during the acquisition of spectroscopic data all deprotected N-
succinimidyl ester compounds showed hydrolysis over time. This was particularly 
evident in the 13C NMR spectra which showed the formation of N-hydroxysuccinimide. 
Furneaux and coworkers 128-129 reported the synthesis of a set of similar trimannosides, 
however they did not report data for the succinimidyl esters. Instead they coupled them 
immediately to amines. Given this and the results from the current work, the succinimidyl 
esters should be stored in protected form in the penultimate step. Hydrogenolytic 
debenzylation would then be performed immediately prior to coupling to RHDV VLP. 
Coordination with the Ward group will be imperative to carry out the necessary biological 
studies on the VLP-oligosaccharide conjugates.  
5.2 Future work 
Future synthetic work for this project is highly dependent on the immunological results 
from the currently synthesized carbohydrate VLP conjugates. Should the trimannoside-
VLP conjugates show enhanced uptake and cross-presentation compared to those 
previously synthesized by Al-Barwani, improving the syntheses would be advantageous.9 
Otherwise, beyond investigations into the effect of the linker on uptake and cross-
presentation, there is not much need to continue with the trimannoside component of this 
project. Blood group antigen derivatives 7 or 8 and 9 or 10 may provide alternate ideal 
ligands for the mannose receptor. Completing the synthesis of ligands specifically for 
targeting DC-SIGN, like Lewis X derivatives 11 or 12, could provide interesting insight 
into the different cross presentation pathways that may be accessed.  
5.2.1 3,6-T``rimannoside moiety with various linkers 
The synthesis of 3,6-trimannosides with various linkers could be carried out utilizing 
synthetic strategies developed in the work outlined in Chapter 3. One option could be to 
use the benzoylated TCA donor 111 in a glycosylation reaction with alcohols of various 
lengths and compositions (Scheme 5.5). Following this glycosylation reaction, 221 could 
be deprotected and converted into the di-benzoate as previously described, giving a 
platform for a bis-glycosylation reaction. Alternatively, the 2-azidoethyl di-benzoate 142 
could be used in a bis-glycosylation with an appropriately protected donor, like 24, then 
the azide could be converted into the amine and this could be coupled to various 
compounds like cyclic anhydrides or dicarboxylic acids. Both this reaction pathways may 
provide a number of trimannosides with various linkers. 
164 
 
Scheme 5.5: Possible synthetic pathway to achieve generic 3,6-trimannosides 












5.2.2 Lewis X derivative 11 
The synthesis of Lewis X derivative 11 could be completed in 5 steps from compound 
195, which has been synthesized in this project (Scheme 5.6). Glycosylation with a 
galactosyl donor, like 208, could provide 216. The allyl ether could be removed to access 
an acceptor that could be used in a glycosylation reaction with L-fucosyl donor 163. This 
would provide the protected Lewis X derivative 220. The methyl ester could be converted 
into the succinimidyl ester, following procedures previously outlined. Lastly, palladium 
catalyzed hydrogenolysis would give the intended target Lewis X derivative 11. Lewis X 
derivative 11 is expected to have a higher binding affinity to DC-SIGN than 188, the 
synthesis of which was completed in this project. 
 
Reagents and conditions: a) 25, TMSOTf, 4Å MS, tol, -20°C; b) iridium(I) catalyst, H2, THF, 
then AcCl, CH2Cl2/MeOH; c) 163, CuBr2, TBAB, 4Å MS, CH2Cl2, DMF; d) 2 M NaOH(aq), THF, 
70°C; e) NHS, EDCI, CH2Cl2; f) Pd/C, H2, EtOH/THF. 
Scheme 5.6: Possible synthetic pathway from 195 to achieve Lewis X 





5.2.3 O-type blood antigen derivatives 9 and 10 
Some preliminary investigations were carried out into the synthesis of O-type blood group 
antigen derivative 10 (Scheme 5.7). Galactoside 214, synthesized in the Lewis X 
derivative pathway, provided a compound which was used in a Fischer glycosylation with 
2-bromoethanol. The reaction produced a mixture of anomeric products 225, and was not 
able to be optimized to reliably produce the β-anomer in excess. The anomeric mixture 
was converted into the more stable azide 226 and the acetyl group was removed, allowing 
for the β-anomer 227b to be separated in a 73% yield over two steps. Acceptor 227b was 
used in a copper(II) promoted glycosylation reaction with thiophenyl fucoside 163 giving 
228 in a 54% yield. Unfortunately, this synthesis was unable to be completed or optimized 
in the current work. 
 
Reagents and conditions: a) HOCH2CH2Br, BF3OEt2, CH2Cl2; b) NaN3, DMF, 60°C; c) IRA-
400(OH-), MeOH/CH2Cl2; d) 163, CuBr2, TBAB, 4Å MS, CH2Cl2, DMF; e) (i) Me3P, THF, 
NaOH, (ii) succinic anhydride, dioxane, 80°C; f) NHS, EDCI, CH2Cl2; g) Pd/C, H2, EtOH/THF. 
Scheme 5.7: Synthetic method to achieve 10 from 214. 
Modification of this synthesis using methyl 6-hydroxyhexanoate (25) as the acceptor and 
galactosyl donor 208 could provide disaccharide 9 (Figure 5.2). 
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Figure 5.2: O-blood antigen derivative 9. 
5.2.4 Proposed synthetic targets 7 and 8 
Disaccharides 7 and 8 could be considered the most intriguing of the three non-mannose 
based oligosaccharides, due to the strong binding properties of the disaccharide moiety to 
the mannose receptor. However, neither synthesis was attempted due to time limitations 
(Figure 5.3). The 1,2-cis-α linkage in combination with the N-acetyl at C-2 of 7 and 8 
provides an interesting challenge to consider. To achieve a 1,2-cis-α linkage, the amino 
functionality of glucosamine must be protected with a non-participating group, 
eliminating the possibility of starting with GlcNAc. 
 
Figure 5.3: Possible synthetic targets 7 and 8. 
Enugala et al.164 compiled an extensive list of amine protecting groups at the 2-position 
in glycosylation reactions and most yielded an excess of the β-product. The best option 
that they found was to use an azide to provide a non-participating amine surrogate, and 
get a mixture of α- and β-anomers. To achieve a hexanoate linker following this synthetic 
pathway, D-glucosamine would need to be benzoylated to give 232 which could be 
converted into azide 233 (Scheme 5.8). Removal of the anomeric benzoate and 
conversion into a donor such as TCA 234 would enable the synthesis of methyl hexanoate 
235. Reduction of the azide and appropriate protecting group strategy would allow for the 
synthesis of 7. This strategy hinges on it being possible to separate the anomeric mixture 




Reagents and conditions: a) BzCl, py, 0°C → rt , b)NaN3, DMF, 60°C; c) (i) HBr in AcOH, 
CH2Cl2 (ii) Ag2CO3, H2O, acetone; e) Cl3CCN, NaH, 0°C; f) 25, TMSOTf, 4Å MS, CH2Cl2, 0°C; 
g) Me3P, THF, 0°C → rt, NaOH; h) AcCl, NaOH; i) NaOMe, MeOH, CH2Cl2; j) TBSCl, TEA, 
4-DMAP, CH2Cl2; k) BnBr, NaH, DMF, 0°C → rt; l) TBAF, THF; m) 163, CuBr2, TBAB, 4Å 
MS, CH2Cl2, DMF; n) NaOH, THF, 70°C; o) NHS, EDCI, CH2Cl2; p) Pd/C, H2, EtOH/THF. 






6.1 General experimental 
6.1.1 Polarimetry 
Specific rotation values for compounds were recorded on a Rudolph Research Analytical 
Autopol IV automatic polarimeter using a 100 mm cell with 3.5 mm aperture, and the 
rotation was measured at 589 nm at 20°C. Samples were prepared at the concentration 
(g/100 mL) using different solvents as indicated. 
6.1.2 Nuclear magnetic resonance (NMR) spectroscopy 
1H NMR spectra were recorded at either 400 MHz on a Varian 400-MR NMR system or 
at 500 MHz on a Varian 500 MHz AR Premium Shielded Spectrometer. All spectra were 
recorded from samples in solution at 25°C in 5mm diameter NMR tubes. Chemical shifts 
are referenced to the central peak of the residual solvent signal (CDCl3 at 7.26 ppm, D2O 
at 4.79 ppm, DMSO-d6 at 2.50 ppm, CD3OD at 3.31 ppm, and acetone-d6 at 2.05 ppm). 
Chemical shifts are reported to the nearest 0.01 ppm and coupling constants (J) have been 
rounded to the nearest 0.1 Hz. Resonances were reported as follows: chemical shift 
(multiplicity, coupling constant(s), number of protons, assigned proton(s)). Multiplicity 
abbreviations are reported using the standard ACS conventions: s (singlet), b (broad 
singlet), d (doublet), dd (doublet doublets), dddd (double double double doublet), t 
(triplet), dt (double triplets), q (quintet), m (multiplet).  
13C NMR spectra were recorded at either 100 MHz on a Varian 400-MR NMR system or 
at 125 MHz on a Varian 500 MHz AR Premium Shielded Spectrometer under the same 
conditions as for the 1H NMR spectra. Chemical shifts are referenced to the central peak 
of the deuterated solvent signal (CDCl3 at 77.16 ppm, DMSO-d6 at 39.52 ppm, CD3OD 
at 49.00 ppm, and acetone-d6 at 29.84 ppm). Chemical shifts have been reported to the 
nearest 0.01 ppm. Resonances were reported as follows: chemical shift (assignment). 
2-Dimensional correlation spectra (gCOSY, gHSQC, gHMBC) were used to assign peaks 
in both the 1H and 13C NMR specta. Coupled HSQC was used to assign α anomeric 
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stereochemistry in the trimannoside series. All NMR data was processed using 
MestraNova x64. 
6.1.3 Numbering of compounds 
The ring positions of glycosyl derivatives were numbered using standard convention for 
carbohydrates with the anomeric position assigned as “1”. For branched oligosaccharides, 
the mannosyl substituent connected through the (1→6)-α- glycosidic linkage is “A” and 
the one connected through the (1→2)-α- or (1→3)-α- is “B”. When a linker was present, 
the positions were assigned as an extension of the central mannosyl ring, with the position 
closest to the anomeric oxygen designated as “7” and extending outwards. 
 
6.1.4 Infrared (IR) Spectroscopy 
Infra-red spectra were recorded on a Bruker Optics Alpha FT-IR spectrometer with a 
diamond Attenuated Total Reflectance (ATR) top plate. No preparations were required 
for sample analysis. Values are reported in wavenumbers, v (cm-1). 
6.1.5 Mass spectrometry 
HRMS (high resolution mass spectrometry) and LRMS (low resolution mass 
spectrometry) spectra were recorded on a Bruker microTOFQ mass spectrometer using 
electrospray ionization (ESI) source in the positive mode.  
6.1.6 Chromatography 
Thin Layer Chromatography (TLC) was performed using aluminium-backed Merck 
sorbent silica gel plates. Compounds were detected under a UV (ultra violet) lamp and 
stained using a vanillin (vanillin in ethanol and 0.01% H2SO4) or phosphomolybdic acid 
(7-10% wt% in EtOH) stain followed by heating to 450°C.  
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Normal phase column chromatography was performed using silica gel (230-400 mesh) 
and the specified eluent/eluent gradient. 
6.1.7 Reaction conditions 
All reactions requiring anhydrous conditions were performed under a dry nitrogen or 
argon atmosphere with glassware and stirring bars dried in an oven (80°C) for at least 10 
hours before use. No special conditions were used to ensure that reactions carried out at 
room temperature were at any specific temperature. Reactions at 0°C were performed in 
a standard ice bath (ice + water + salt) and ones between -20°C and -40°C in either a slush 
(liquid nitrogen + solvent) or liquid (dry ice + acetone). 
6.1.8 Reagents and solvents 
Anhydrous acetonitrile (CH3CN), dichloromethane (CH2Cl2), tetrahydrofuran (THF), 
methanol (MeOH), and toluene were dried using the PURE-SOLV MD-6 purification 
system. These solvents were further dried over 4Å molecular sieves for at least 3 hours 
before use. Solvents used in glycosylation reactions (CH2Cl2 and toluene) were 
additionally distilled over CaH2. Anhydrous N,N-dimethylformamide (DMF) was 
purchased in sure/seal bottles. All other reagents were used as received.  
6.1.9 Resins and beads 
4Å molecular sieves (MS) and 3Å MS were freshly activated before use via the following 
method: MS heated in tube furnace at 320°C for one hour and cooled to room temperature 
under high vacuum. Sieves were stored under vacuum and considered freshly activated if 
used within 72 hours of this process. Unless otherwise stated, MS were in bead form.  
Amberlite® IRA-400 (OH-) exchange resin refers to beads of standard Amberlite® IRA-
400 that have been converted to the hydroxide form by the following process: wash with 
2 M NaOH(aq), water, then methanol and dried. The standard form was purchased from 
Sigma-Aldrich. 
Amberlite® IRA 120 (H+) exchange resin is a strongly acidic cation exchange resin and 




6.1.10 New Compounds 
Novel compounds are indicated by the italicized term ‘title compound(s)’ while known 
compounds are indicated by the term ‘title compound(s)’. 
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6.2 Experimental protocols 
Methyl 6-hydroxyhexanoate (25) 9, 103-104 
 
A solution of 2% sulfuric acid was added to ε-caprolactone (5.5 g, 48.2 mmol) in MeOH. 
The mixture was stirred at reflux for 10 min and then cooled to room temperature. Solid 
Na2CO2 was added and the mixture was filtered. Concentration of the filtrate in vacuo 
gave a residue that was diluted with EtOAc and then washed with water. The organic 
phase was dried over MgSO4 and the solvent was evaporated to give the title compound 
as a clear colourless liquid 25 (6.36 g, 100%) which was purified by Kuglrohr distillation 
(2mBar, 150°C) as needed. 
1H NMR (400 MHz, CDCl3) δ 3.66 (s, 3H, OCH3), 2.32 (q, J = 6.9, 6.3 Hz, 2H, H-2), 
1.60 (ddt, J = 30.5, 15.7, 8.2 Hz, 6H, H-2, H-4, H-6), 1.45 – 1.34 (m, 2H, H-3). 13C NMR 
(100 MHz, CDCl3) δ 173.66 (C=O), 61.14 (C-2), 50.71, 50.70, 33.22, 31.49, 24.69. 
 
1,2,3,4,6-Penta-O-benzoyl-D-mannopyranose (44) 107, 110 
 
D-(+)-mannose (5.10 g, 27.8 mmol) was suspended in a stirred solution of py (50 mL) 
and cooled to 0°C. Benzoyl chloride (18.3 mL, 194 mmol) was added to the reaction at 
such a rate that the reaction temperature remained below 10°C. The solution was warmed 
to room temperature and then stirred for 24 hours. Water (10 mL) was added and the 
solution was stirred for 15 minutes to quench any excess benzoyl chloride. Additional 
water was added and the solution was extracted with CH2Cl2. The combined organic 
extracts were washed with 1 M HCl(aq), sat. NaHCO3(aq) and brine. The organic extract 
was dried over MgSO4, filtered, and the solvent removed to give the title compound 44 
(19.16 g, 100%) as a white foam, which was used without further purification.  
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1H NMR (400 MHz, CDCl3) δ 7.71 – 7.26 (m, 25H, Ph), 6.62 (d, J = 2.0 Hz, 1H, H-1), 
6.28 (t, J = 10.2 Hz, 1H, H-4), 6.06 (dd, J = 10.2, 3.3 Hz, 1H, H-3), 5.91 (dd, J = 3.3, 2.0 
Hz, 1H, H-2), 4.69 (dd, J = 12.2, 2.5 Hz, 1H, H-6), 4.56 (dq, J = 8.1, 2.7, 2.0 Hz, 1H, H-
5), 4.50 (dd, J = 12.2, 3.7 Hz, 1H, H-6). 13C NMR (125 MHz, CDCl3) δ 166.10, 165.74, 
165.35, 165.20, 163.89 (C=O), 134.13, 133.72, 133.60, 133.46, 133.11 (i-Ph), 130.23, 
130.21, 130.02, 129.87, 129.83, 129.06, 128.88, 128.86, 128.73, 128.53, 128.48, 128.46 
(Ph), 91.45 (C-1), 71.26 (C-5), 70.07 (C-3), 69.51 (C-2), 66.25 (C-4), 62.42 (C-6); v(max) 
(ATR-IR) 2158, 1725 (C=O), 1260 (C-O), 1093, 1068, 1025 (C-O), 707 cm-1; HRMS-
ESI [M+Na+] calculated for C41H32O11Na+: 723.1837. Found: 723.1781. 
 
2,3,4,6-Tetra-O-benzoyl-α-D-mannopyranosyl bromide (45) 107, 110 
 
Hydrogen bromide in glacial acetic acid (33%, 15 mL, 76 mmol) was added to a stirred 
solution of 44 (8.9 g, 12.70 mmol) in anhyd. CH2Cl2 (20 mL). The solution was stirred 
overnight at room temperature before being poured into ice water and the aqueous layer 
was extracted with CH2Cl2. The combined organic extracts were washed with sat. 
NaHCO3(aq) then brine. The solution was dried over MgSO4 and evaporated to give the 
title compound 45 (7.23 g, 86%) as a yellow foam which was used without further 
purification. 
1H NMR (400 MHz, CDCl3) δ 8.12 – 8.07 (m, 2H, Ph), 8.06 – 7.95 (m, 4H, Ph), 7.87 – 
7.80 (m, 2H, Ph), 7.64 – 7.50 (m, 3H, Ph), 7.48 – 7.36 (m, 7H, Ph), 7.32 – 7.27 (m, 2H, 
Ph), 6.59 (dd, J = 1.7, 0.7 Hz, 1H, H-1), 6.29 (dd, J = 10.2, 3.0 Hz, 1H, H-3), 6.27 – 6.20 
(m, 1H, H-4), 5.91 (dd, J = 3.0, 1.7 Hz, 1H, H-2), 4.74 (dd, J = 12.5, 2.4 Hz, 1H, H-6), 





3,4,6-Tri-O-benzoyl-1,2-O-(methyl orthobenzoate)-β-D-mannopyranose (46)107, 109-
110 
 
Anhyd. MeOH (6 mL), potassium fluoride (2.210 g, 38 mmol) and 3Å molecular sieves 
were added to a stirred solution of 45 (5.0178 g, 7.61 mmol) in anhyd. acetonitrile (30 
mL). The solution was vigorously stirred at 40°C for 18 hours under N2. The suspension 
was filtered and the filtrate was evaporated to give the title compound 46 (4.41 g, 95%) 
as a white foam which was used without further purification.   
1H NMR (400 MHz, CDCl3) δ 8.04 – 7.99 (m, 2H, Ph), 7.93-7.89 (m, 3H, Ph), 7.72 – 
7.67 (m, 2H, Ph), 7.56 – 7.46 (m, 4H, Ph), 7.40 – 7.28 (m, 9H, Ph), 5.89 (dd, J = 9.9, 9.3 
Hz, 1H, H-4), 5.81 (d, J = 3.0 Hz, 1H, H-1), 5.66 (dd, J = 9.9, 4.0 Hz, 1H, H-3), 5.08 (dd, 
J = 4.0, 3.0 Hz, 1H, H-2), 4.52 (dd, J = 12.1, 3.4 Hz, 1H, H-6), 4.35 (dd, J = 12.1, 4.7 Hz, 
1H, H-6), 4.10 (ddd, J = 9.2, 4.7, 3.3 Hz, 1H, H-5), 3.23 (s, 3H, OCH3). 13C NMR (100 
MHz, CDCl3) δ 166.14, 166.09, 165.25 (C=O), 136.32, 133.60, 133.51, 133.08 (i-Ph), 
130.17, 130.12, 130.08, 129.90, 129.87, 129.81, 129.67, 129.40, 129.18, 129.07, 129.01, 
128.68, 128.54, 128.51, 128.39, 128.29, 128.15, 126.59, 126.57, 126.54 (Ph), 122.49 
(Corth), 98.01 (C-1), 72.13, 71.28, 66.55, 63.16, 51.58 (OCH3); v(max) (ATR-IR) 2945, 
1719 (C=O), 1266 (C-O), 1091, 1069 (C-O), 708 cm-1; HRMS-ESI [M+Na+] calculated 
for C35H30O10Na+: 633.1704. Found: 633.1731. 
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Sodium methoxide in MeOH (5.4 M, 1.4 mL, 7.22 mmol) was added dropwise to a 
solution of orthoester 46 (4.41 g, 7.22 mmol) in CH2Cl2/MeOH (1:2, 15 mL) which was 
stirred overnight at room temperature. Silica gel (10 g) was then added and the reaction 
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solution was evaporated. The residue was purified using column chromatography 
(MeOH/CH2Cl2, 1:9) to give the title compound 47 (1.98 g, 92%) as a white foam. 
1H NMR (400 MHz, CDCl3) δ 7.64 – 7.59 (m, 2H, Ph), 7.39 – 7.34 (m, 3H, Ph), 5.97 (d, 
J = 5.8 Hz, 1H, H-1), 4.64 (dd, J = 5.8, 2.5 Hz, 1H, H-2), 4.30 (dd, J = 13.0, 0.9 Hz, 1H, 
H-4), 4.17 (dd, J = 8.1, 5.9 Hz, 1H, H-3), 4.08 (dd, J = 13.0, 3.6 Hz, 1H, H-6), 3.84 – 
3.66 (m, 2H, H-5, H-6), 3.49 (s, 3H, OCH3), 2.46 (s, 1H, OH), 2.21 (s, 1H, OH); 13C 
NMR (100 MHz, CDCl3) δ 137.62, 137.00 (i-Ph), 129.71, 129.42, 128.32, 128.23, 
126.32, 126.19 (Ph), 122.70 (Corth), 97.79 (C-1), 78.96 (C-2), 75.17 (C-5), 71.85 (C-3), 
67.00 (C-4), 61.69 (C-6), 50.82 (OCH3); HRMS-ESI [M+Na+] calculated for 
C14H18O7Na+: 321.0945. Found: 321.0923. 
 
1,2,3,4,6-Penta-O-acetyl-D-mannopyranose (54) 9, 105, 107 
  
Acetic anhydride (41.1 mL, 436 mmol) was slowly added to a stirred solution of D-(+)-
mannose (11.2 g, 62.2 mmol) in py (40 mL) at 0°C. The reaction mixture was warmed to 
room temperature and left stirring overnight, after which the mixture was cooled in an ice 
bath and water was added. The solution was extracted with EtOAc and the combined 
organic extracts were washed with 1 M HCl(aq), water, 5% NaHCO3(aq), water again and 
dried over anhyd. MgSO4. The solvents were removed in vacuo to give the title compound 
54 (23.85 g, 5:1 α/β, 98%) as a clear, colourless oil which was used without further 
purification.  
Rf = 0.35 (3:1 EtOAc/PE); 1H NMR (400 MHz, CDCl3) δ 6.09 (d, J = 1.9 Hz, 1H, α H-
1), 5.86 (d, J = 1.2 Hz, 0H, β H-1), 5.48 (dd, J = 3.4, 1.1 Hz, 0H, H-2), 5.38 – 5.33 (m, 
1H), 5.26 (t, J = 2.3 Hz, 1H), 5.13 (dd, J = 10.0, 3.3 Hz, 0H), 4.34 – 4.23 (m, 1H), 4.15 – 
4.08 (m, 2H), 4.07 – 4.02 (m, 1H, α H-6), 3.83 – 3.76 (m, 0H, β H-6), 2.21 (s, 1H, β CH3), 
2.18 (s, 2H, α CH3), 2.17 (s, 2H, α CH3), 2.10 (s, 1H, β CH3), 2.09 (s, 3H, CH3), 2.05 (s, 
3H, CH3), 2.04 (s, 2H, β CH3), 2.01 (s, 3H, α CH3); 13C NMR (100 MHz, CDCl3) δ 170.77 
(C=O), 170.11 (C=O), 169.86 (C=O), 169.65 (C=O), 168.18 (C=O), 90.74 (C-1), 73.45, 
70.79, 70.75, 68.87, 68.48, 68.31, 65.68, 65.54, 62.24, 62.20, 21.01 (CH3), 20.91 (CH3), 
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20.80 (CH3). v(max) (ATR-IR) 2991 (C-H stretch), 1742 (C=O stretch), 1433, 1369 (C-H 
bend), 1209, 1147, 1086, 1049 (C-O stretch), 1024, 971 cm-1; HRMS-ESI [M+Na+] 
calculated for C16H22O11Na+: 413.1060. Found: 413.1047. 
 
2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl bromide (55) 9, 105, 107 
  
Hydrobromic acid in glacial acetic acid (33%, 31.5 mL, 161 mmol) was added to a stirred 
solution of 54 (10.465 g, 26.8 mmol) in anhyd. CH2Cl2 (20 mL). The solution was stirred 
overnight at room temperature before being poured into ice water and the aqueous layer 
was extracted with CH2Cl2. The combined organic extracts were washed with sat. 
NaHCO3(aq) then brine, dried over MgSO4, and the solvent was removed to give 55 
(10.873 g, quant.) as an orange oil which was used without further purification.  
Rf = 0.56 (1:1 EtOAc/PE);  1H NMR (400 MHz, CDCl3) δ 6.29 (d, J = 0.9 Hz, 1H, H-1), 
5.72 (dd, J = 10.2, 3.4 Hz, 1H, H-3), 5.45 (dd, J = 3.4, 1.6 Hz, 1H, H-2), 5.37 (t, J = 10.2 
Hz, 1H, H-4), 4.33 (dd, J = 12.5, 4.9 Hz, 1H, H-6), 4.22 (dddd, J = 10.2, 4.9, 2.2, 0.7 Hz, 
1H, H-5), 4.14 (dd, J = 12.4, 2.2 Hz, 1H, H-6), 2.17 (s, 3H, CH3), 2.10 (s, 3H, CH3), 2.07 
(s, 3H, CH3), 2.01 (s, 3H, CH3); 13C NMR (100 MHz, CDCl3) δ 170.64, 169.82 , 169.69 
(C=O), 83.19 (C-1), 72.99, 72.30, 68.08, 65.47, 61.60, 20.92 (CH3), 20.83 (CH3), 20.80 
(CH3), 20.73 (CH3); HRMS-ESI [M+Na+] calculated for C14H19O979BrNa+: 433.0105. 
Found: 433.0091. 
 
3,4,6-Tri-O-acetyl-1,2-O-ethylidene-β-D-mannopyranosee (56) 112 
 
Mannosyl bromide 55 (13.67 g, 33.2 mmol) was dissolved in anhyd. CH3CN (30 mL, 
dried overnight on 4Å molecular sieves) under an inert atmosphere and NaBH4 (7.55 g, 
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199 mmol) was added to the stirred solution. The mixture was then stirred at room 
temperature for 22 hours. The solution was diluted with EtOAc, washed with water and 
brine, and dried over MgSO4. The organic layer was filtered through a Celite® bed and 
concentrated. The crude material was purified by column chromatography (PE/EtOAc 
gradient) to yield the title compound 56 (Major/Minor =7:1, 10.34 g, 94%) as a white 
solid. 
Rf  = 0.53 (1:1 EtOAc/PE);  1H NMR (500 MHz, CDCl3) δ 5.35 (1H, t, J= 9.7 Hz, H-4), 
5.31 (1H, d, J= 0.6 Hz, H-1), 5.30 (1H, q, J= 4.9 Hz, Heth), 5.22 (1H, dd, J= 9.9, 4.0 Hz, 
H-3), 4.27 (1H, dd, J= 4.0, 2.4 Hz, H-2), 4.22 (1H, dd, J= 12.1, 5.3 Hz, H-6), 4.15 (1H, 
dd, J= 12.1, 2.7 Hz, H-6), 3.69 (1H, ddd, J= 9.6, 5.2, 2.7 Hz, H-5), 2.12 (3H, s, CH3), 
2.07 (3H, s, CH3), 2.05 (3H, s, CH3), 1.54 (3H, d, J= 5.0 Hz, CH3 eth); 13C NMR (125 
MHz, CDCl3) δ 170.86, 170.51, 169.67 (C=O), 104.98 (Ceth), 96.69 (C-1), 77.49 (C-2), 
71.77 (C-5), 70.75 (C-3), 66.18 (C-4), 62.68 (C-6), 21.73 (CH3 eth), 20.92 (CH3), 20.90 
(CH3), 20.85 (CH3). v(max) (ATR-IR) 2934 (C-H stretch), 1737 (C=O stretch), 1434, 1225, 
1050 (C-O stretch), 880, 734 (C-H bend) cm-1; HRMS-ESI [M+Na+] calculated for 
C14H20O9Na+: 355.1000. Found: 355.1007. 
 
1,2-O-Ethylidene-β-D-mannopyranose (57) 113 
 
Method A: IRA-400 (OH-) exchange resin beads (approx. 1 g) were added to a solution 
of 56 (7.18 g, 21.62 mmol) in MeOH (30 mL). The reaction was left stirring overnight at 
room temperature after which the mixture was filtered and the solvent was removed in 
vacuo to give the title compound 57 (major/minor =7:1, 4.30 g, 96%) as a clear oil which 
was used without further purification.  
Rf  = 0.33 (10% MeOH in CH2Cl2); 1H NMR (500 MHz, D2O) δ 5.41 (1H, dd, J= 2.2 Hz, 
H-1), 5.33 (1H, q, J= 4.9 Hz, Heth), 4.27 (1H, dd, J= 4.3, 2.3 Hz, H-2), 3.98 (1H, dd, J= 
9.5, 4.3 Hz, H-3), 3.89 (1H, dd, J= 12.2, 2.5 Hz, H-6), 3.74 (1H, dd, J= 12.4, 6.1 Hz, H-
6), 3.71 (1H, t, J= 9.7 Hz, H-4), 3.49 – 3.41 (1H, m, H-5), 3.36 (3H, s, 3x OH), 1.49 (3H, 
dd, J= 4.7, 0.9 Hz, CH3 eth); 13C NMR (125 MHz, D2O) δ 104.20 (Ceth), 96.38 (C-1), 79.86 
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(C-2), 75.21 (C-5), 70.71 (C-3), 67.12 (C-4), 60.83 (C-6), 20.33 (CH3 eth). v(max) (ATR-
IR) 3242 (O-H stretch), 2923, 2854 (C-H stretch), 1730, 1553, 1453, 1374 (C-H bend), 
1239 (C-O stretch), 1072 (C-O stretch) cm-1; HRMS-ESI [M+Na+] calculated for 
C8H14O6Na+: 229.0683. Found: 229.0671. 
Method B: Sodium methoxide (0.5 M in MeOH, 2 mL, 1.00 mmol) was added to a stirred 
solution of 56 (800 mg, 2.407 mmol) in MeOH/CH2Cl2 (2:1, 15 mL) and was allowed to 
stir at room temperature for 30 min. The reaction mixture was diluted with MeOH and 
the solvent was removed in vacuo to give the crude product 57 as mixture of endo/exo 





TEA (11.6 mL, 83 mmol), 4-DMAP (382 mg, 3.12 mmol), and TBSCl (4.08 g, 27.1 
mmol) were added in that order to a stirred solution of 57 (4.295 g, 20.83 mmol) in anhyd. 
CH2Cl2 (25 mL). The reaction was left to stir overnight before the solvent was removed 
in vacuo and the resulting residue was purified by column chromatography (100% 
EtOAc) to give the title compound 58 (Major/Minor =7:1, 6.13 g, 92%)  as a clear 
colourless oil. 
Rf = 0.57 (100% EtOAc); 1H NMR (500 MHz, CDCl3) δ  5.30 (1H, q, J= 4.9 Hz, , Heth), 
5.23 (1H, d, J= 2.3 Hz, H-1), 4.16 (1H, dd, J= 4.0, 2.4 Hz, , H-2), 3.95 (1H, dd, J= 10.5, 
4.6 Hz, H-6), 3.91 (1H, t, J= 9.0 Hz, H-4), 3.85 (1H, dd, J= 8.3, 3.1 Hz, H-3), 3.80 (1H, 
dd, J= 10.4, 6.5 Hz, H-6), 3.56 – 3.49 (1H, b, OH), 3.29 (1H, ddd, J= 8.9, 6.4, 4.5 Hz, H-
5), 2.77 (1H, b, OH), 1.47 (3H, d, J= 4.9 Hz, CH3 eth), 0.90 (9H, s, t-Bu), 0.10 (3H, s, Si-
CH3), 0.09 (3H, s, Si-CH3); 13C NMR (125 MHz, CDCl3) δ 104.47 (Ceth), 96.82 (C-1), 
79.05 (C-2), 73.12 (C-5), 72.43 (C-3), 71.16 (C-4), 65.09 (C-6), 25.94 (C(CH3)3), 21.76 
(CH3 eth), 18.33 (t-Bu), -5.38 (SiCH3), -5.40 (SiCH3); v(max) (ATR-IR) 3398 (O-H stretch), 
2929, 2885 (C-H stretch), 1463, 1397 (C-H bend), 1252, 1140, 1057 (C-O stretch), 945, 
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877, 835, 739 (C-H bend) cm-1; HRMS-ESI [M+Na+] calculated for C14H28O6SiNa+: 




BnBr (5.4 mL, 45.5 mmol) was added to a stirred solution of 58 (4.86 g, 15.17 mmol) 
and NaH (60% in oil, 2.43 g, 60.7 mmol) in anhyd. DMF (15 mL) at 0°C. The reaction 
was left to slowly warm to room temperature overnight. The solvent was removed and 
the resulting residue was diluted with Et2O, washed with water then brine and dried over 
MgSO4. The solvent was evaporated and the residue was purified by column 
chromatography (EtOAc/PE, 1:9 to 1:1) to give the title compound 59 (Major/Minor 
=12:1, 7.60 g, 100%) as a pale yellow oil.  
Rf = 0.80 (2:1 PE/EtOAc); 1H NMR (500 MHz, CDCl3) δ 7.45 – 7.28 (10H, m, Ph), 5.33 
(1H, q, J= 4.9 Hz, Heth), 5.15 (1H, d, J= 2.2 Hz, H-1), 4.94 (1H, d, J= 10.7 Hz, PhCH2), 
4.83 (1H, d, J= 12.1 Hz, PhCH2), 4.79 (1H, d, J= 11.2 Hz, PhCH2), 4.77 (1H, d, J= 10.5 
Hz, PhCH2), 4.11 (1H, dd, J= 4.0, 2.3 Hz, H-2), 4.07 (1H, t, J= 9.3 Hz, H-4), 3.95 (1H, 
dd, J= 11.2, 3.4 Hz, H-6), 3.83 (1H, dd, J= 11.2, 2.0 Hz, H-6), 3.80 (1H, dd, J= 9.3, 4.0 
Hz, H-3), 3.26 (1H, ddd, J= 9.3, 3.4, 2.0 Hz, H-5), 1.55 (3H, d, J= 4.9 Hz, CH3 eth), 0.93 
(9H, s, t-Bu), 0.10 (3H, s, SiCH3), 0.09 (3H, s, SiCH3); 13C NMR (125 MHz, CDCl3) δ 
138.76 (i-Ph), 138.05 (i-Ph), 128.54, 128.51, 128.15, 128.09, 127.97, 127.78 (Ph), 104.44 
(Ceth), 96.83 (C-1), 78.87 (C-3), 78.13 (C-2), 75.47 (C-5), 75.21 (PhCH2), 74.61 (C-3), 
72.35 (PhCH2), 62.25 (C-6), 26.05 (C(CH3)3), 21.88 (CH3 eth), 18.42 (t-Bu), -5.00 (Si-
CH3), -5.21 (Si-CH3); v(max) (ATR-IR) 2929, 2856, 1496, 12 52, 1145, 1099, 1061, 878, 
835, 777, 734, 697, 632 cm-1; HRMS-ESI [M+Na+] calculated for C28H40O6Na+: 







Mannoside 59 (4.52 g, 9.04 mmol) was dissolved in THF (20 mL) and TBAF (1 M, 9.04 
mL, 9.04 mmol) was added to the solution. The mixture was allowed to stir overnight at 
room temp. The solvent was then removed in vacuo and the crude residue was purified 
on silica gel (1:1 PE/EtOAc) to afford the title compound 32 (3.31 g, 25:1 major/minor, 
95%) as a pale yellow oil.  
1H NMR (500 MHz, CDCl3) δ 7.42 – 7.28 (m, 10H, Ph), 5.28 (q, J = 4.9 Hz, 1H, Heth), 
5.21 (d, J = 2.6 Hz, 1H, H-1), 4.95 (d, J = 10.9 Hz, 1H, PhCH2), 4.86 – 4.75 (m, 2H, 
PhCH2), 4.69 (d, J = 11.0 Hz, 1H, PhCH2), 4.15 (dd, J = 4.0, 2.6 Hz, 1H, H-2), 3.93 (t, J 
= 9.3 Hz, 1H, H-4), 3.85 – 3.79 (m, 2H, H-3, H-6), 3.73 (ddd, J = 12.0, 7.5, 4.8 Hz, 1H, 
H-6), 3.38 (ddd, J = 9.3, 4.8, 3.0 Hz, 1H, H-5), 2.10 – 2.00 (m, 1H, OH), 1.53 (d, J = 4.9 
Hz, 3H, CH3). 13C NMR (125 MHz, CDCl3) δ 138.24, 137.85 (i-Ph), 128.66, 128.64, 
128.22, 128.21, 128.14, 128.05 (Ph), 104.20 (Ceth), 97.03 (C-1), 78.61 (C-3), 77.89 (C-
2), 75.42 (PhCH2 or C-5), 75.33 (PhCH2 or C-5), 74.77 (C-4), 72.35 (PhCH2), 62.27 (C-
6), 21.65 (CH3). v(max) (ATR-IR) 3469, 3030, 2873, 1604, 1496, 1452, 1400, 1372, 1323, 
1154, 1091, 1059, 1028, 879, 735, 698 cm-1; HRMS-ESI [M+Na+] calculated for 
C22H26O6Na+: 409.1622. Found: 409.1603. 
 
1,2,6-Tri-O-acetyl-3,4-di-O-benzyl-D-mannopyranose (60) 116-118 
 
Hydrochloric acid (37%, 9.6 mL) was added to a stirred solution of 32 (7089 mg, 1.834 
mmol) in dioxane (24.4 mL) and the reaction was left overnight. The solution was diluted 
with water and the aqueous layer was extracted with EtOAc, the combined organic layers 
were then washed with sat. NaHCO3(aq) followed by brine and dried with MgSO4, and the 
solvent was removed in vacuo. The resulting crude oil was dissolved in py. (5 mL) and 
then cooled to 0°C. Acetic anhydride (5 mL) was then added and the reaction was allowed 
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to stir overnight at room temperature. The product was extracted with EtOAc and the 
combined organic extract was washed with 10% HCl, water, 5% NaHCO3, and water 
again and was dried over anhyd. MgSO4. The solvents were removed in vacuo and the 
crude product was purified by column chromatography (2:1 PE/EtOAc) to give the title 
compound 60 (790 mg, 7:1 α/β, 89%) as a pale yellow oil. 
1H NMR (400 MHz, CDCl3) δ 7.39 – 7.27 (m, 10H, Ph), 6.07 (d, J = 2.0 Hz, 1H, H-1), 
5.37 (dd, J = 3.4, 2.1 Hz, 1H, H-2), 4.92 (d, J = 10.6 Hz, 1H, PhCH2), 4.74 (d, J = 11.0 
Hz, 1H, PhCH2), 4.58 (d, J = 4.9 Hz, 1H, PhCH2), 4.55 (d, J = 5.3 Hz, 1H, PhCH2), 4.31 
(dd, J = 4.7, 3.4 Hz, 2H, H-6), 3.99 (dd, J = 9.2, 3.4 Hz, 1H, H-3), 3.91 (ddd, J = 9.9, 4.4, 
2.6 Hz, 1H, H-5), 3.79 (t, J = 9.6 Hz, 1H, H-4), 2.17 (s, 3H, CH3), 2.09 (s, 3H, CH3), 2.06 
(s, 3H, CH3). 13C NMR (125 MHz, CDCl3) δ 170.85, 170.09, 168.36 (C=O), 137.87, 
137.58 (i-Ph), 128.70, 128.65, 128.31, 128.28, 128.22, 128.16 (Ph), 91.21 (C-1), 77.80 
(C-3), 75.57 (PhCH2), 73.64 (C-4), 72.10 (PhCH2), 71.93 (C-5), 67.48 (C-2), 63.16 (C-
6), 21.07, 21.02, 20.97 (CH3). v(max) (ATR-IR) 3457, 3032, 2933, 1739, 1368, 1218, 1071, 
1025, 969, 914, 736, 699 cm-1 ; C26H30O9Na+: 509.1782. Found: 509.1768. 
 
2,6-Di-O-acetyl-3,4-di-O-benzyl-D-mannopyranose (61) 118, 121 
  
Triacetylated mannoside 60 (1.54 g, 3.17 mmol) was dissolved in a solution of 
THF/MeOH (7:3, 120 mL) and cooled to 0°C. Gaseous ammonia was then bubbled 
through the solution until saturation and the reaction was stirred at 0°C for 1 hour and 
monitored by TLC. The solution was concentrated under reduced pressure to afford a 
residue which was then purified by column chromatography (1:1 EtOAc/PE) to give the 
title compound 61 (1.33 g, 10:1 α/β, 95%) as a colourless oil.  
1H NMR (400 MHz, CDCl3) δ 7.34 – 7.26 (m, 6H, Ph), 7.26 – 7.21 (m, 4H, Ph), 5.37 – 
5.31 (m, 1H, H-2), 5.17 (d, J = 1.8 Hz, 1H, H-1), 4.88 (d, J = 10.8 Hz, 1H, PhCH2), 4.68 
(d, J = 11.1 Hz, 1H, PhCH2), 4.54 (d, J = 6.7 Hz, 1H, PhCH2), 4.51 (d, J = 7.0 Hz, 1H, 
PhCH2), 4.32 (dd, J = 11.9, 2.4 Hz, 1H, H-6), 4.25 (dd, J = 11.9, 5.1 Hz, 1H, H-6), 4.04 
(ddd, J = 9.3, 6.3, 2.8 Hz, 2H, H-5, H-3), 3.71 (t, J = 9.6 Hz, 1H, H-4), 2.12 (d, J = 0.8 
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Hz, 3H, CH3), 2.02 (d, J = 0.8 Hz, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 171.02, 
170.51 (C=O), 138.12, 137.85 (i-Ph), 128.58, 128.57, 128.25, 128.17, 127.99 (Ph), 92.63 
(C-1), 77.66 (C-3), 75.34 (PhCH2), 74.22 (C-4), 71.94 (PhCH2), 69.96 (C-5), 69.00 (C-
2), 63.65 (C-6), 21.20, 21.01 (CH3). v(max) (ATR-IR) 3406, 3031, 2943, 1738, 1369, 1231, 
1052, 912, 735, 698 cm-1; HRMS-ESI [M+Na+] calculated for C24H28O8Na+: 467.1676. 
Found: 467.1648. 
 
2,6-Di-O-acetyl-3,4-di-O-benzyl-α-D-mannopyranosyl trichloroacetimidate  
(33) 118, 121 
  
Trichloroacetonitrile (620 μL, 6.17 mmol) and NaH (60% in oil, 5 mg, 0.123 mmol) were 
added to a solution of 61 (549 mg, 1.234 mmol) in anhyd. CH2Cl2 (10 mL) at 0°C, under 
an atmosphere of N2. The mixture was stirred for 2 hours at 0°C. The solvent was then 
removed in vacuo and the resulting oil was purified by column chromatography 
(PE/EtOAc gradient) to afford the title compound 33 (726 mg, 100%) as a yellow oil. 
1H NMR (400 MHz, CDCl3) δ 8.70 (s, 1H, NH), 7.39 – 7.27 (m, 10H, Ph), 6.25 (d, J = 
1.9 Hz, 1H, H-1), 5.50 (dd, J = 3.3, 2.1 Hz, 1H, H-2), 4.92 (d, J = 10.7 Hz, 1H, PhCH2), 
4.75 (d, J = 11.2 Hz, 1H, PhCH2), 4.59 (d, J = 11.0 Hz, 2H, PhCH2), 4.35 (dd, J = 12.1, 
2.4 Hz, 1H, H-6), 4.30 (dd, J = 12.0, 4.6 Hz, 1H, H-6), 4.08 – 4.00 (m, 2H, H-3, H-5), 






Methyl 6-[2,6-di-O-acetyl-3,4-di-O-benzyl-α-D-mannopyranosyloxy]hexanoate (70) 
and methyl 6-[3,4-di-O-benzyl-α-D-mannopyranosyloxy]hexanoate (14) 
   
Glycosyl donor 33 (583.2 mg, 0.990 mmol) and methyl 6-hydroxyhexanoate (25) (188 
mL, 1.288 mmol), were co-evaporated and the resulting residue was dissolved in freshly 
distilled toluene (10 mL). 4Å sieves (approx. 1 g) were added and the mixture was 
allowed to stir at room temperature for 1 hour.  The reaction was cooled to -20°C and 
TMSOTf (36 μL, 0.198 mmol) was added. The reaction was allowed to warm to -10°C 
over the course of 1 hour and monitored by TLC. The reaction was diluted with CH2Cl2 
and washed with water, brine and dried over MgSO4. The solvent was removed in vacuo 
and the residue was purified by column chromatography to give a small portion of title 
compound 70 as a clear colourless oil. The solvent was removed from the remaining 
fractions and the residue was dissolved in CH2Cl2/MeOH (10 mL/20 mL) and stirred over 
IRA-400 (OH-) exchange resin overnight. The solvent was removed in vacuo and the 
resulting residue was purified by column chromatography to give the title compound 14 
(422.2 mg, 87% over two steps) as a clear oil.  
Data for 70: [α]20D = +68.0 (c 1.4, CH2Cl2);  1H NMR (400 MHz, CDCl3) δ 7.36 – 7.27 
(m, 9H, Ph), 7.26 – 7.23 (m, 1H, Ph), 5.34 (dd, J = 3.4, 1.8 Hz, 1, H-2), 4.88 (d, J = 10.7 
Hz, 1H, PhCH2), 4.77 (d, J = 1.8 Hz, 1H, H-1), 4.70 (d, J = 11.0 Hz, 1H, PhCH2), 4.54 
(d, J = 3.6 Hz, 1H, PhCH2), 4.52 (d, J = 4.0 Hz, 1H, PhCH2), 4.33 (dd, J = 11.9, 4.8 Hz, 
1H, H-6), 4.29 (dd, J = 11.9, 2.6 Hz, 1H, H-6), 3.98 (dd, J = 9.2, 3.4 Hz, 1H, H-3), 3.82 
(ddd, J = 10.0, 4.8, 2.5 Hz, 1H, H-5), 3.71 (t, 1H, H-4), 3.64 (s, 3H, OCH3), 3.61 (dt, 1H, 
H-7), 3.38 (dt, J = 9.6, 6.5 Hz, 1H, H-7), 2.30 (t, J = 7.5 Hz, 2H. H-11), 2.13 (s, 3H, CH3), 
2.05 (s, 3H, CH3), 1.68 – 1.52 (m, 4H, H-10, H-8), 1.40 – 1.30 (m, 2H, H-9); 13C NMR 
(125 MHz, CDCl3) δ 174.13, 170.92, 170.49 (C=O), 138.13, 137.93 (i-Ph), 128.59, 
128.57, 128.26, 128.03, 127.96 (Ph), 97.90 (C-1), 78.33 (C-3), 75.43 (PhCH2), 74.26 (C-
4), 71.94 (PhCH2), 69.81 (C-5), 68.79 (C-2), 67.96 (C-7), 63.60 (C-6), 51.65 (OCH3), 
34.07 (C-11), 29.18 (C-link), 25.86 (C-link), 24.81 (C-link), 21.22 (CH3), 21.00 (CH3). 
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v(max) (ATR-IR) 2931, 2867, 1738, 1496, 1453, 1232, 1164, 1137, 1074, 742, 699 cm-1 ; 
HRMS-ESI [M+Na+] calculated for C31H40O10Na+: 595.2514. Found: 595.2527. 
Data for 14: 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.27 (m, 10H, Ph), 4.88 (d, J = 10.9 
Hz, 1H, PhCH2), 4.85 (d, J = 1.7 Hz, 1H, H-1), 4.71 (s, 2H, PhCH2), 4.66 (d, J = 10.9 Hz, 
1H, PhCH2), 4.02 (dd, J = 3.2, 1.7 Hz, 1H, H-2), 3.89 (dd, J = 9.2, 3.1 Hz, 1H, H-3), 3.87 
– 3.81 (m, 2H, H-4, H-6), 3.78 (dd, J = 11.9, 4.2 Hz, 1H, H-6), 3.68 – 3.60 (m, 5H, H-5, 
H-7, OCH3), 3.38 (dt, J = 9.7, 6.4 Hz, 1H, H-7), 2.31 (t, J = 7.5 Hz, 2H, H-11), 2.20 (s, 
2H, OH), 1.67 – 1.50 (m, 4H, H-link), 1.41 – 1.28 (m, 2H, H-link). 13C NMR (125 MHz, 
CDCl3) δ 174.19 (C=O), 138.35, 138.02 (i-Ph), 128.68, 128.59, 128.17, 128.09, 127.96 
(Ph), 99.26 (C-1), 80.25 (C-3), 75.40 (PhCH2), 74.27, 72.24 (PhCH2), 71.59 (C-5), 68.64 
(C-2), 67.63 (C-7), 62.20 (C-6), 51.65 (OCH3), 34.07 (C-11), 29.18 (C-link), 25.85 (C-
link), 24.81 (C-link). HRMS-ESI [M+Na+] calculated for C27H36O8Na+: 511.2302. 
Found: 511.2295.  
 
3,4,6-Tri-O-acetate-1,2-O-(ethyl orthoacetate)-β-D-mannopyranose (71) 9, 107, 124 
 
A solution of 54 (8.34 g, 20.28 mmol) in CHCl3:collidine (20 mL : 4.2 mL) containing 
TBAB (0.458 g, 1.42 mmol) and absolute ethanol (4 mL) was stirred at reflux for 
approximately 24 hours. The cooled reaction mixture was diluted with Et2O and the 
precipitate was removed by filtration. The filtrate was washed with distilled water, sat. 
NaHCO3(aq), and brine. The organic layer was dried over MgSO4, filtered, and the solvent 
was removed to give the title compound 71 (7.59 g, 100%) as a white solid. A small 
amount of the residue was recrystallised from Et2O/PE to give a pure sample for data 
collection.  
1H NMR (400 MHz, CDCl3) δ 5.47 (d, J = 2.6 Hz, 1H, H-1), 5.30 (t, J = 9.7 Hz, 1H, H-
4), 5.15 (dd, J = 9.9, 4.0 Hz, 1H, H-3), 4.60 (dd, J = 4.0, 2.6 Hz, 1H, H-2), 4.23 (dd, J = 
12.1, 4.9 Hz, 1H, H-6), 4.14 (dd, J = 12.1, 2.7 Hz, 1H, H-6), 3.68 (ddd, J = 9.5, 4.9, 2.7 
Hz, 1H, H-5), 3.61 – 3.49 (m, 2H, OCH2CH3), 2.12 (s, 3H, CH3), 2.07 (s, 3H, CH3), 2.05 
(s, J = 0.6 Hz, 3H, CH3), 1.75 (s, 3H, CH3 orth), 1.18 (t, J = 7.1 Hz, 3H, OCH2CH3); 13C 
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NMR (100 MHz, CDCl3) δ 170.81, 170.54, 169.57 (C=O), 124.38 (Corth), 97.50 (C-1), 
76.52 (C-2), 71.49 (C-5), 70.78 (C-3), 65.7 (C-4), 62.51 (C-6), 58.31 (OCH2CH3), 24.84 
(CH3 orth), 20.93 (CH3) , 20.88 (CH3), 20.83 (CH3), 15.20 (OCH2CH3); v(max) (ATR-IR) 
2976, 2950, 2158, 2025, 1737 (C=O), 1227, 1196, 1053 (C-O), 1031 (C-O), 896, 595 cm-
1; HRMS-ESI [M+Na+] calculated for C16H24O10Na+: 399.1262. Found: 399.1280. 
 
1,2-O-(Ethyl orthoacetate)-β-D-mannopyranose (72) 9, 107, 124 
 
Method A: IRA-400 (OH-) exchange resin beads (approx. 1 g) were added to a solution 
of 71 (5.17 g, 13.74 mmol) in methanol (30 mL). The reaction was left stirring overnight 
at room temperature after which the mixture was filtered and the solvent was removed in 
vacuo to give the title compound 72 (3.30 g, 96%) as a clear oil.  
1H NMR (400 MHz, CDCl3) δ 5.50 (d, J = 2.8 Hz, 1H, H-1), 4.52 (dd, J = 4.0, 2.8 Hz, 
1H, H-2), 3.93 – 3.68 (m, 4H, H-3, H-4, H-6), 3.67 – 3.52 (m, 2H, OCH2CH3), 3.35 (ddd, 
J = 8.6, 4.6, 3.4 Hz, 1H, H-5), 2.70 (s, 1H, OH), 2.42 (s, 1H, OH), 1.69 (s, 3H, CH3 orth), 
1.20 (t, J = 7.1 Hz, 3H, OCH2CH3). 13C NMR (100 MHz, CDCl3) δ 123.57 (Corth), 97.68 
(C-1), 78.91, 74.96, 72.00, 67.51, 61.94, 58.15 (OCH2CH3), 24.86 (CH3 orth), 15.13 
(OCH2CH3); HRMS-ESI [M+Na+] calculated for C10H18O7Na+: 273.0945. Found: 
273.0928. 
Method B: Sodium methoxide (0.5 M in MeOH, 2 mL, 1.00 mmol) was added to a stirred 
solution of 71 (1.52 g, 4.039 mmol) in MeOH/CH2Cl2 (2:1, 15 mL) and was allowed to 
stir at room temperature overnight. The reaction mixture was diluted with MeOH and the 
solvent was removed in vacuo to give the crude product 72 (980 mg, 97%) as a clear oil, 





3,4,6-Tri-O-benzyl-1,2-O-(ethyl orthoacetate)-β-D-mannopyranose (73) 9, 107, 124 
 
BnBr (7.69 mL, 64.7 mmol) was added to a stirred solution of 72 (3.24 g, 12.95 mmol) 
and Nah (60% in oil, 3.11 g, 78 mmol) in anhyd. DMF (20 mL) at 0°C. The reaction was 
left to slowly warm to room temperature and then stirred overnight. The reaction was then 
quenched with MeOH and the solvent removed. The residue was diluted with Et2O, 
washed with water then brine and dried over MgSO4. The solvent was removed and the 
residue was purified by column chromatography (EtOAc/PE, 1:9 to 1:1) to give the title 
compound 73 (6.081 g, 90%) as a pale yellow foam. 
1H NMR (400 MHz, CDCl3) δ 7.43 – 7.25 (m, 15H, Ph), 5.33 (d, J = 2.5 Hz, 1H, H-1), 
4.89 (d, J = 10.8 Hz, 1H, PhCH2), 4.78 (d, J = 2.1 Hz, 2H, PhCH2), 4.61 (d, J = 11.5 Hz, 
1H, PhCH2), 4.56 (d, J = 2.5 Hz, 1H, PhCH2), 4.48 (d, J = 15.5 Hz, 1H, PhCH2), 4.38 
(dd, J = 4.0, 2.6 Hz, 1H, H-2), 3.92 (t, J = 9.3 Hz, 1H, H-4), 3.77 – 3.67 (m, 3H, H-3, H-
6), 3.61 – 3.48 (m, 2H, OCH2CH3), 3.42 (ddd, 1H, H-5), 1.74 (s, 3H, CH3 orth), 1.22 (t, J 
= 7.0 Hz, 3H, OCH2CH3); 13C NMR (100 MHz, CDCl3) δ 138.38, 138.00 (i-Ph), 128.69, 
128.63, 128.52, 128.43, 128.19, 128.17, 128.11, 127.89, 127.66, 127.63, 127.10 (Ph), 
123.87 (Corth), 97.64 (C-1) , 79.19 (C-3), 77.04 (C-2), 75.37 (PhCH2), 74.40 (C-4 or C-
5), 74.30 (C-4 or C-5), 73.50 (PhCH2), 72.52 (PhCH2), 69.16 (C-6), 58.07 (OCH2CH3), 
24.88 (CH3 orth), 15.39 (OCH2CH3); v(max) s(ATR-IR) 3030 (C-H), 2976, 2928, 2887, 1585 
(C=C), 1158 (C-O), 1097, 1069 (C-O), 732, 694 cm-1; HRMS-ESI [M+Na+] calculated 
for C31H36O7Na+: 543.2353. Found: 543.2311. 
 
3,4,6-Tri-O-benzyl-1,2-O-(methyl orthoacetate)-β-D-mannopyranose (239) 165-166 
 
A solution of 54 (5.12 g, 12.45 mmol) in CHCl3:collidine (30 mL : 2.6 mL) containing 
TBAB (280 mg, 0.872 mmol) and methanol (2 mL) was stirred at reflux for 
approximately 24 hours. The cooled reaction mixture was diluted with Et2O and the 
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precipitate was removed by filtration. The filtrate was washed with distilled water, 
saturated NaHCO3, and brine. The organic layer was dried over MgSO4, filtered, and the 
solvent removed to give a white solid. This crude material was then dissolved in a small 
amount of CH2Cl2 and diluted with MeOH (30 mL). IRA-400 (OH-) exchange resin beads 
(approx. 1 g) were added and the mixture was stirred slowly overnight. The solvent was 
removed and the resulting clear oil was then dissolved in anhyd. DMF (20 mL) and cooled 
to 0°C. NaH (60% in oil, 2.09 g) was added followed by the dropwise addition of BnBr 
(6.65 mL, 56.0 mmol). The reaction was allowed to slowly warm to room temperature 
and was stirred overnight. The reaction was then quenched with MeOH and the solvent 
removed. The residue was diluted with Et2O, washed with water then brine and dried over 
MgSO4. The solvent was removed in vacuo and the residue was purified by column 
chromatography (EtOAc/PE, 1:9 to 1:1) to give the title compound 239 (4.98 g, 79% over 
three steps) as a pale yellow oil. 
1H NMR (400 MHz, CDCl3) δ 7.43 – 7.21 (m, 15H, Ph), 5.35 (d, J = 2.5 Hz, 1H, H-1), 
4.90 (d, J = 10.8 Hz, 1H, PhCH2), 4.79 (d, J = 1.8 Hz, 2H, PhCH2), 4.59 (t, J = 11.7 Hz, 
3H, PhCH2), 4.40 (dd, J = 4.0, 2.6 Hz, 1H, H-2), 3.92 (t, J = 9.3 Hz, 1H, H-4), 3.78 – 3.68 
(m, 3H, H-3, H-6, H-6), 3.46 – 3.39 (m, 1H, H-5), 3.29 (d, J = 0.7 Hz, 3H, OCH3), 1.74 
(s, 3H, CH3 orth). HRMS-ESI [M+Na+] calculated for C30H34O7Na+: 529.2197. Found: 
529.2186. 
 
2-O-Acetyl-3,4,6-tri-O-benzyl-D-mannopyranose (74) 9, 107, 124 
 
Method A: Orthoester 73 (5.96 g, 11.45 mmol) was dissolved in 60% aqueous acetic acid 
(200 mL) and the mixture was stirred overnight. The solvent was removed and the residue 
was dissolved in CH2Cl2. The organic phase was washed with water followed by sat. 
NaHCO3(aq) and dried over MgSO4. The solvent was removed under vacuum and the 
crude oil was purified by column chromatography (PE/EtOAc gradient) to give the title 
compound 74 (5.13 g, 91%) as a colourless oil. 
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 1H NMR (400 MHz, CDCl3) δ 7.39 – 7.30 (m, 9H, Ph), 7.30 – 7.27 (m, 3H, Ph), 7.20 – 
7.12 (m, 3H, Ph), 5.39 (dd, J = 3.3, 1.9 Hz, 1H, H-2), 5.24 (dd, J = 3.8, 1.9 Hz, 1H, H-1), 
4.86 (d, J = 10.9 Hz, 1H, PhCH2), 4.71 (d, J = 11.2 Hz, 1H, PhCH2), 4.62 (d, J = 3.8 Hz, 
1H, PhCH2), 4.55 (d, J = 6.8 Hz, 1H, PhCH2), 4.52 (d, J = 7.6 Hz, 1H, PhCH2), 4.47 (d, 
J = 10.8 Hz, 1H, PhCH2), 4.06 (td, J = 9.1, 3.3 Hz, 2H, H-3, H-5), 3.77 (d, J = 9.7 Hz, 
1H, H-4), 3.73 – 3.69 (m, 2H, H-6), 2.15 (s, 3H, CH3); 13C NMR (100 MHz, CDCl3) δ 
170.61 (C=O), 138.39, 138.03, 137.96 (i-Ph), 128.71, 128.57, 128.51, 128.48, 128.44, 
128.31, 128.20, 128.18, 128.14, 128.07, 128.03, 127.99, 127.86, 127.84, 127.76 (Ph), 
92.56 (C-1), 77.76 (C-3), 75.21(PhCH2), 74.72 (C-4), 73.53 (PhCH2), 71.89 (PhCH2), 
71.20 (C-6), 69.40 (C-2), 69.20 (C-5), 21.26 (CH3); HRMS-ESI [M+Na+] calculated for 
C29H32O7Na+: 515.2040. Found: 515.2002. 
Method B: Orthoester 239 (1.11 g, 2.197 mmol) was dissolved in 60% aqueous acetic 
acid (50 mL) and the mixture was stirred overnight. The solvent was removed and the 
residue was dissolved in CH2Cl2. The organic phase was washed with water followed by 
sat. NaHCO3(aq) and dried over MgSO4. The solvent was removed under vacuum and the 
crude oil was purified by column chromatography (PE/EtOAc gradient) to give the title 
compound 74 (1.02 g, 94%) as a colourless oil.  
 
2-O-Acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl trichloroacetimidate  
(24) 9, 107, 124 
 
NaH (60% in oil, 3.8 mg, 0.096 mmol) and trichloroacetonitrile (480 μL, 4.78 mmol) 
were added to a solution of 74 (471 mg, 0.956 mmol) in anhyd. CH2Cl2 (10 mL) at 0°C, 
under an atmosphere of N2. The mixture was stirred for two hours at 0°C. The solvent 
was then removed in vacuo and the residue was purified by column chromatography 
(PE/EtOAc 1:1) to afford the title compound 24 (601 mg, 100%) as a clear oil. 
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1H NMR (400 MHz, CDCl3) δ 8.67 (s, 1H, NH), 7.39 – 7.26 (m, 13H, Ph), 7.18 (dd, J = 
7.2, 2.3 Hz, 2H, Ph), 6.30 (d, J = 2.0 Hz, 1H, H-1), 5.49 (d, J = 2.3 Hz, 1H, H-2), 4.87 (d, 
J = 10.6 Hz, 1H, PhCH2), 4.73 (d, J = 11.3 Hz, 1H, PhCH2), 4.68 (d, J = 12.1 Hz, 1H, 
PhCH2), 4.58 (d, J = 11.2 Hz, 1H, PhCH2), 4.54 (d, J = 10.2 Hz, 1H, PhCH2), 4.51 (d, J 
= 12.0 Hz, 1H, PhCH2), 4.07 – 3.95 (m, 3H, H-3, H-4, H-5), 3.84 (dd, J = 11.2, 1H, H-
6), 3.72 (dd, J = 11.1, 1.7 Hz, 1H, H-6), 2.19 (d, J = 1.9 Hz, 3H, CH3); 13C NMR (100 
MHz, CDCl3) δ 170.12 (C=O), 160.15 (C=N), 138.16, 138.09, 137.52 (i-Ph) , 128.44, 
128.36, 128.31, 128.26, 128.10, 127.93, 127.79, 127.61 (Ph), 95.45 (C-1), 77.44 (C-3), 
75.33 (PhCH2), 74.47 (C-4 or C-5), 73.66 (C-4 or C-5), 73.43 (PhCH2), 72.10 (PhCH2), 
68.29 (C-2), 67.23 (C-6), 21.14 (CH3); HRMS-ESI [M+Na+] calculated for 




   
Glycosyl donor 24 (437.6 mg, 0.687 mmol) and acceptor 14 (141.8 mg, 0.290 mmol) 
were co-evaporated twice with toluene and the resulting residue was dissolved in freshly 
distilled toluene (12 mL). 4Å sieves (approx. 1 g) were added and the mixture was 
allowed to stir at room temperature for 1 hour.  The reaction was cooled to -20°C and 
TMSOTf (26.3 μL, 0.145 mmol) was added. The reaction was allowed to warm to -10°C 
over the course of 1 hour and monitored by TLC. The reaction was diluted with CH2Cl2 
and washed with 1 M NaOH(aq) then brine and dried over MgSO4. The solvent was 
removed in vacuo and the residue was purified by column chromatography (PE/EtOAc 
gradient) to give title compound 78 (272 mg, 65%) as a clear colourless oil. 
[α]20D = + 93.8 (c 1.0, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.37 – 7.21 (m, 36H, Ph), 
7.19 – 7.16 (m, 2H, Ph), 7.15 – 7.11 (m, 2H, Ph), 5.57 (dd, J = 3.4, 1.8 Hz, 1H, H-2A), 
5.41 (dd, J = 3.2, 1.8 Hz, 1H, H-2B), 5.09 (d, J = 1.8 Hz, 1H, H-1A), 4.93 (d, J = 1.8 Hz, 
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1H, H-1B), 4.88 (d, J = 11.0 Hz, 1H, PhCH2), 4.84 (dd, J = 10.8, 2.6 Hz, 2H, PhCH2), 
4.79 (d, J = 1.7 Hz, 1H, H-1), 4.73 (d, J = 10.8 Hz, 1H, PhCH2), 4.68 (dd, J = 8.3, 2.3 Hz, 
3H, PhCH2), 4.66 – 4.61 (m, 2H, PhCH2), 4.54 (dd, J = 11.0, 8.8 Hz, 2H, PhCH2), 4.49 – 
4.46 (m, 3H, PhCH2), 4.46 – 4.40 (m, 2H, PhCH2), 4.05 – 3.68 (m, 15H, ring protons), 
3.67 – 3.59 (m, 5H, ring protons, OCH3), 3.55 (dt, J = 9.7, 6.5 Hz, 1H, H-7), 3.24 (dt, J 
= 9.7, 6.3 Hz, 1H, H-7), 2.27 (t, J = 7.6 Hz, 2H, H-11), 2.12 (d, J = 3.5 Hz, 6H, CH3), 
1.60 (p, J = 7.7 Hz, 2H, H-link), 1.49 (tt, J = 8.0, 6.5 Hz, 2H, H-link), 1.35 – 1.21 (m, 2H, 
H-link). 13C NMR (125 MHz, CDCl3) δ 174.11 (C=Olink), 170.31, 170.22 (C=O), 138.71, 
138.49, 138.40, 138.32, 138.13, 137.96 (i-Ph), 128.51, 128.48, 128.46, 128.44, 128.41, 
128.39, 128.37, 128.32, 128.28, 128.22, 128.06, 128.01, 127.90, 127.86, 127.77, 127.72, 
127.69, 127.67, 127.63, 127.61, 127.56 (Ph), 99.79 (C-1A), 98.66 (C-1), 97.58 (C-1B), 
80.10, 78.24, 75.30, 75.16, 75.13, 74.88, 74.80, 74.49, 74.26, 73.51, 73.48, 72.16, 72.14, 
72.10, 72.01, 71.92, 71.71 (C-2A), 71.51, 71.46 (C-2B), 70.77, 69.13, 68.83, 68.80, 68.63, 
67.39 (C-7), 66.75, 51.56, 34.06 (C-11), 29.16 (C-link), 25.91 (C-link), 24.86 (C-link), 
21.24 (CH3), 21.20 (CH3). v(max) (ATR-IR) 3062, 3030, 2924, 2868, 1741, 1495, 1453, 
1366, 1234, 1137, 1095, 1053, 979, 739, 698 cm-1 ; HRMS-ESI [M+Na+] calculated for 
C85H96O20Na+: 1459.6387. Found: 1459.6393. 
 
6-[2,6-Di-O-(3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4-di-O-benzyl-α-D-
mannopyranosyloxy]hexanoic acid (83) 
 
NaOH(aq) (2 M, 2 mL) was added to a solution of 78 (416 mg, 0.289 mmol) in THF (10 
mL) and stirred for 24 hours at 75°C. The solution was allowed to cool to room 
temperature and was neutralised with amberlite 15 (H+) ion exchange resin, then filtered 
and the solvent was evaporated. The crude product was purified by column 
chromatography (PE/EtOAc, 1:1, 1% AcOH) to give title compound 83 (365.5 mg, 94%) 
as a clear colourless oil. 
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[α]20D = +127.6 (c 1.1 g/100 mL, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.10 (m, 
40H, Ph), 5.12 (s, 1H, H-1B), 5.10 (s, 1H, H-1A), 4.90 (s, 1H, H-1), 4.89 – 4.40 (m, 16H, 
PhCH2), 4.17 – 4.14 (m, 1H, H-2B), 4.11 (s, 1H, H-2A), 3.98 (d, J = 2.7 Hz, 1H, H-2), 
3.94 – 3.60 (m, 15H, ring protons), 3.49 (dt, J = 7.3 Hz, 1H, H-7), 3.21 (dt, J = 7.2 Hz, 
1H, H-7), 2.29 (t, J = 7.2 Hz, 2H, H-11), 1.59 (p, J = 7.4 Hz, 2H, H-link), 1.54 – 1.40 ( 
2H, H-link), 1.36 – 1.20 (m, 2H, H-link). 13C NMR (125 MHz, CDCl3) δ 177.08 (C=O), 
138.54, 138.42, 138.37, 138.27, 138.05, 137.99, 137.92 (i-Ph), 128.64, 128.60, 128.56, 
128.53, 128.42, 128.40, 128.03, 127.99, 127.96, 127.93, 127.89, 127.86, 127.82, 127.69, 
127.67 (Ph), 101.41 (C-1B), 99.54 (C-1A), 98.63 (C-1), 80.36, 79.82, 75.72 (C-2), 75.34, 
75.25, 75.13, 74.80, 74.51, 74.42, 73.50, 73.48, 73.46, 72.32, 72.29, 71.78, 71.43, 71.37, 
69.27, 69.07, 68.61 (C-2B), 68.30 (C-2A), 67.39 (C-7), 65.62, 33.69 (C-11), 28.99 (C-
link), 25.67 (C-link), 24.54 (C-link). v(max) (ATR-IR) 3436, 3030, 2916, 1746, 1496, 1453, 
1364, 1220, 1047, 981, 737, 697 cm-1; HRMS-ESI [M+Na+] calculated for C80H90O18Na+: 
1361.6019. Found: 1361.6024. 
N-succinimidyl 6-[2,6-di-O-(3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4-di-O-
benzyl-α-D-mannopyranosyloxy] hexanoate (79) 
  
Trimannoside 83 (183.4 mg, 0.137 mmol), EDCI.HCl (31.9 mg, 0.205 mmol), and N-
hydroxysuccinimide (23.64 mg, 0.205 mmol) were dissolved in CH2Cl2 and allowed to 
stir overnight at room temperature. The reaction mixture was diluted with CH2Cl2 and 
washed with NH4Cl(aq) then dried over MgSO4 and the solvent was evaporated. The crude 
residue was purified by column chromatography (PE/EtOAc gradient) to give the title 
compound 79 (165.7 mg, 84%) as a clear colourless oil.  
[α]20D = +106.3 (c 1.6, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ δ 7.40 – 7.09 (m, 40H, 
Ph), 5.10 (dd, J = 3.4, 1.7 Hz, 2H, H-1A and B), 4.91 (d, J = 1.8 Hz, 1H, H-1), 4.88 – 4.76 
(m, 3H, PhCH2), 4.72 – 4.42 (m, 13H, PhCH2), 4.16 (t, J = 2.4 Hz, 1H, H-2A or B), 4.12 (t, 
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J = 2.4 Hz, 1H, H-2A or B), 3.99 (t, J = 2.5 Hz, 1H, H-2), 3.97 – 3.59 (m, 16H, sugar ring 
protons), 3.51 (dt, J = 9.8, 6.3 Hz, 1H, H-7), 3.20 (dt, J = 9.8, 6.1 Hz, 1H, H-7), 2.76 – 
2.64 (m, 4H, O-Succ), 2.56 (t, J = 7.3 Hz, 2H, H-11), 1.71 (p, J = 7.5 Hz, 2H, H-link), 
1.53 – 1.44 (m, 2H, H-link), 1.42 – 1.32 (m, 2H, H-link). 13C NMR (125 MHz, CDCl3) δ 
169.30, 168.63 (C=O), 138.60, 138.54, 138.47, 138.13, 138.05, 137.93 (i-Ph), 128.62, 
128.58, 128.52, 128.51, 128.49, 128.40, 128.37, 128.36, 128.01, 127.99, 127.98, 127.93, 
127.90, 127.86, 127.83, 127.80, 127.75, 127.64, 127.60 (Ph), 101.56 (C-1A or B), 99.70 
(C-1A or B), 98.69 (C-1), 79.89, 79.75, 76.06, 75.31 (C-2), 75.18, 75.08, 74.72, 74.53, 
74.41, 73.50, 73.45, 72.27, 72.23, 71.72 (C-2A or B), 71.45 (C-2A or B), 71.41 (C-7), 71.38, 
31.04 (C-11), 29.00 (C-link), 25.64 (C-Succ), 25.54 (C-link), 24.53 (C-link). v(max) (ATR-
IR) 3469, 3030, 2922, 1737, 1048, 738, 698 cm-1; HRMS-ESI [M+Na+] calculated for 
C84H93O20NNa+: 1458.6183. Found: 1458.6211.  
 
6-[2,6-Di-O-(α-D-mannopyranosyl)-3,4-di-O-benzyl-α-D-
mannopyranosyloxy]hexanoic acid (240) 
 
Trimannoside 83 (209 mg, 0.156 mmol) was dissolved in EtOH/THF (1:1, 14 mL) and 
10% Pd/C catalyst (200 mg) was added. The reaction was purged of atmosphere and H2(g) 
was bubbled through (x3). The solution was allowed to stir under H2(g) overnight at room 
temperature. The reaction mixture was diluted with EtOH and filtered through a Celite® 
and the solvent was removed. The title compound 240 (70 mg, 73%) was obtained as a 
white foam. 
1H NMR (500 MHz, D2O) δ 5.09 (d, J = 1.8 Hz, 1H, H-1), 5.03 (d, J = 1.9 Hz, 1H, H-1), 
4.95 – 4.91 (m, 1H, H-1), 4.11 – 4.05 (m, 1H, H-2), 3.98 (ddd, J = 15.0, 6.2, 3.5 Hz, 3H, 
ring), 3.93 – 3.86 (m, 3H, ring), 3.85 – 3.62 (m, 12H, ring protons, H-7), 3.57 (dt, J = 9.8, 
6.0 Hz, 1H, H-7), 2.41 (t, J = 7.4 Hz, 2H, H-11), 1.64 (p, J = 7.2, 6.2 Hz, 4H, H-link), 
1.41 (dq, J = 15.6, 7.9, 7.4 Hz, 2H, H-link). 13C NMR (125 MHz, D2O) δ 181.66 (C=O), 
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105.00 (C-1), 102.10 (C-1), 100.85 (C-1), 81.54, 75.92, 75.39, 73.82, 73.29, 73.05, 73.01, 
72.65, 72.61, 70.50 (C-7), 69.38, 69.28, 67.90, 63.67, 63.55 (ring carbons), 36.32 (C-11), 
30.73 (C-link), 27.54 (C-link), 26.60 (C-link). HRMS-ESI [M+Na+] calculated for 





Trimannoside 79 (103 mg, 0.072 mmol) was dissolved in EtOH/THF (1:1, 6 mL) and 
10% Pd/C catalyst (100 mg) was added. The reaction was purged of atmosphere and H2(g) 
was bubbled through (x3). The solution was allowed to stir under H2(g) overnight at room 
temperature. The reaction mixture was diluted with EtOH and filtered through Celite® 
and the solvent was removed. The resulting residue was re-dissolved in water and 
subjected to freeze drying conditions to give the title compound 3 (50.5 mg, 98%) as an 
off-white powder. 
1H NMR (500 MHz, DMSO-d6) δ 4.87 – 4.85 (d, 1H, OH), 4.84 (d, J = 1.6 Hz, 1H, H-
1B), 4.83 – 4.80 (m, 2H, H-1, OH), 4.77 (d, J = 5.6 Hz, 1H, OH), 4.71 (d, J = 1.6 Hz, 1H, 
H-1A), 4.69 – 4.66 (m, 2H, OH), 4.65 (d, J = 4.5 Hz, 1H, OH), 4.54 (d, J = 5.9 Hz, 1H, 
OH), 4.49 (d, J = 6.0 Hz, 1H, OH), 4.47 (t, J = 5.8 Hz, 1H, 6-OH), 4.42 (t, J = 6.0 Hz, 
1H, 6-OH), 3.73 (ddd, J = 4.8, 3.2, 1.6 Hz, 1H, H-2), 3.68 – 3.34 (m, 17H, ring protons), 
2.81 (s, 4H, Succ), 2.67 (t, J = 7.3 Hz, 2H, H-11), 1.69 – 1.33 (m, 6H, H-link). 13C NMR 
(125 MHz, DMSO-d6) δ 170.24, 168.92 (C=O), 102.33 (C-1), 99.44 (C-1A), 98.19 (C-
1B), 77.90, 74.13, 73.66, 72.05, 70.88, 70.76, 70.49, 70.29, 70.08 (C-2), 67.11, 66.99, 
66.81, 66.16, 65.21, 61.28, 61.22, 30.12 (C-11), 28.44 (C-link), 25.43 (C-Succ), 24.83 
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This reaction occurred when 3 was left overnight in an NMR tube of CD3OD.  
1H NMR (500 MHz, CD3OD) δ 5.08 (d, J = 1.7 Hz, 1H, H-1), 4.93 (d, J = 1.7 Hz, 1H, H-
1), 4.92 (d, J = 1.7 Hz, 1H, H-1), 4.00 (dd, J = 3.3, 1.8 Hz, 1H), 3.92 (dd, J = 11.6, 4.3 
Hz, 1H), 3.88 (dd, J = 3.4, 1.7 Hz, 1H), 3.83 (ddd, J = 11.9, 4.7, 2.0 Hz, 2H), 3.80 – 3.76 
(m, 2H), 3.76 – 3.68 (m, 3H), 3.68 – 3.65 (m, 1H), 3.64 – 3.56 (m, 5H), 3.44 (dtd, J = 9.4, 
6.2, 3.0 Hz, 1H), 2.33 (t, J = 7.4 Hz, 1H), 2.30 (t, J = 7.4 Hz, 1H), 1.62 (ddt, J = 16.5, 
11.3, 8.3 Hz, 4H), 1.39 (s, 3H), 1.17 (t, J = 7.0 Hz, 4H). 13C NMR (125 MHz, CD3OD) δ 
175.97, 126.11, 104.46 (C-1), 101.56 (C-1), 99.90 (C-1), 81.38, 75.02, 74.57, 73.76, 
72.56, 72.43, 72.05, 71.98, 71.91, 68.79, 68.64, 68.53, 68.45, 66.25, 63.03, 63.00, 58.32, 
34.72, 30.89, 30.26, 26.88, 25.77, 18.36. HRMS-ESI [M+Na+] calculated for 








2-Bromoethyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (92) 135, 167-168 
 
2-bromoethanol (4 mL, 50 mmol) and 4Å molecular sieves (1 g) were added to a stirred 
solution of pentaacetate 54 (8.37 g, 21.44 mmol) in anhyd. CH2Cl2 (15 mL) and the 
resulting solution was stirred for 30 minutes at room temperature. BF3OEt2 (16 mL, 130 
mmol) was then added dropwise and the reaction was stirred for 3 days at room 
temperature. The reaction mixture was then added to cold brine, the organic layer 
extracted, and again washed with brine, dried over MgSO4 and concentrated in vacuo. 
The crude residue was recyrstallised using Et2O/PE and filtered. The resulting solvent 
was removed and the remaining residue was purified using column chromatography 
(PE/EtOAc gradient) to give the product 92 (8.79 g, 90%) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 5.35 (dd, J = 10.0, 3.3 Hz, 1H, H-3), 5.33 – 5.24 (m, 2H, 
H-2, H-4), 4.87 (d, J = 1.8 Hz, 1H, H-1), 4.29 (dd, J = 12.2, 5.3 Hz, 1H, H-6), 4.13 (dd, 
J = 12.3, 2.4 Hz, 1H, H-6), 4.05 (ddd, J = 9.7, 5.3, 2.4 Hz, 1H, H-5), 3.91 – 3.80 (m, 1H, 
H-7), 3.67 (ddd, J = 11.4, 6.1, 3.7 Hz, 1H, H-7), 3.55 – 3.37 (m, 2H, H-8), 2.16 (s, 3H, 
CH3), 2.10 (s, 3H, CH3), 2.05 (s, 3H, CH3), 1.99 (s, 3H, CH3). v(max) (ATR-IR) 2959, 
1740, 1367, 1215, 1135, 1084, , 1041 cm-1 ; HRMS-ESI [M+Na+] calculated for 
C16H2379BrO10Na+: 477.0367. Found: 477.0379. 
 
2-Azidoethyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (93) 135, 167-168 
 
Sodium azide (1.142 g, 17.57 mmol) was added to a solution of 92 (2.00 g, 4.39 mmol) 
in anhyd. DMF (10 mL) and the reaction mixture was stirred for 3 hours at 60°C. The 
reaction was quenched with the addition of water and diluted with Et2O. The organic layer 
was washed with water (x3), dried over MgSO4, and the solvent was removed in vacuo. 
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The resulting solid was crystallised from Et2O/PE to give the title compound 93 (1.81 g, 
98%) as a white solid.  
1H NMR (400 MHz, CDCl3) δ 5.37 (dd, J = 10.1, 3.3 Hz, 1H, H-3), 5.31 (t, J = 9.8 Hz, 
1H, H-4), 5.28 (dd, J = 3.4, 1.8 Hz, 1H, H-2), 4.87 (d, J = 1.8 Hz, 1H, H-1), 4.29 (dd, J = 
12.3, 5.4 Hz, 1H, H-6), 4.13 (dd, J = 12.3, 2.5 Hz, 1H, H-6), 4.05 (ddd, J = 9.7, 5.3, 2.4 
Hz, 1H, H-5), 3.87 (ddd, J = 10.6, 6.8, 3.8 Hz, 1H, H-7), 3.67 (ddd, J = 11.7, 6.0, 3.6 Hz, 
1H, H-7), 3.54 – 3.39 (m, 2H, H-8), 2.16 (s, 3H, CH3), 2.11 (s, 3H, CH3), 2.05 (s, 3H, 
CH3), 2.00 (s, 3H, CH3). v(max) (ATR-IR) 2955, 2107, 1733, 1435, 1225, 1171 cm-1; 
HRMS-ESI [M+Na+] calculated for C16H23N3O10Na+: 440.1276. Found: 440.1297. 
 
2-Azidoethyl α-D-mannopyranoside (94) 135, 167-168 
 
IRA-400 (OH-) exchange resin beads (approx. 1.5 g) were added to a solution of 93 (1.8 
g, 4.31 mmol) in methanol (20 mL). The reaction was left slowly stirring at room 
temperature for 18 hours after which the mixture was filtered and the solvent was 
removed in vacuo to give the title compound 94 (1.07 g, 99%) as a clear oil.  
1H NMR (400 MHz, D2O) δ 4.95 – 4.92 (m, 1H, H-1), 4.00 (ddd, J = 3.5, 1.8, 0.9 Hz, 1H, 
H-2), 3.98 – 3.89 (m, 2H), 3.88 – 3.83 (m, 1H), 3.82 – 3.75 (m, 1H), 3.75 – 3.65 (m, 3H), 
3.54 (qdd, J = 13.6, 6.5, 3.2 Hz, 2H, H-8). v(max) (ATR-IR) 3374, 3291, 2925, 2878, 2106, 
1306, 1058, 1031, 972 cm-1; HRMS-ESI [M+Na+] calculated for C8H15N3O6Na+: 






2-Azidoethyl 4-O-benzyl-6-O-(tert-butyldiphenylsilyl)-α-D-mannopyranoside  
(99) 123 
 
TBDPSCl (3.46 mL, 13.30 mmol) was added dropwise to a solution of 94 (2.21 g, 8.87 
mmol) and imidazole (0.91 g, 13.30 mmol) in anhyd. DMF (20 mL) at room temperature. 
The mixture was stirred overnight and the solvent was removed. The resulting mixture 
was diluted in CH2Cl2, washed with water (x3), dried over MgSO4 and concentrated.   
The resulting residue was dissolved in 2,2’-dimethoxypropane (30 mL) and toluene-p-
sulfonic acid (p-TSA) (1.40 g, 5.58 mmol) was added to the solution which was then left 
to stir overnight. Et3N (1 mL) was added to the reaction mixture and the solvent was 
evaporated. The residue was dissolved in anhyd. DMF (10 mL) and allowed to cool to 
0°C, then NaH (60% in oil, 0.885 g, 22.12 mmol) followed by BnBr (2.1 mL, 17.70 
mmol) were added slowly to the stirred solution. The reaction mixture was allowed to 
warm to room temperature and stirred for 12 hours. MeOH was added to the reaction to 
quench the excess of NaH and the solvent was removed. Et2O was added to the reaction 
residue, which was then washed with water (x2) and dried over MgSO4 and the solvent 
was removed in vacuo.  
The crude oil was then dissolved in a mixture of CH2Cl2 (30 mL) and TFA (5 mL) and 
was left to stir overnight at room temperature. A mixture of ice water at 0°C was added 
to the reaction, which was then neutralized with sat. NaHCO3(aq), washed with sat. 
NaHCO3(aq) (x2) and brine, dried with MgSO4, and the solvent was removed under 
vacuum. The residue was purified by column chromatography to give 99 (3.48 g, 68% 
over 4 steps) as an oil. 
[α]20D = +44.2 (c 1.2, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.76 – 7.68 (m, 4H, 
TBDPS-Ph), 7.45 – 7.27 (m, 9H, Ph), 7.25 – 7.20 (m, 2H, Ph), 4.89 (d, J = 1.3 Hz, 1H, 
H-1), 4.74 (d, J = 11.3 Hz, 1H, PhCH2), 4.65 (d, J = 11.3 Hz, 1H, PhCH2), 4.01 – 3.96 
(m, 2H, H-2, H-3), 3.94 (d, J = 3.2 Hz, 2H, H-6, H-6), 3.86 (ddd, J = 10.8, 5.3, 4.4 Hz, 
1H, H-7), 3.79 – 3.73 (m, 1H, H-5), 3.70 (dt, J = 9.8, 3.2 Hz, 1H, H-4), 3.59 (ddd, J = 
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10.6, 5.7, 4.7 Hz, 1H, H-7), 3.37 – 3.33 (m, 2H, H-8), 2.36 (d, J = 5.1 Hz, 1H, OH), 2.28 
(d, J = 4.4 Hz, 1H, OH), 1.08 (s, 9H, t-Bu). 13C NMR (125 MHz, CDCl3) δ 138.32, 135.98, 
135.77, 135.76 (i-Ph), 133.70, 133.38, 129.80, 128.71, 128.70, 128.05, 128.03, 127.83, 
127.74 (Ph), 99.64 (C-1), 75.91 (C-4 or C-5), 74.90 (PhCH2), 72.63 (C-4 or C-5), 71.75 
(C-2 or C-3), 71.05 (C-2 or C-3), 66.45 (C-7), 63.23 (C-6), 50.61 (C-8), 26.98 (t-Bu), 
19.46 (C(CH3)3). v(max) (ATR-IR) 3424, 3069, 2929, 2857, 2101, 1427, 1101, 739, 700 
cm-1; HRMS-ESI [M+Na+] calculated for C31H39N3O6SiNa+: 600.2500. Found: 600.2495. 
 
2-Azidoethyl 4-O-benzyl-6-O-(tert-butyldiphenylsilyl)-3-O-(4-methoxybenzyl)-α-D-
mannopyranoside (95) 123 
 
A mixture of mannose derivative 99 (304 mg, 0.526 mmol) and dibutyltin oxide (144 mg, 
0.579 mmol) in toluene (10 mL) was refluxed under Dean-Stark conditions for 3 hours. 
The reaction mixture was allowed to cool to room temperature and anhyd. DMF (2 mL) 
was added to the mixture. 4-methoxybenzyl chloride (80 μL, 0.579 mmol) and Bu4NI 
(214 mg, 0.580 mmol) were added and the reaction was heated at reflux for 3 hours. The 
reaction mixture was then diluted with EtOAc, washed with water (x2) and dried over 
MgSO4. The solvent was evaporated and the resulting residue was columned via silica 
chromatography (CH2Cl2, 2% EtOAc) to afford the title compound 95 (253 mg, 69%) as 
an oil.  
[α]20D = +28.2 (c 0.9, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.74 – 7.67 (m, 4H, 
TBDPS-Ph), 7.44 – 7.13 (m, 12H, Ar-H), 6.90 – 6.82 (m, 2H, Ar-PMB), 4.93 (d, J = 1.6 
Hz, 1H, H-1), 4.84 (d, J = 10.9 Hz, 1H, PhCH2), 4.63 (s, 2H, ArCH2-PMB), 4.55 (d, J = 
10.9 Hz, 1H, PhCH2), 4.05 (dt, J = 4.1, 2.1 Hz, 1H, H-2), 3.95 – 3.84 (m, 4H, H-3, H-6, 
H-7), 3.80 (s, 4H, H-4, OCH3), 3.72 (dt, J = 9.8, 3.4 Hz, 1H, H-5), 3.60 (ddd, J = 10.8, 
6.9, 3.8 Hz, 1H, H-7), 3.41 – 3.29 (m, 2H, H-8), 1.04 (s, 9H, t-Bu). 13C NMR (125 MHz, 
CDCl3) δ 159.60 (i-Ph-OMe), 138.44, 136.00, 135.77 (i-Ph), 133.82, 133.45, 130.14, 
129.82, 129.72, 128.49, 128.04, 127.80, 127.78, 127.71 (Ar/Ph), 114.11 (PMB), 99.38 
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(C-1), 79.96 (C-3), 75.27 (PhCH2), 74.14 (C-5), 72.92 (ArCH2-PMB), 68.47 (C-2), 66.41 
(C-7), 63.32 (C-6), 55.42 (OCH3), 50.61 (C-8), 26.92 (t-Bu), 19.42 (C(CH3)3). v(max) 
(ATR-IR) 3474, 2957, 2102, 1514, 1249, 822, 665 cm-1; HRMS-ESI [M+Na+] calculated 





Mannoside 95 (977 mg, 1.400 mmol) was dissolved in anhyd. DMF (8 mL) and cooled 
to 0°C. NaH (60% in oil, 140 mg, 3.50 mmol) was added to the solution followed by the 
dropwise addition of BnBr (333 μl, 2.80 mmol). The reaction was allowed to warm to 
room temperature and was stirred overnight. The solvent was removed under vacuum and 
the resulting residue was diluted with Et2O, washed with sat. NaHCO3(aq) followed by 
brine and dried over MgSO4 and the solvent was removed. The crude material was 
purified by column chromatography (PE/EtOAc gradient) to give title compound 100 
(1.09 g, 100%) as a colourless oil.  
[α]20D = +7.02 (c 0.9, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.75 – 7.67 (m, 4H,TBDPS- 
Ph), 7.42 – 7.12 (m, 18H, Ar-H), 6.87 – 6.82 (m, 2H, Ar-PMB), 4.89 (d, J = 10.8 Hz, 1H, 
PhCH2), 4.87 (d, J = 1.8 Hz, 1H, H-1), 4.81 (d, J = 12.4 Hz, 1H, PhCH2), 4.67 (d, J = 
12.3 Hz, 1H, PhCH2), 4.58 (s, 2H, ArCH2-PMB), 4.55 (d, J = 10.9 Hz, 1H, PhCH2), 4.00 
(t, J = 9.5 Hz, 1H, H-4), 3.96 – 3.87 (m, 3H, H-3, H-6), 3.85 – 3.80 (m, 1H, H-7), 3.80 
(s, 4H, OCH3, H-7), 3.68 (ddt, J = 10.1, 5.1, 2.6 Hz, 1H, H-2), 3.53 (ddd, J = 10.8, 7.4, 
3.5 Hz, 1H, H-5), 3.35 (ddd, J = 13.2, 7.4, 3.5 Hz, 1H, H-8), 3.27 (ddd, J = 13.2, 5.7, 3.5 
Hz, 1H, H-8), 1.04 (s, 9H, t-Bu). 13C NMR (125 MHz, CDCl3) δ 159.31 (i-Ph-OMe), 
138.70, 138.69, 136.03, 135.79 (i-Ph), 133.99, 133.59, 130.84, 129.67, 129.65, 129.58, 
128.45, 128.44, 128.08, 127.80, 127.76, 127.67, 127.65 (Ar/Ph), 113.92 (PMB), 98.29 
(C-1), 80.02 (C-3), 75.51 (C-5), 75.21 (PhCH2), 74.73 (C-4), 73.66 (C-2), 73.09 (PhCH2), 
72.17 (ArCH2-PMB), 66.27 (C-7), 63.46 (C-6), 55.42 (OCH3), 50.64 (C-8), 26.91 (t-Bu), 
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19.44 (C(CH3)3). v(max) (ATR-IR) 2929, 2856, 2101, 1512, 1247, 1105, 822, 738, 700 cm-
1; HRMS-ESI [M+Na+] calculated for C46H53N3O7SiNa+: 810.3545. Found: 810.3506. 
2-Azidoethyl 2,4-O-benzyl-3-O-(4-methoxybenzyl)-α-D-mannopyranoside (101) 
 
Mannoside 100 (787 mg, 0.999 mmol) was dissolved in anhyd. THF (7 mL) under an N2 
atmosphere. TBAF (1 M in THF, 2 mL, 2.0 mmol) was slowly added to the solution and 
the reaction mixture was stirred overnight at room temperature. The solvent was removed 
and the resulting crude product was purified by column chromatography (EtOAc/PE, 1:1) 
to give title compound 101 (545 mg, 100%) as a clear colourless oil.  
[α]20D = +46.0 (c 0.8, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.26 (m, 14H, Ar-
H), 6.88 – 6.83 (m, 2H, Ar-PMB), 4.94 (d, J = 11.0 Hz, 1H, PhCH2), 4.85 – 4.76 (m, 2H, 
PhCH2, H-1), 4.58 (s, 2H, ArCH2-PMB), 3.96 – 3.92 (m, 2H, H-3, H-4), 3.86 – 3.81 (m, 
1H, H-7), 3.81 (s, 5H, OCH3, H-2, H-6), 3.76 (dd, J = 11.7, 4.7 Hz, 1H, H-6), 3.65 (ddt, 
J = 9.8, 5.1, 2.7 Hz, 1H, H-5), 3.53 (ddd, J = 10.6, 7.2, 3.4 Hz, 1H, H-7), 3.37 (ddd, J = 
13.3, 7.2, 3.4 Hz, 1H, H-8), 3.29 (ddd, J = 13.3, 5.8, 3.4 Hz, 1H, H-8). 13C NMR (100 
MHz, CDCl3) δ 159.34 (i-Ph-OMe), 138.52, 138.37 (i-Ph), 130.66, 129.52, 128.55, 
128.54, 128.18, 127.99, 127.88 (Ar/Ph), 113.94 (PMB), 98.76 (C-1), 79.86 (C-3), 75.31 
(PhCH2), 75.03 (C-2), 74.80 (C-4), 73.30 (PhCH2), 72.67 (C-5), 72.19 (ArCH2-PMB), 
66.65 (C-7), 62.52 (C-6), 55.41 (OCH3), 50.60 (C-8). v(max) (ATR-IR) 3457, 3031, 2912, 
2102, 1612, 1513, 1247, 1028, 798, 734, 698 cm-1; HRMS-ESI [M+Na+] calculated for 







2-Azidoethyl 2,4-O-benzyl-O-α-D-mannopyranoside (91)  
 
Mannoside 101 (550 mg, 1.001 mmol) was dissolved in CH2Cl2 (35 mL) and the solution 
was allowed to cool to -20°C. TFA (10.5 mL) was added to the solution and the solution 
was allowed to warm to -10°C and stirred for 1 hour. Then, ethanol and CH2Cl2 were 
added to the solution. The reaction mixture was washed with sat. NaHCO3(aq) and brine 
and was dried over MgSO4. The solvent was removed and the resulting residue was 
purified by column chromatography (EtOAc/PE, 1:1) to give 91 (297 mg, 69%) as an oil.  
[α]20D = +54.7 (c 0.9, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.41 – 7.27 (m, 10H, Ph), 
4.91 (d, J = 11.2 Hz, 1H, PhCH2), 4.89 (d, J = 1.5 Hz, 1H, H-1), 4.72 (d, J = 11.8 Hz, 1H, 
PhCH2), 4.67 (d, J = 11.3 Hz, 1H, PhCH2), 4.65 (d, J = 11.8 Hz, 1H, PhCH2), 4.03 (dd, J 
= 9.1, 3.7 Hz, 1H, H-3), 3.86 (dd, J = 11.9, 2.8 Hz, 1H, H-6), 3.83 – 3.75 (m, 3H, H-2, 
H-6, H-7), 3.71 (t, J = 9.4 Hz, 1H, H-4), 3.64 (ddd, J = 9.7, 4.3, 2.8 Hz, 1H, H-5), 3.58 – 
3.51 (m, 1H, H-7), 3.38 (ddd, J = 12.7, 6.9, 3.1 Hz, 1H, H-8), 3.35 – 3.28 (m, 1H, H-8). 
13C NMR (125 MHz, CDCl3) δ 138.37, 137.68 (i-Ph), 128.70, 128.56, 128.54, 128.21, 
128.11, 127.99, 127.92 (Ph), 97.63 (C-1), 78.36 (C-2), 76.29 (C-4), 74.95 (PhCH2-2), 
73.41 (PhCH2-4), 71.84 (C-5), 71.61 (C-3), 66.55 (C-7), 62.29 (C-6), 50.50 (C-8). v(max) 
(ATR-IR) 3449, 3030, 2916, 2101, 1512, 1284, 1092, 738, 699 cm-1; HRMS-ESI 











Glycosyl donor 24 (194 mg, 0.451 mmol) and acceptor 91 (660 mg, 1.037 mmol) were 
coevaporated and the resulting residue was dissolved in freshly distilled toluene. 4Å 
sieves (approx. 500 mg) were added and the mixture was allowed to stir at room 
temperature for 1 hour.  The reaction was cooled to -20°C and TMSOTf (38 μl, 0.207 
mmol) was added. The reaction was allowed to warm to -10°C over the course of 1 hour. 
The reaction was diluted with CH2Cl2 and washed with water, brine and dried over 
MgSO4. The solvent was removed in vacuo and the residue was purified by column 
chromatography (PE/EtOAc gradient) to give 102 (461 mg, 74%) as a clear colourless 
oil.  
[α]20D = +83.6 (c 1.3, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.35 – 7.11 (m, 40H, Ph), 
5.51 (dd, J = 3.4, 1.8 Hz, 1H, H-2B), 5.45 (dd, J = 3.1, 1.9 Hz, 1H, H-2A), 5.20 (d, J = 1.8 
Hz, 1H, H-1B), 4.96 (d, J = 1.9 Hz, 1H, H-1A), 4.86 (t, J = 10.4 Hz, 2H, PhCH2), 4.80 (d, 
J = 1.8 Hz, 1H, H-1), 4.75 (d, J = 11.2 Hz, 1H, PhCH2), 4.68 – 4.60 (m, 6H, PhCH2), 4.51 
– 4.41 (m, 7H, PhCH2), 4.15 (dd, J = 9.3, 3.1 Hz, 1H, H-3B), 4.01 (dd, J = 8.9, 3.3 Hz, 
1H, H-3A), 3.95 – 3.58 (m, 16H, ring protons, H-7), 3.45 (ddd, J = 10.6, 7.0, 3.5 Hz, 1H, 
H-7), 3.26 (ddd, J = 13.2, 7.0, 3.5 Hz, 1H, H-8), 3.16 (ddd, J = 13.2, 6.2, 3.5 Hz, 1H, H-
8), 2.15 (s, 3H, CH3), 2.09 (s, 3H, CH3); 13C NMR (100 MHz, CDCl3) δ 170.46, 170.25 
(C=O), 138.77, 138.61, 138.44, 138.34, 138.14, 137.99, 137.93 (i-Ph), 128.57, 128.55, 
128.52, 128.51, 128.49, 128.48, 128.42, 128.40, 128.39, 128.37, 128.34, 128.33, 128.19, 
127.95, 127.95, 127.92, 127.91, 127.83, 127.81, 127.78, 127.77, 127.76, 127.68, 127.64, 
127.59 (Ph), 99.77 (C-1B), 97.98 (C-1A), 97.55 (C-1), 78.24, 77.68, 75.24, 75.05, 75.02, 
74.40, 74.28, 73.59, 73.51, 73.49, 72.61, 72.37, 71.95, 71.62, 71.45, 71.40, 69.04, 68.88, 
68.82, 68.54, 66.65, 66.43, 50.43 (C-8), 21.27, 21.14 (CH3); v(max) (ATR-IR) 3031, 2103, 
1742, 1454, 1284, 1054, 735, 696 cm-1; HRMS-ESI [M+Na+] calculated for 
C80H87N3O18Na+: 1400.5877. Found: 1400.5786. 
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4-Oxy-ethylamino-[3,6-di-O-(3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-2,4-di-O-
benzyl-α-D-mannopyranosyloxy]4-oxo-butanoic acid (106) 
  
IRA-400 (OH-) exchange resin (approx. 500 mg) was added to a stirred solution of 102 
(229 mg, 0.166 mmol) in MeOH and CH2Cl2 (2:1, 15 mL). The reaction was left stirring 
overnight at room temperature after which the mixture was filtered and the solvent was 
removed in vacuo. The residue was purified over silica gel via column chromatography 
to give title compound 104 (182.4 mg, 85%) as a clear colourless oil. HRMS-ESI 
[M+Na+] calculated for C76H83N3O16Na+: 1316.5666. Found: 1316.5639. 
Trimannoside 104 (466 mg, 0.360 mmol) was dissolved in anhyd. THF (15 mL) and 
allowed to cool to 0°C under inert atmosphere. Trimethylphosphine (1 M, 2.88 mL, 2.88 
mmol) was added and the solution was allowed to warm to room temperature over the 
course of 1 hour. The solution was then stirred at room temperature for 4 hours. NaOH 
(2 M, 4 mL, 0.360 mmol) was added to the solution and the reaction mixture was allowed 
to stir overnight at room temperature (to hydrolyse imino-phosphorane intermediate). The 
reaction was diluted with CH2Cl2, washed with water, dried over MgSO4 and the solvent 
was removed by vacuum to give a cloudy oil, which was shown to be the amino 
intermediate by high resolution mass spectrometry. HRMS-ESI [M+H+] calculated for 
C76H85NO16H+: 1268.5941. Found: 1268.5888.  
Succinic anhydride (47 mg, 0.468 mmol) was dissolved into 10 mL of dioxane, and the 
crude material dissolved in 10 mL of dioxane were slowly added. The solution was 
warmed at 80°C for 30 minutes, and the mixture was allowed to cool to room temperature. 
The solvent was removed and the resulting residue was purified by column 
chromatography to give the title product 106 (295 mg, 60%) as an oil. 
[α]20D = +44.7 (c 1.1, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.14 (m, 40H, Ph), 
6.64 (t, J= 5.5 Hz, 1H, NH), 5.34 (d, J= 1.7 Hz, 1H, H-1A or B), 5.06 (d, J= 1.7 Hz, 1H, H-
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1A or B), 4.85 (dd, J= 12.8, 11.0 Hz, 2H, PhCH2), 4.80 (d, J= 1.8 Hz, 1H, H-1), 4.70 (d, J= 
11.1 Hz, 1H, PhCH2), 4.67 – 4.43 (m, 13H, PhCH2), 4.26 (dd, J= 9.6, 3.0 Hz, 1H, H-3), 
4.11 (dd, J= 3.2, 1.8 Hz, 1H, H-2A or B), 4.04 (dd, J= 3.3, 1.8 Hz, 2H, H-2A or B), 3.96 – 
3.53 (m, 14H, ring protons, H-7), 3.44 – 3.32 (m, 2H, H-8, H-6), 3.31 – 3.19 (m, 1H, H-
8), 2.68 – 2.53 (m, 2H, H-link), 2.43 (t, J= 6.2 Hz, 2H, H-link). 13C NMR (125 MHz, 
CDCl3) δ 174.78, 172.73 (C=O), 138.48, 138.46, 138.30, 138.28, 138.03, 137.97, 137.86, 
137.70 (i-Ph), 128.69, 128.62, 128.55, 128.55, 128.52, 128.44, 128.42, 128.10, 128.08, 
128.03, 128.01, 127.88, 127.85, 127.81, 127.78, 127.74, 127.68, 127.66 (Ph), 101.51 (C-
1A or B), 99.58 (C-1A or B), 97.00 (C-1), 80.00, 79.65 (C-3), 77.71, 75.47, 75.22, 75.02, 
74.95, 74.41, 74.34, 73.52, 73.50, 72.26, 72.17, 71.94, 71.54, 71.32, 69.26, 68.95, 68.70 
(C-2A or B), 68.06 (C-2A or B), 66.06, 65.96, 39.30, 31.29, 30.05. v(max) (ATR-IR) 3365, 
3031, 2924, 1724, 1654, 1454, 1363, 1317, 1269, 1209, 1098, 1065, 1028 cm-1. HRMS-




Trimannoside 106 (99.5 mg, 0.073 mmol), EDCI (21 mg, 0.109 mmol), and NHS (12.5 
mg, 0.109 mmol) were dissolved in CH2Cl2 (6 mL) and allowed to stir overnight at room 
temperature. The reaction mixture was diluted with CH2Cl2 and washed with sat. 
NH4Cl(aq) then dried over MgSO4 and the solvent was evaporated. The crude residue was 
purified by column chromatography (Pe/EtOAc gradient) to give the title compound 103 
(94.2 mg, 88%) as an oil.  
1H NMR (400 MHz, CDCl3) δ 7.34 – 7.26 (m, 31H, Ph), 7.24 – 7.12 (m, 9H, Ph), 6.12 
(d, J = 6.2 Hz, 1H, NH), 5.19 (d, J = 1.7 Hz, 1H, H-1B), 5.02 (d, J = 1.7 Hz, 1H, H-1A), 
4.83 (dd, J = 12.6, 10.9 Hz, 3H, PhCH2), 4.77 (d, J = 1.9 Hz, 1H, H-1), 4.72 – 4.35 (m, 
13H, PhCH2), 4.11 (dd, J = 9.3, 3.0 Hz, 1H, H-3), 4.08 – 4.04 (m, 1H, H-2), 4.02 – 3.94 
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(m, 2H, H-2, H-2), 3.93 – 3.52 (m, 27H, ring protons, H-7), 3.45 – 3.20 (m, 3H, H-6, H-
8), 2.93 – 2.84 (m, 2H, H-link), 2.69 (s, 4H, Succ), 2.43 (dt, J = 8.3, 6.3 Hz, 2H, H-link). 
13C NMR (125 MHz, CDCl3) δ 170.16, 169.21, 168.26 (C=O), 138.58, 138.51, 138.37, 
138.32, 138.29, 138.07, 138.05, 137.94 (i-Ph), 128.71, 128.67, 128.65, 128.62, 128.60, 
128.57, 128.54, 128.52, 128.49, 128.46, 128.45, 128.43, 128.42, 128.38, 128.34, 128.20, 
128.14, 128.12, 128.08, 128.04, 128.01, 127.98, 127.95, 127.92, 127.88, 127.87, 127.84, 
127.81, 127.79, 127.76, 127.73, 127.71, 127.68 (Ph), 101.57 (C-1B), 99.71 (C-1A), 97.50 
(C-1), 80.15, 79.80, 77.77, 75.27, 75.09, 75.04, 74.55, 74.37, 73.55, 73.52, 72.39, 72.18, 
72.01, 71.85, 71.65, 71.36, 69.64, 69.00, 68.76, 68.11, 67.00, 66.25, 39.51 (C-link), 
32.07, 30.79 (C-link), 27.00 (C-link), 25.64 (Succ), 22.83 (C-link). HRMS-ESI [M+Na+] 





Trimannoside 103 (43.2 mg, 0.029 mmol) was dissolved in EtOH/THF (1:1, 6 mL) and 
Pd/C catalyst (10%, 40 mg) was added. The reaction was purged of atmosphere and H2 
gas was bubbled through (x3). The solution was allowed to stir under H2 gas overnight at 
room temperature. The reaction mixture was diluted with EtOH and filtered through 
Celite® and the solvent was removed. The resulting residue was re-dissolved in water and 
subjected to freeze drying conditions to give the final product 6 (21.7 mg) as an off-white 





Phenyl 2,3,4,6-tetra-O-acetyl-1-deoxy-1-thio-D-mannopyranoside (126) 169-170 
 
BF3OEt2 (4.73 mL, 38.3 mmol) was added dropwise to a stirred solution of tetraacetate 
54 (14.95 g, 38.3 mmol) and thiophenol (4.03 mL, 38.3 mmol) in anydrous CH2Cl2 (40 
mL) at 0°C and allowed to warm to room temperature overnight. The reaction was diluted 
with CH2Cl2 and washed with 0.5 M NaOH(aq), water, and brine, then dried over MgSO4. 
The solvents were removed in vacuo to give crude product as a yellow foam. 
Crystallization from Et2O/PE gave the pure product 126 as a mixture of anomers (16.44 
g, 10:1 α/β, 97%) as a white solid. α-anomer data reported. 
1H NMR (400 MHz, CDCl3) δ 7.51 – 7.45 (m, 2H, Ph), 7.34 – 7.26 (m, 3H, Ph), 5.51 – 
5.47 (m, 2H, H-2, H-4), 5.37 – 5.28 (m, 2H, H-1, H-3), 4.58 – 4.49 (m, 1H, H-5), 4.30 
(dd, J = 12.2, 5.9 Hz, 1H, H-6), 4.10 (dd, J = 12.2, 2.4 Hz, 1H, H-6), 2.15 (s, 2H, CH3), 
2.07 (s, 2H, CH3), 2.05 (s, 3H, CH3), 2.01 (s, 3H, CH3). v(max) (ATR-IR) 1748, 1369, 
1225, 1105 cm-1; HRMS-ESI [M+Na+] calculated for C20H24O9SNa+: 463.1033. Found: 
463.1066. 
 
Phenyl 1-deoxy-1-thio-D-mannopyranoside (127) 169-170 
 
Method A: IRA-400 (OH-) exchange resin beads (approx. 1 g) were added to a solution 
of 126 (16.44 g, 37.3 mmol) in CH2Cl2/MeOH (1:2, 60 mL). The reaction was left stirring 
overnight at room temperature after which the mixture was filtered and the solvent was 
removed in vacuo to give the title compound 127 as a mixture of anomers (10.1 g, 10:1 
α/β, 99%) as a clear oil which was used without further purification. 
1H NMR (400 MHz, CD3OD) δ 7.57 – 7.54 (m, 2H, Ph), 7.37 – 7.27 (m, 3H, Ph), 5.45 
(dd, J = 1.6, 0.6 Hz, 1H, H-1), 4.11 (dd, J = 3.0, 1.6 Hz, 1H, H-2), 4.09 – 4.03 (m, 1H, H-
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5), 3.85 (dd, J = 12.0, 2.6 Hz, 1H, H-6), 3.78 – 3.65 (m, 3H, H-3, H-4, H-6). HRMS-ESI 
[M+Na+] calculated for C12H16O5SNa+: 295.0611. Found: 295.0622. 
Method B: Sodium methoxide in MeOH (0.5 M, 600 μL, 0.257 mmol) was added to a 
solution of mannoside 126 (5.66 g, 12.85 mmol) in CH2Cl2/MeOH (1:2, 30 mL) which 
was stirred overnight at room temperature. The solvent was removed by vacuum to give 
the product 127 (3.46 g, 10:1 α/β, 99%) as a clear oil which was used without further 
purification. 
 
Phenyl 6-O-(tert-butyldiphenylsilyl)-1-deoxy-1-thio-D-mannopyranoside (128) 139, 171 
 
To a solution of 127 (1.043 g, 3.83 mmol) and imidazole (391 mg, 5.74 mmol) in dry 
DMF (12 mL), TBDPSCl (1.5 mL, 5.77 mmol) was added dropwise at room temperature. 
The mixture was stirred overnight and the solvent was removed. The resulting mixture 
was diluted in CH2Cl2, washed with water (x3), dried over MgSO4 and concentrated and 
the crude oil 128 as a mixture of anomers (1.17 g, 5:1 α/β, 60%) was used without further 
purification.  
1H NMR (400 MHz, CD3OD) δ 7.84 – 7.01 (m, 15H, Ph), 5.50 (dd, J = 1.6, 0.6 Hz, 1H, 
H-1), 4.27 – 4.21 (m, 1H, H-5), 4.13 (td, J = 1.8, 1.0 Hz, 1H, H-2), 4.06 (dd, J = 11.0, 2.0 
Hz, 1H, H-6), 3.92 (dd, J = 11.0, 6.6 Hz, 1H, H-6), 3.71 – 3.68 (m, 2H, H-3, H-4), 1.05 
(d, J = 1.0 Hz, 9H, t-Bu). v(max) (ATR-IR) 3315, 3096, 2956, 2930, 2570, 1660, 1583, 







mannopyranoside (129) 139 
 
128 (1.17 g, 2.291 mmol) and p-TSA (363 mg, 1.443 mmol) were dissolved in 2,2-
dimethoxypropane (30 mL) and the reaction mixture was stirred overnight at room 
temperature. The reaction was neutralized with the addition of Et3N, diluted with CH2Cl2, 
washed with water, and dried over MgSO4. The solvent was removed under vacuum and 
the resulting crude material was purified by column chromatography (PE/EtOAc 
gradient) to give the title compound 129 as a mixture of anomers (1.02 g, 7:3 α/β, 81%) 
as a white foam. 
 1H NMR (400 MHz,CDCl3) δ 7.70 – 7.61 (m, 4H, Ph), 7.47 – 7.32 (m, 8H, Ph), 7.24 – 
7.15 (m, 3H, Ph), 5.75 (dt, J = 1.2, 0.6 Hz, 1H, H-1), 4.35 (dd, J = 5.7, 1.2 Hz, 1H, H-2), 
4.19 (dd, J = 7.4, 5.7 Hz, 1H, H-3), 4.09 – 4.04 (m, 1H, H-5), 3.96 (dd, J = 9.9, 7.5 Hz, 
1H, H-4), 3.89 (dd, J = 10.9, 4.1 Hz, 1H, H-6), 3.84 (dd, J = 10.9, 4.8 Hz, 1H, H-6), 1.55 
(s, 3H, CH3), 1.41 – 1.36 (m, 3H, CH3), 1.05 (s, 9H, t-Bu). 13C NMR (100 MHz, CDCl3) 
δ 135.79, 135.66, 131.95, 130.02, 129.97, 129.12, 127.97, 127.89, 127.66 (Ph), 109.93 
(Ciso), 84.17 (C-1), 78.26 (C-3), 76.21 (C-2), 71.58 (C-4), 70.30 (C-5), 64.61 (C-6), 28.21 
(CH3), 26.95 (t-Bu), 26.54 (CH3), 19.36. v(max) (ATR-IR) 3464, 3071, 2988, 2881, 1242, 
1160, 1063, 867, 740, 703, 503 cm-1; HRMS-ESI [M+Na+] calculated for 





Sodium hydride (454 mg, 11.35 mmol) was added to a stirred solution of 129 (2.50 g, 
4.54 mmol) and benzyl bromide (1.1 mL 9.26 mmol) in anhyd. DMF at 0°C. The reaction 
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was left to slowly warm to room temperature and then stirred overnight. The reaction was 
quenched with water and then diluted with Et2O, washed with 5% NaHCO3(aq), then brine 
and dried over MgSO4. The solvent was removed and the residue was purified by column 
chromatography (PE/EtOAc gradient) to give the title compound 130 (2.90 g, 98%) as a 
clear colourless oil.  
1H NMR (500 MHz, CDCl3) δ 7.69 – 7.65 (m, 5H, Ph), 7.49 – 7.26 (m, 12H, Ph), 7.23 – 
7.18 (m, 3H, Ph), 5.86 (s, 1H, H-1), 4.94 (d, J = 11.3 Hz, 1H, PhCH2), 4.65 (d, J = 11.3 
Hz, 1H, PhCH2), 4.42 – 4.34 (m, 2H, H-3, H-4), 4.14 (ddd, J = 10.0, 3.7, 1.8 Hz, 1H, H-
2), 3.99 (dd, J = 11.3, 3.8 Hz, 1H, H-6), 3.92 (ddt, J = 10.3, 7.0, 3.3 Hz, 1H, H-5), 3.83 
(dd, J = 11.2, 1.8 Hz, 1H, H-6), 1.57 (s, 3H, CH3), 1.42 (s, 3H, CH3), 1.03 (s, 9H, t-Bu). 
13C NMR (125 MHz, CDCl3) δ 135.99, 135.69 (i-Ph), 131.40, 129.67, 129.62, 129.08, 
128.55, 128.44, 128.03, 127.93, 127.80, 127.78, 127.73, 127.65, 127.34 (Ph), 109.68 
(Ciso), 84.28 (C-1), 78.86 (C-3), 76.77 (C-4), 75.91 (C-5), 73.52 (PhCH2), 71.20 (C-2), 
62.98 (C-6), 28.16 (CH3), 26.92 (t-Bu), 26.75 (CH3). HRMS-ESI [M+Na+] calculated for 
C38H44O5SSiNa+: 663.2571. Found: 663.2538. 
 
Phenyl 4-O-benzyl-6-O-(tert-butyldiphenylsilyl)-1-deoxy-1-thio-α-D-
mannopyranoside (131)  
  
Mannoside 130 (2.52g, 3.93 mmol) was dissolved in CH2Cl2 (30 mL) and TFA (5 mL) 
was added to the reaction at room temperature. The solution was stirred overnight. Ice 
water (0°C) was added to the reaction, which was neutralized with sat. NaHCO3(aq), 
washed with sat. NaHCO3(aq) (x2) and brine, dried with MgSO4, and the solvent was 
removed under vacuum. The crude material was purified by column chromatography 
(PE/EtOAc gradient) to give title compound 131 (1.8 g, 76%) as a clear colourless oil. 
1H NMR (500 MHz, CDCl3) δ 7.76 – 7.66 (m, 4H, Ph), 7.46 – 7.26 (m, 13H, Ph), 7.25 – 
7.17 (m, 3H, Ph), 5.55 (dd, J = 1.0 Hz, 1H, H-1), 4.80 (d, J = 11.3 Hz, 1H, PhCH2), 4.74 
(d, J = 11.3 Hz, 1H, PhCH2), 4.22 – 4.15 (m, 2H, H-2, H-5), 4.02 (dd, J = 11.5, 3.9 Hz, 
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1H, H-6), 3.96 (dd, J = 9.0, 3.0 Hz, 1H, H-3), 3.94 – 3.89 (m, 2H, H-4, H-6), 2.43 (s, 2H, 
OH), 1.08 (s, 9H, t-Bu). 13C NMR (125 MHz, CDCl3) δ 138.32, 136.05, 135.74, 134.63 
(i-Ph), 133.75, 133.21, 131.08, 129.80, 129.77, 129.11, 128.78, 128.13, 128.09, 127.86, 
127.72, 127.29 (Ph), 87.72 (C-1), 76.10 (C-3), 75.03 (PhCH2), 73.37 (C-2), 72.67 (C-5), 
72.37 (C-4), 62.99 (C-6), 27.00 (t-Bu). HRMS-ESI [M+Na+] calculated for 
C35H40O5SSiNa+: 623.2258. Found: 623.2270. 
 
Phenyl 4-O-benzyl-6-O-(tert-butyldiphenylsilyl)-3-(para-methoxybenzyl)-1-deoxy-1-




A mixture of mannose derivative 131 (910 mg, 1.515 mmol) and dibutyltin oxide (415 
mg, 1.666 mmol) in toluene (10 mL) was refluxed under Dean-Stark conditions for 3 
hours. The reaction mixture was allowed to cool to room temperature and DMF (2 mL) 
was added to the mixture. 4-methoxybenzyl chloride (226 μL, 1.66 mmol) and TBAI (615 
mg, 1.66 mmol) were added and the mixture was heated at reflux for 3 hours. The mixture 
was then diluted with EtOAc, washed with water, and dried over MgSO4. The solvent 
was evaporated and the resulting residue was columned via silica chromatography 
(CH2Cl2/2% EtOAc) to give an inseparable mixture of 132 and 133 (971 mg, 5:1, 89%) 
as an oil.  
Data for 132: 1H NMR (500 MHz, CDCl3) δ inter alia 7.75 – 7.64 (m, 4H, TBDPS-Ph), 
7.46 – 7.27 (m, 13H, Ar), 7.24 – 7.19 (m, 5H, Ph), 6.91 – 6.87 (m, 2H, Ar-PMB), 5.62 
(d, J= 1.5 Hz, 1H, H-1), 4.88 (d, J= 10.8 Hz, 1H, PhCH2), 4.67 (s, 2H, ArCH2-PMB), 
4.64 (d, J= 10.8 Hz, 1H, PhCH2), 4.26 (dd, J= 3.3, 1.6 Hz, 1H, H-2), 4.19 (ddd, J= 9.7, 
4.3, 1.7 Hz, 1H, H-5), 4.01 (d, J= 9.5 Hz, 1H, H-4), 3.99 – 3.97 (m, 1H, H-6), 3.89 – 3.84 
(m, 2H, H-3, H-6), 3.82 (s, 3H, OCH3), 2.60 (s, 1H, OH), 1.04 (s, 9H, t-Bu). 13C NMR 
(125 MHz, CDCl3) δ 136.08, 135.74 (TBDPS-Ph), 131.06, 129.92, 129.87, 129.69, 
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129.66, 129.08, 128.54, 128.07, 127.84, 127.80, 127.79, 127.66, 127.20 (Ar/Ph), 114.17 
(PMB-Ar), 87.36 (C-1), 80.15 (C-3), 75.45 (PhCH2), 74.41 (C-4), 73.65 (C-5), 72.02 
(ArCH2-PMB), 70.22 (C-2), 63.01 (C-6), 55.45 (OCH3), 26.93 (t-Bu). HRMS-ESI 
[M+Na+] calculated for C43H52O9SiNa+: 663.2571. Found: 663.2538. 
 
Phenyl 4-O-benzyl-2-O-benzoyl-6-O-(tert-butyldiphenylsilyl)-3-(para-methoxybenzyl)-




Benzoyl chloride (1 mL) was added dropwise to a stirred solution of 132 (167 mg, 0.232 
mmol) and pyridine (1 mL) that had been cooled in an ice bath. The reaction was allowed 
to stir overnight at room temperature. Water (2 mL) was added and the solution was 
stirred for 15 min to quench any excess benzoyl chloride. Additional water (15 mL) was 
added and the solution was extracted with CH2Cl2. The combined organic extracts were 
washed with HCl (1 M), water and brine. The organic extract was dried, filtered and the 
solvent removed to give the crude material which was then purified by column 
chromatography (PE/EtOAc gradient) to give the title compound(s) 125 and 134 as an 
inseparable mixture (185 mg, 5:1, 97%) as an oil. 
1H NMR (500 MHz, CDCl3) δ inter alia 7.92 – 7.87 (m, 6H, Ph), 7.87 – 7.82 (m, 2H, Ph), 
7.50 – 7.33 (m, 7H, Ph), 7.30 – 7.23 (m, 7H, Ph), 7.22 – 7.16 (m, 2H, Ph), 7.16 – 7.08 
(m, 4H, Ph), 7.08 – 6.89 (m, 14H, Ph/Ar), 6.56 – 6.51 (m, 2H, Ar-PMB), 5.61 (dd, J = 
3.3, 1.7 Hz, 1H, H-2), 5.40 (d, J = 1.6 Hz, 1H, H-1), 4.68 (d, J = 10.7 Hz, 1H, PhCH2), 
4.48 (d, J = 11.0 Hz, 1H, PhCH2), 4.40 (d, J = 10.7 Hz, 1H, PhCH2), 4.28 (d, J = 11.0 Hz, 
1H, PhCH2), 3.98 (d, J = 5.8 Hz, 2H, H-4, H-5), 3.83 (dd, J = 11.4, 2.5 Hz, 1H, H-6), 
3.76 (dt, J = 6.1, 3.2 Hz, 1H, H-3), 3.65 (d, J = 11.3 Hz, 1H, H-6), 3.50 (s, 3H, OCH3), 
0.80 (s, 9H, t-Bu). 13C NMR (125 MHz, CDCl3) δ 165.88, 162.50 (C=O), 159.44 (i-Ph 
PMB-OMe), 138.56, 136.05, 135.73, 134.68, 134.43 (i-Ph), 133.75, 133.33, 133.09, 
131.54, 130.72, 130.16, 130.01, 129.97, 129.96, 129.77, 129.69, 129.14, 129.02, 128.53, 
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128.49, 128.08, 127.85, 127.76, 127.70, 127.55 (Ph/Ar), 113.95 (Ar-PMB), 86.61 (C-1), 
78.55 (C-3), 75.61 (PhCH2), 74.43 (C-4 or C-5), 73.80 (ArCH2-PMB), 71.56 (C-2), 71.12 
(C-4 or C-5), 62.78 (C-6), 55.37 (OCH3), 26.92 (t-Bu). HRMS-ESI [M+Na+] calculated 
for C50H52O7SSiNa+: 847.3095. Found: 847.3082. 
 
Methyl 6-[4-O-benzyl-2-O-benzoyl-6-O-(tert-butyldiphenylsilyl)-1-deoxy-1-thio-D-
mannopyranosyloxy]hexanoate (136) and methyl 6-[4-O-benzyl-2-O-benzoyl-6-O-
(tert-butyldiphenylsilyl)-3-(para-methoxybenzyl)-1-deoxy-1-thio-D-
mannopyranosyloxy]hexanoate (135) 
   
Glycosyl donor mixture of 125 and 134 (130 mg, 5:1, 0.158 mmol) and linker 25 (25.3 g, 
0.173 mmol) were co-evaporated and the resulting residue was dissolved in CH2Cl2 (7 
mL). 4Å sieves (approx. 500 mg) were added and the mixture was allowed to stir at room 
temperature for 1 hour.  The reaction was cooled to -30 °C then NIS (35.4 mg, 0.158 
mmol) and TMSOTf (5.7 μL, 0.032 mmol) was added. The reaction was kept between -
30 °C and -15 °C over the course of 2 hours and monitored by TLC. The reaction was 
diluted with CH2Cl2 and washed with Na2S2O3, then dried over MgSO4 and the solvent 
was removed in vacuo. The residue was purified by column chromatography (PE/EtOAc 
gradient) to give a clean portion of title compound 136 (80 mg, 69%) as a clear colourless 
oil and a small portion of title compound 135 (5 mg, 4%) was isolated as a clear colourless 
oil. 
Data collected for 136: 1H NMR (500 MHz, CDCl3) δ 8.12 – 8.09 (m, 2H, Ph-Bz), 7.77 – 
7.67 (m, 4H, Ph-TBDPS), 7.57 (td, J = 7.3, 1.4 Hz, 1H, Ph-Bz), 7.45 – 7.24 (m, 13H, Ph), 
5.40 (dd, J = 3.5, 1.7 Hz, 1H, H-2), 4.95 (d, J = 1.7 Hz, 1H, H-1), 4.88 (d, J = 11.0 Hz, 
1H, PhCH2), 4.75 (d, J = 11.0 Hz, 1H, PhCH2), 4.29 (dt, J = 8.5, 4.0 Hz, 1H, H-3), 4.10 
(t, J = 9.6 Hz, 1H, H-4), 4.05 (dd, J = 11.3, 3.7 Hz, 1H, H-6), 3.96 (dd, J = 11.3, 1.8 Hz, 
1H, H-6), 3.72 (ddd, J = 9.7, 3.7, 1.7 Hz, 1H, H-5), 3.70 – 3.62 (m, 4H, H-7, OCH3), 3.42 
(dt, J = 9.7, 6.4 Hz, 1H, H-7), 2.30 (t, J = 7.5 Hz, 2H, H-11), 2.22 (d, J = 5.0 Hz, 1H, 
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OH), 1.68 – 1.53 (m, 4H, H-link), 1.37 (pd, J = 7.2, 3.3 Hz, 2H, H-link), 1.11 (s, 9H, t-
Bu). 13C NMR (125 MHz, CDCl3) δ 174.17, 166.45 (C=O), 138.41, 136.05, 135.77 (i-
Ph), 133.77, 133.40, 133.24, 130.08, 129.86, 129.80, 129.74, 128.62, 128.61, 128.54, 
128.05, 127.96, 127.84, 127.70, 127.69 (Ph), 97.60 (C-1), 76.02 (C-4), 75.23 (PhCH2), 
73.31 (C-2), 72.32 (C-5), 70.93 (C-3), 67.60 (C-7), 63.01 (C-6), 51.61 (OCH3), 34.07 (C-
11), 29.21 (C-link), 26.97 (t-Bu), 25.88 (C-link), 24.84 (C-link). HRMS-ESI [M+Na+] 
calculated for C43H52O9SiNa+: 763.3273. Found: 763.3293. 
Data collected for 135: 1H NMR (500 MHz, CDCl3) δ 8.15 – 8.10 (m, 2H, Ph), 7.79 – 
7.70  (m, 4H, Ph), 7.55 (ddt, J = 8.8, 7.3, 1.3 Hz, 1H, Ph), 7.44 – 7.14 (m, 16H, Ph/Ar), 
6.82 – 6.76 (m, 2H, Ar-PMB), 5.63 (dd, J = 3.1, 1.8 Hz, 1H, H-2), 4.94 (d, J = 1.8 Hz, 
1H, H-1), 4.91 (d, J = 10.7 Hz, 1H, PhCH2), 4.74 (d, J = 10.9 Hz, 1H, PhCH2), 4.62 (d, J 
= 10.7 Hz, 1H, PhCH2), 4.52 (d, J = 10.9 Hz, 1H, PhCH2), 4.13 (t, J = 9.5 Hz, 1H, H-4), 
4.08 (dd, J = 9.5, 3.1 Hz, 1H, H-3), 4.04 (dd, J = 11.2, 3.9 Hz, 1H, H-6), 3.93 (dd, J = 
11.1, 1.7 Hz, 1H, H-6), 3.78 – 3.71 (m, 4H, H-5, OCH3), 3.69 – 3.63 (m, 4H, H-7, OCH3), 
3.43 (tt, J = 9.7, 6.5 Hz, 1H, H-7), 2.31 (t, J = 7.5 Hz, 2H, H-11), 1.71 – 1.54 (m, 4H, H-
link), 1.36 (dqd, J = 11.6, 7.4, 4.2 Hz, 2H, H-link), 1.10 (s, 9H, t-Bu). 13C NMR (125 
MHz, CDCl3) δ 174.18, 166.05 (C=O), 159.30 (i-Ph PMB-OMe), 138.69, 136.04, 135.80 
(i-Ph), 133.81, 133.38, 133.21, 130.45, 130.15, 130.14, 129.84, 129.76, 129.70, 128.49, 
128.45, 128.08, 127.83, 127.71, 127.69 (Ph/Ar), 113.84 (Ar-PMB), 97.95 (C-1), 78.46 
(C-3), 75.44 (PhCH2), 74.34 (C-4), 72.63 (C-5), 71.44 (PhCH2), 69.54 (C-2), 67.54 (C-
7), 63.10 (C-6), 55.35 (OCH3), 51.61 (OCH3), 34.10 (C-11), 29.23 (C-link), 26.95 (t-Bu), 
25.91 (C-link), 24.88 (C-link). HRMS-ESI [M+Na+] calculated for C51H60O10SiNa+: 
883.3848. Found: 883.3847. 
 
2,3,4,6-Tetra-O-benzoyl-D-mannopyranose (149) 141-142 
 
HBr/HOAc (33%, 10 mL) was added to a stirred solution to a solution of 44 (4.71 g, 6.722 
mmol) in CH2Cl2 (30 mL) at 0°C. The mixture was stirred at room temperature overnight, 
and ice water was added to quench the reaction. The mixture was washed with sat. 
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NaHCO3(aq) and brine, then the organic extract was dried over Mg2SO4 and evaporated 
under reduced pressure to afford a pale yellow foam. The crude product was dissolved in 
acetone (18 mL) and water (0.9 mL). The solution was treated with Ag2CO3 (2.78 g, 10.08 
mmol), and stirred at room temperature for 2 hours. The mixture was filtered over a bed 
of Celite® and the solvent was removed. The crude foam was purified by column 
chromatography (2:1 PE/EtOAc) to give the final product 149 (5:1 α/β, 6.18 g, 92%) as 
a white foam. 
1H NMR (400 MHz, CDCl3) δ 8.11 (dt, J = 8.7, 1.7 Hz, 2H, α-Ph), 8.07 (dd, J = 8.3, 1.5 
Hz, 0H, β-Ph), 8.06 – 8.00 (m, 2H, α-Ph), 7.99 – 7.94 (m, 2H, α-Ph), 7.94 – 7.90 (m, 0H, 
β-Ph), 7.88 – 7.83 (m, 2H, α-Ph), 7.83 – 7.79 (m, 0H, β-Ph), 7.58 (tt, J = 7.5, 1.3 Hz, 3H, 
α-Ph), 7.54 – 7.46 (m, 1H, β-Ph), 7.46 – 7.32 (m, 8H, α-Ph), 7.28 (d, J = 7.9 Hz, 2H, β-
Ph), 6.17 (t, J = 10.1 Hz, 1H, α H-4), 6.06 (d, J = 10.1 Hz, 0H, β H-4), 6.01 (dd, J = 10.2, 
3.3 Hz, 1H, α H-3), 5.90 (dd, J = 3.2, 1.1 Hz, 0H, β H-2), 5.74 (dd, J = 3.3, 1.9 Hz, 1H, α  
H-2), 5.66 (dd, J = 10.1, 3.1 Hz, 0H, β H-3), 5.53 (dd, J = 3.9, 1.9 Hz, 1H, α H-1), 5.34 – 
5.28 (m, 0H, β H-1), 4.76 (dd, J = 12.2, 2.6 Hz, 1H, α H-6), 4.67 (dt, J = 10.0, 3.2 Hz, 
1H, α H-5), 4.51 (dd, J = 12.2, 4.4 Hz, 0H, β H-6), 4.45 (dd, J = 12.2, 3.7 Hz, 1H, α H-
6), 4.19 (ddd, J = 10.0, 4.4, 2.8 Hz, 0H, β H-5), 3.94 (d, J = 9.5 Hz, 0H, β H-6). 13C NMR 
(100 MHz, CDCl3) δ 171.27, 166.34 (α C=O), 166.22, 166.08 (β C=O), 165.57, 165.48 
(α C=O), 165.36 β C=O), 133.71, 133.55 (β i-Ph), 133.45, 133.43 (α i-Ph), 133.37 (β i-
Ph), 133.18 (α i-Ph), 133.15 (β i-Ph), 133.09 (α i-Ph), 130.01, 129.83, 129.80, 129.77, 
129.75, 129.27, 129.07, 128.99, 128.65, 128.56, 128.45, 128.34, 128.30 (α/β Ph), 93.43 
(β C-1), 92.34 (α C-1), 77.22 (β C), 72.66 (β C), 72.02 (β C), 71.27 (β C), 70.83 (α C-2), 
69.76 (α C-3), 68.87 (α C-5), 66.85 (α C-4), 66.40 (β C), 62.82 (β C), 62.72 (α C-6). 








2,3,4,6 -Tetra-O-benzoyl-α-D-mannopyranosyl trichloroacetimidate (111) 128, 141-142 
 
149 (3.68 g, 6.17 mmol) was dissolved in anhyd. CH2Cl2 (30 mL) and cooled to 0°C. NaH 
(60% in oil, 15 mg, 0.62 mmol) was added to the mixture followed by trichloroacetonitrile 
(3.1 mL, 30.84 mmol). The reaction was allowed to stir at 0°C for 2 hours before the 
solvent was removed in vacuo and the resulting crude material was purified by column 
chromatography (3:1 PE:EtOAc) to give 111 (4.23 g, 93%) as a white foam. 
1H NMR (400 MHz, CDCl3) δ 8.86 (s, 1H, NH), 8.11 – 8.04 (m, 5H, Ph), 7.99 – 7.93 (m, 
3H, Ph), 7.88 – 7.80 (m, 2H, Ph), 7.64 – 7.55 (m, 3H, Ph), 7.52 (ddt, J = 7.7, 6.9, 1.3 Hz, 
1H, Ph), 7.48 – 7.34 (m, 10H, Ph), 7.31 – 7.26 (m, 7H, Ph), 6.57 (d, J = 1.9 Hz, 1H, H-
1), 6.23 (t, J = 10.1 Hz, 1H, H-4), 5.97 (dd, J = 10.1, 3.3 Hz, 1H, H-3), 5.94 (dd, J = 3.4, 
2.0 Hz, 1H, H-2), 4.73 (dd, J = 12.3, 2.5 Hz, 1H, H-6), 4.63 (ddd, J = 10.2, 4.2, 2.5 Hz, 
1H, H-5), 4.50 (dd, J = 12.3, 4.2 Hz, 1H, H-6). HRMS-ESI [M+Na+] calculated for 
C36H28O10Cl3NNa+: 762.0671. Found: 762.0682. 
 
Methyl 6-[2,3,4,6-O-benzoyl-α-D-mannopyranosyloxy]hexanoate (117) 128-129 
 
A solution of trichloroacetimidate 111 (2.0 g, 3.14 mmol) and linker 25 (487 mg, 3.33 
mmol) in CH2Cl2 (25 mL) was stirred for 30 min at room temperature over 4Å molecular 
sieves (approx. 1 g). The solution was cooled to 0°C in an ice bath and TMSOTf (100 μl, 
0.551 mmol) was added. After 40 min the reaction was quenched by addition of Et3N (0.5 
mL), diluted into CH2Cl2, washed with 1 M NaOH(aq) followed by brine and then dried 
over MgSO4. The solvent was evaporated in vacuo and the resulting crude material was 
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purified by column chromatography (PE/EtOAc gradient) to give 117 (1.72 g, 76%) as a 
colourless oil. 
 1H NMR (400 MHz, CDCl3) δ 8.14 – 8.02 (m, 4H, Ph), 7.97 (dd, J = 8.1, 1.4 Hz, 2H, 
Ph), 7.84 (dd, J = 8.1, 1.4 Hz, 2H, Ph), 7.64 – 7.55 (m, 2H, Ph), 7.50 (td, J = 7.7, 1.2 Hz, 
1H, Ph), 7.45 – 7.31 (m, 7H, Ph), 7.26 (t, J = 7.7 Hz, 1H, Ph), 6.12 (t, J = 10.1 Hz, 1H, 
H-4), 5.92 (dd, J = 10.1, 3.3 Hz, 1H, H-3), 5.70 (dd, J = 3.4, 1.8 Hz, 1H, H-2), 5.09 (d, J 
= 1.8 Hz, 1H, H-1), 4.71 (dd, J = 12.1, 2.5 Hz, 1H, H-6), 4.50 (dd, J = 12.1, 4.4 Hz, 1H, 
H-6), 4.43 (ddd, J = 10.1, 4.4, 2.5 Hz, 1H, H-5), 3.85 (dt, J = 9.6, 6.6 Hz, 1H, H-7), 3.68 
(d, J = 0.8 Hz, 3H, OCH3), 3.58 (dt, J = 9.6, 6.5 Hz, 1H, H-7), 2.37 (t, J = 7.4 Hz, 2H, H-
11), 1.81 – 1.55 (m, 4H, H-link), 1.53 – 1.36 (m, 2H, H-link). 13C NMR (100 MHz, 
CDCl3) δ 174.14, 166.26, 165.61, 165.59, 165.54 (C=O), 133.56, 133.54, 133.28, 133.18 
(i-Ph), 129.92, 129.90, 129.80, 129.40, 129.15, 129.05, 128.67, 128.54, 128.52, 128.39 
(Ph), 97.75 (C-1), 70.65 (C-2), 70.24 (C-3), 68.92 (C-5), 68.51 (C-7), 67.03 (C-4), 62.99 
(C-6), 51.63 (OCH3), 34.01 (C-11), 29.15 (C-link), 25.76 (C-link), 24.73 (C-link). 
HRMS-ESI [M+Na+] calculated for C41H40O12Na+: 747.2412. Found: 747.2399. 
 
Methyl 6-[O-α-D-mannopyranosyloxy]hexanoate (118) 129 
 
NaOMe (0.5 M, 1 mL) was added to a stirred solution of 117 (900 mg, 1.242 mmol) in 
CH2Cl2/MeOH (1:2, 15 mL). The reaction was allowed to stir at room temperature for 3 
hours. The solvent was removed and the crude material was purified by column 
chromatography (CHCl3/MeOH, to 4:1) to give 118 (1.103 g, 89%) as a pale yellow oil.  
1H NMR (400 MHz, CD3OD) δ 4.73 (d, J = 1.7 Hz, 1H, H-1), 3.82 (dd, J = 11.7, 2.4 Hz, 
1H, H-6), 3.77 (dd, J = 3.4, 1.7 Hz, 1H, H-2), 3.76 – 3.71 (m, 1H, H-7), 3.71 – 3.66 (m, 
2H, H-6, H-3), 3.65 (d, J = 0.7 Hz, 3H, OCH3), 3.60 (t, J = 9.5 Hz, 1H, H-4), 3.51 (ddd, 
J = 9.6, 5.8, 2.3 Hz, 1H, H-5), 3.42 (dt, J = 9.6, 6.2 Hz, 1H, H-7), 2.34 (t, J = 7.4 Hz, 2H, 
H-11), 1.71 – 1.53 (m, 4H, H-link), 1.60 – 1.48 (m, 2H, H-link). 13C NMR (100 MHz, 
CD3OD) δ 101.57 (C-1), 74.63 (C-5), 72.65 (C-3), 72.27 (C-2), 68.64 (C-4), 68.30 (C-7), 
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62.95 (C-6), 51.99 (OCH3), 34.71 (C-11), 30.24 (C-link), 26.88 (C-link), 25.80 (C-link). 
HRMS-ESI [M+Na+] calculated for C13H24O8Na+: 331.1363. Found: 331.1360. 
 
Methyl 6-[2,4-di-O-benzoyl-α-D-mannopyranosyloxy]hexanoate (145) and methyl 6-
[2,6-di-O-benzoyl-α-D-mannopyranosyloxy]hexanoate (151) 
 
p-TSA (9 mg, 10% solution in MeCN, 0.05 mmol) and TFA (6 μL, 0.07 mmol) were 
added to a stirred suspension of 118 (318 mg, 1.03 mmol) and triethyl orthobenzoate (600 
μL, 2.68 mmol) in MeCN (10 mL). After 15 minutes, the solution was evaporated and the 
residue dissolved in MeCN (10 mL). TFA (700 μL, 90%(aq), 0.08 mmol) was added and 
the mixture stirred for 10 minutes. The solvent was removed in vacuo and the crude 
material was purified by column chromatography. Title compound 145 was eluded first 
from the column (220 mg, 42%) while the related isomer 151 eluded second (222 mg, 
42%), both as white foams. 
Data for 145: 1H NMR (500 MHz, CDCl3) δ 8.13 – 8.04 (m, 4H, Ph), 7.61 (tdd, J = 7.4, 
2.3, 1.2 Hz, 2H, Ph), 7.53 – 7.41 (m, 4H, Ph), 5.49 (t, J = 9.9 Hz, 1H, H-4), 5.40 (dt, J = 
3.2, 1.2 Hz, 1H, H-2), 5.07 – 5.02 (m, 1H, H-1), 4.43 (dd, J = 9.9, 3.5 Hz, 1H, H-3), 3.95 
(ddd, J = 10.1, 4.4, 2.4 Hz, 1H, H-5), 3.81 (dd, J = 12.4, 2.3 Hz, 1H, H-6), 3.79 – 3.72 
(m, 2H, H-6, H-7), 3.68 (d, J = 1.0 Hz, 3H, OCH3), 3.53 – 3.47 (m, 1H, H-7), 2.41 – 2.28 
(m, 2H, H-11), 1.76 – 1.59 (m, 4H, H-link), 1.44 (p, J = 7.6 Hz, 2H, H-link). 13C NMR 
(125 MHz, CDCl3) δ 174.22, 167.47, 166.23 (C=O), 133.84, 133.73 (i-Ph), 130.10, 
130.06, 129.46, 129.29, 128.77, 128.70 (Ph), 97.68 (C-1), 73.21 (C-2), 70.73 (C-5), 70.63 
(C-4), 68.93 (C-3), 68.31 (C-7), 61.72 (C-6), 51.69 (OCH3), 34.07 (C-11), 29.21 (C-link), 
25.84 (C-link), 24.80 (C-link). HRMS-ESI [M+Na+] calculated for C27H32O10Na+: 
539.1888. Found: 539.1863. 
Data for 151: 1H NMR (500 MHz, CDCl3) δ 8.12 – 8.07 (m, 2H, Ph), 7.95 – 7.89 (m, 2H, 
Ph), 7.63 – 7.58 (m, 1H, Ph), 7.50 (tt, J = 7.4, 1.3 Hz, 1H, Ph), 7.47 – 7.40 (m, 2H, Ph), 
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7.28 – 7.19 (m, 2H, Ph), 5.37 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 4.94 (d, J = 1.7 Hz, 1H, H-
1), 4.88 (dd, J = 12.1, 3.3 Hz, 1H, H-6), 4.53 (dd, J = 12.1, 1.8 Hz, 1H, H-6), 4.21 – 4.16 
(m, 1H, H-3), 3.97 – 3.88 (m, 2H, H-4, H-5), 3.74 (dt, J = 9.6, 6.6 Hz, 1H, H-7), 3.67 (s, 
3H, OCH3), 3.47 (dt, J = 9.6, 6.2 Hz, 1H, H-7), 2.33 (t, J = 7.4 Hz, 2H, H-11), 1.70 – 1.58 
(m, 4H, H-link), 1.44 – 1.35 (m, 2H, H-link). 13C NMR (125 MHz, CDCl3) δ 174.32, 
167.39, 166.21 (C=O), 133.47, 133.43 (i-Ph), 130.12, 130.01, 129.98, 129.89, 129.62, 
128.78, 128.65, 128.52 (Ph), 97.88 (C-1), 72.48 (C-2), 71.06 (C-5), 70.23 (C-3), 68.14 
(C-4), 68.02 (C-7), 63.72 (C-6), 51.73 (OCH3), 34.06 (C-11), 29.17 (C-link), 25.88 (C-
link), 24.75 (C-link). HRMS-ESI [M+Na+] calculated for C27H32O10Na+: 539.1888. 
Found: 539.1864. 
 
Phenyl 2,4-di-O-benzoyl-1-deoxy-1-thio-α-D-mannopyranoside (146) 172 and Phenyl 
2,6-di-O-benzoyl-1-deoxy-1-thio-α-D-mannopyranoside (152) 
 
 p-TSA (7 mg as a 10% w/v solution MeCN, 0.041 mmol) and TFA (4 uL, 0.048 mmol) 
were added to a stirred suspension of 127 (186 mg, 0.680 mmol) and triethyl 
orthobenzoate (400 uL, 1.78 mmol) in MeCN (4 mL). After 15 minutes, the solution was 
evaporated and the residue dissolved in MeCN (4 mL). TFA(aq) (500 uL, 90%) was added 
and the mixture stirred for 10 minutes. The solvent was removed in vacuo and the crude 
material was purified by column chromatography. Title compound 146 eluded first from 
the column (137 mg, 42%) as a while the related isomer 152 eluded second (134 mg, 
41%) both as clear, colourless oils. 
Data for 146: 1H NMR (500 MHz, CDCl3) δ 8.11 – 8.04 (m, 4H, Ph), 7.66 – 7.27 (m, 
11H, Ph), 5.72 (d, J = 1.6 Hz, 1H, H-1), 5.69 (dd, J = 3.4, 1.6 Hz, 1H, H-2), 5.58 (t, J = 
9.9 Hz, 1H, H-4), 4.47 (ddd, J = 10.0, 4.2, 2.4 Hz, 1H, H-5), 4.42 (dd, J = 9.8, 3.4 Hz, 
1H, H-3), 3.81 (dd, J = 12.7, 2.4 Hz, 1H, H-6), 3.76 (dd, J = 12.7, 4.2 Hz, 1H, H-6), 3.16 
(d, J = 4.3 Hz, 2H, OH). 13C NMR (125 MHz, CDCl3) δ 167.42, 166.04 (C=O), 133.90, 
133.73, 132.99, 132.21 (i-Ph), 130.07, 130.01, 129.35, 129.24, 129.02, 128.69, 128.68, 
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128.19, 86.10 (C-1), 74.43 (C-2), 71.74 (C-5), 70.56 (C-4), 69.45 (C-3), 61.48 (C-6). 
HRMS-ESI [M+Na+] calculated for C26H24O7SNa+: 503.1135. Found: 503.1128. 
Data for 152: 1H NMR (500 MHz, CDCl3) δ 8.09 – 7.90 (m, 4H, Ph), 7.62 – 7.36 (m, 6H, 
Ph), 7.34 – 7.16 (m, 5H, Ph), 5.69 – 5.66 (m, 1H, H-2), 5.64 (d, J = 1.4 Hz, 1H, H-1), 
4.82 (dd, J = 12.1, 4.9 Hz, 1H, H-6), 4.59 (ddd, J = 12.0, 6.0, 2.6 Hz, 1H, H-6), 4.50 (ddt, 
J = 10.0, 5.1, 2.9 Hz, 1H, H-5), 4.18 (dd, J = 9.4, 3.3 Hz, 1H, H-3), 4.04 (t, J = 9.5 Hz, 
1H, H-4), 3.50 (s, 2H, OH). 13C NMR (125 MHz, CDCl3) δ 167.25, 166.12 (C=O), 
133.49, 133.37, 132.01 (i-Ph), 129.96, 129.89, 129.75, 129.47, 129.22, 129.20, 128.55, 
128.51, 127.91 (Ph), 86.29 (C-1), 73.96 (C-2), 71.81 (C-5), 70.84 (C-3), 68.44 (C-4), 
63.91 (C-6). HRMS-ESI [M+Na+] calculated for C26H24O7SNa+: 503.1135. Found: 
503.1109. 
 
2-Azidoethyl 2,4-di-O-benzoyl-α-D-mannopyranoside (142) 140, 143 and 2-azidoethyl 
2,6-di-O-benzoyl-α-D-mannopyranoside (154) 140, 143 
 
p-TSA (22 mg, as a 10% w/v solution MeCN, 0.124 mmol) and TFA (13 ul, 0.175 mmol) 
were added to a stirred suspension of 94 (620 mg, 2.49 mmol) and triethyl orthobenzoate 
(1.5 mL, 6.47 mmol) in MeCN (10 mL). After 15 minutes, the solution was evaporated 
and the residue dissolved in MeCN (10 mL). TFA(aq) (1.5 mL, 90%) was added and the 
mixture stirred for 10 minutes. The solvent was removed in vacuo and the crude material 
was purified by column chromatography. The title compound 142 was eluded first from 
the column (572 mg, 50%) while the related title compound 154 eluded second (512.6 
mg, 45%), both as a white foam. 
Data for 142: 1H NMR (400 MHz, CDCl3) δ 8.18 – 8.01 (m, 4H, Ph), 7.62 (td, J = 7.2, 
1.4 Hz, 2H, Ph), 7.53 – 7.41 (m, 4H, Ph), 5.53 (t, J = 9.9 Hz, 1H, H-4), 5.45 (dd, J = 3.5, 
1.7 Hz, 1H, H-2), 5.12 (d, J = 1.7 Hz, 1H, H-1), 4.48 (dd, J = 9.9, 3.5 Hz, 1H, H-3), 4.05 
– 3.92 (m, 2H, H-5, H-7), 3.84 (dd, J = 12.7, 2.3 Hz, 1H, H-6), 3.80 – 3.69 (m, 2H, H-6, 
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H-7), 3.55 (ddd, J = 13.2, 7.4, 3.2 Hz, 1H, H-8), 3.42 (ddd, J = 13.3, 5.8, 3.2 Hz, 1H, H-
8), 2.16 (s, 2H, OH). 13C NMR (100 MHz, CDCl3) δ 167.50, 166.18 (C=O), 133.95, 
133.85 (i-Ph), 130.13, 130.08, 129.28, 129.11, 128.81, 128.75 (Ph), 97.81 (C-1), 72.79 
(C-2), 71.01 (C-5), 70.27 (C-4), 68.55 (C-3), 67.33 (C-7), 61.53 (C-6), 50.63 (C-8). 
HRMS-ESI [M+Na+] calculated for C22H23N3O3Na+: 480.1377. Found: 480.1384. 
Data for 154: 1H NMR (400 MHz, CDCl3) δ 8.17 – 8.07 (m, 2H, Ph), 7.93 – 7.86 (m, 2H, 
Ph), 7.62 (dddt, J = 8.7, 7.3, 2.4, 1.5 Hz, 1H, Ph), 7.56 – 7.41 (m, 3H, Ph), 7.23 (dt, J = 
7.4, 0.9 Hz, 2H, Ph), 5.41 (dt, J = 3.3, 1.6 Hz, 1H, H-2), 5.01 (t, J = 1.9 Hz, 1H, H-1), 
4.92 (ddd, J = 12.2, 7.2, 3.8 Hz, 1H, H-6), 4.53 (dt, J = 12.3, 1.6 Hz, 1H, H-6), 4.22 (dd, 
J = 8.7, 3.1 Hz, 1H, H-3), 4.02 – 3.87 (m, 3H, H-4, H-5, H-7), 3.72 – 3.66 (m, 1H, H-7), 
3.45 (qdd, J = 12.9, 6.2, 3.2 Hz, 2H, H-8), 2.68 (d, J = 51.5 Hz, 2H, OH). 13C NMR (100 
MHz, CDCl3) δ 167.43, 166.12 (C=O), 133.53, 133.52 (i-Ph), 129.99, 129.87, 129.71, 
129.44, 128.68, 128.54 (Ph), 98.06 (C-1), 72.09 (C-2), 71.39 (C-4 or C-5), 69.85 (C-3), 
67.84 (C-4 or C-5), 67.10 (C-7), 63.52 (C-6), 50.61 (C-8). HRMS-ESI [M+Na+] 





Trichloroacetimidate donor 24 (590 mg, 0.926 mmol) and mannosyl acceptor 145 (215 
mg, 0.416 mmol) were coevaporated with anhyd. toluene (10 mL, x3) and allowed to dry 
under high vacuum for 1 hour. Freshly distilled toluene (20 mL) and 4Å molecular sieves 
(approx. 1 g) were added and the mixture was stirred for 30 minutes at room temperature 
under an inert atmosphere. The reaction mixture was then cooled to -40°C and TMSOTf 
(23 μL, 0.125 mmol) was added. The reaction was kept between -40°C and -30°C for 4 
hours and monitored by TLC (4:1 toluene:Et2O). Et3N (0.25 mL) was added dropwise 
222 
and the reaction mixture was diluted with CH2Cl2 and filtered to remove molecular sieves. 
The filtrate was then washed with 1 M NaOH(aq) followed by brine and dried over MgSO4. 
The solvent was removed and the resulting crude oil was purified by column 
chromatography (100% toluene to 4:1 toluene:Et2O) to give an inseparable mixture of di- 
and trimannosides. The mixture was resubjected to the conditions above and purified 
again as described to give solely title compound 147 (434 mg, 71%) as a clear, colourless 
oil.  
1H NMR (500 MHz, CDCl3) δ 8.17 – 8.04 (m, 4H, Ph), 7.59 – 7.36 (m, 6H, Ph), 7.35 – 
7.11 (m, 23H, Ph), 7.12 – 6.92 (m, 4H, Ph), 5.73 (t, J = 10.0 Hz, 1H, H-4), 5.47 (dd, J = 
3.4, 1.8 Hz, 1H, H-2B), 5.33 (dd, J = 3.4, 1.8 Hz, 1H, H-2A), 5.04 (d, J = 2.0 Hz, 1H, H-
1B), 4.99 (d, J = 2.0 Hz, 2H, H-1A, H-2), 4.86 (d, J = 1.7 Hz, 1H, H-1), 4.82 (d, J = 10.8 
Hz, 1H, PhCH2), 4.71 – 4.34 (m, 10H, PhCH2, ring protons), 4.33 (dd, J = 11.1, 3.9 Hz, 
2H), 4.17 (d, J = 11.1 Hz, 1H), 4.07 (dd, J = 10.4, 4.9 Hz, 2H, ring protons), 3.95 (dd, J 
= 9.3, 3.3 Hz, 1H, H-3), 3.92 – 3.60 (m, 12H, ring protons, OCH3), 3.59 – 3.39 (m, 4H, 
ring protons, H-7), 2.33 (t, J = 7.5 Hz, 2H, H-11), 2.10 (s, 3H, CH3), 1.91 (s, 3H, CH3), 
1.74 – 1.54 (m, 4H, H-link), 1.47 – 1.36 (m, 2H, H-link). 13C NMR (125 MHz, CDCl3) δ 
174.12 (C=Olinker), 170.33, 169.93 (C=OAc), 165.89, 165.51 (C=OBz), 138.72, 138.68, 
138.37, 138.30, 138.12, 137.89 (i-Ph), 133.55, 133.52 (i-PhBz), 130.10, 129.98, 129.59, 
129.36, 128.75, 128.69, 128.44, 128.39, 128.35, 128.33, 128.29, 128.18, 128.12, 128.09, 
127.93, 127.90, 127.83, 127.76, 127.74, 127.63, 127.60, 127.53, 127.49, 127.35 (Ph), 
99.93 (C-1B), 97.91 (C-1A), 97.33 (C-1), 78.56, 77.70, 76.38, 75.11, 74.48, 74.22, 73.71, 
73.39, 72.42, 72.13 (C-2), 71.84, 71.59, 71.56, 69.26, 68.99 (C-4), 68.73 (C-2), 68.61 (C-
2), 68.34, 68.23, 66.88, 51.60 (OCH3), 34.04 (C-11), 29.14 (C-link), 25.83 (C-link), 24.80 
(C-link), 21.17 (CH3), 20.90 (CH3). HRMS-ESI [M+Na+] calculated for C85H92O22Na+: 









Trimannoside 147 (107 mg, 0.073 mmol) was dissolved in CH2Cl2 (1 mL) and diluted in 
MeOH (6 mL), then K2CO3 (5 mg, 0.073 mmol) was added. The reaction was allowed to 
stir overnight at room temperature. Upon completion, the reaction mixture was 
neutralised with IRA-120 (H+) exchange resin, filtered, and the solvent was removed. The 
crude material was purified by column chromatography (PE/EtOAc gradient) to give title 
compound 159 (54 mg, 63%) as a clear, colourless oil.  
1H NMR (500 MHz, CDCl3) δ 7.41 – 7.22 (m, 25H, Ph), 7.22 – 7.12 (m, 5H, Ph), 5.10 
(d, J = 1.8 Hz, 1H, H-1B), 4.96 (d, J = 1.8 Hz, 1H, H-1A), 4.81 (dd, J = 10.9, 5.5 Hz, 2H, 
PhCH2), 4.76 – 4.41 (m, 11H, H-1, PhCH2), 4.25 – 4.17 (m, 2H, H-2A or B, ring proton), 
4.12 (dt, J = 3.1, 1.4 Hz, 1H, H-2A or B), 4.09 – 4.04 (m, 2H, ring protons), 3.98 – 3.56 (m, 
17H, ring protons, OCH3, H-7), 3.55 – 3.49 (m, 1H, H-6), 3.33 (dt, J = 9.7, 6.3 Hz, 1H, 
H-7), 2.31 (t, J = 7.5 Hz, 2H, H-11), 1.64 (p, J = 7.6 Hz, 2H, H-link), 1.61 – 1.50 (m, 2H, 
H-link), 1.36 (p, J = 7.7 Hz, 2H, H-link). 13C NMR (125 MHz, CDCl3) δ 174.22 (C=O), 
138.19, 138.10, 138.07, 137.85, 137.47 (i-Ph), 128.68, 128.66, 128.61, 128.59, 128.55, 
128.53, 128.50, 128.28, 128.27, 128.17, 128.16, 128.09, 128.01, 127.99, 127.96, 127.90, 
127.87, 127.75 (Ph), 100.70 (C-1B), 100.64 (C-1), 99.50 (C-1A), 82.10, 80.31, 80.30, 
75.39, 74.95, 74.76, 74.52, 73.74, 73.51, 72.46, 72.02, 71.60, 71.26, 71.09, 69.68, 69.23, 
68.96, 68.34, 67.42, 66.34, 65.57, 51.63, 34.05 (C-11), 29.17 (C-link), 25.90 (C-link), 






mannopyranosyloxy]hexanoic acid (158) 
 
Branched trimannoside 147 (366 mg, 0.250 mmol) was dissolved in CH2Cl2 (5 mL) and 
MeOH (20 mL). NaOMe (0.5 M, 700 μL) was added to the solution and the reaction was 
allowed to stir at room temperature for 3 hours and followed by TLC. The solvent was 
removed and the crude material was dry loaded onto a silica column and purified 
(EtOAc/EtOH) to give the title compound 158 (202 mg, 70%) as a pale pink oil. 
[α]20D = +107.56 (c 1.54, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.21 (m, 26H, 
Ph), 7.20 – 7.10 (m, 4H, Ph), 5.11 (d, J = 1.8 Hz, 1H, H-1B), 4.95 (d, J = 1.6 Hz, 1H, H-
1A), 4.80 (dd, J = 10.9, 2.2 Hz, 2H, PhCH2), 4.73 – 4.62 (m, 4H, PhCH2), 4.57 (d, J = 1.7 
Hz, 1H, H-1), 4.56 – 4.44 (m, 6H, PhCH2), 4.22 – 4.17 (m, 1H), 4.16 (dd, J = 3.3, 1.7 Hz, 
1H, H-2B), 4.10 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 4.08 (dd, J = 3.3, 1.9 Hz, 1H, H-2A), 4.05 
– 3.99 (m, 1H), 3.96 – 3.55 (m, 13H, ring protons, H-7), 3.52 (dd, J = 9.8, 8.0 Hz, 1H, H-
6), 3.33 (dt, J = 9.6, 5.8 Hz, 1H, H-7), 2.35 – 2.29 (m, 2H, H-11), 1.70 – 1.45 (4H, H-
link), 1.39 (p, J = 7.4 Hz, 2H, linker). 13C NMR (125 MHz, CDCl3) δ 176.45 (C=O), 
138.19, 138.13, 138.07, 137.88, 137.50 (i-Ph), 128.74, 128.69, 128.66, 128.61, 128.57, 
128.54, 128.53, 128.44, 128.42, 128.33, 128.28, 128.24, 128.19, 128.13, 128.11, 128.07, 
128.05, 128.03, 128.01, 127.99, 127.95, 127.92, 127.79 (Ph), 100.77 (C-1B), 100.52 (C-
1), 99.43 (C-1A), 81.93, 80.33, 80.30, 75.44, 75.02, 74.75, 74.56, 73.73, 73.55, 72.46, 
72.11, 71.64, 71.30, 71.00, 69.62, 69.32, 68.95, 68.42, 67.27, 66.64, 66.10, 33.56 (C-11), 
28.90 (C-link), 25.76 (C-link), 24.51 (C-link). HRMS-ESI [M+Na+] calculated for 







Carboxylic acid 158 (150 mg, 0.129 mmol) was dissolved in anhyd. CH2Cl2 (5 mL) under 
an inert atmosphere. N-hydroxysuccinimide (22 mg, 0.193 mmol) and EDCI.HCl (37 mg, 
0.193 mmol) were added and the reaction was allowed to stir overnight at room 
temperature. The reaction mixture was diluted with CH2Cl2 and the organic layer was 
washed with sat. NH4Cl(aq) and dried over MgSO4. The solvent was removed and the 
crude oil was purified by column chromatography (3:1 EtOAc:PE to 100% EtOAc) to 
afford title compound 157 (141 mg, 87%) as a colourless oil. 
1H NMR (500 MHz, CDCl3) δ 7.40 – 7.22 (m, 25H, Ph), 7.22 – 7.10 (m, 5H, Ph), 5.11 
(d, J = 1.8 Hz, 1H, H-1B), 4.95 (d, J = 1.6 Hz, 1H, H-1A), 4.81 (dd, J = 10.9, 3.8 Hz, 2H, 
PhCH2), 4.74 – 4.62 (m, 5H, PhCH2), 4.58 (d, J = 1.7 Hz, 1H, H-1), 4.57 – 4.46 (m, 5H, 
PhCH2), 4.22 – 4.16 (m, 2H, H-2A), 4.11 – 4.09 (m, 1H, H-2), 4.07 (dt, J = 3.3, 1.6 Hz, 
1H, H-2B), 4.04 (dd, J = 10.8, 4.1 Hz, 1H, H-3), 3.96 – 3.50 (m, 14H, H-7, ring protons), 
3.34 (dt, J = 9.7, 5.7 Hz, 1H, H-7), 2.75 (d, J = 9.9 Hz, 4H, O-Succ), 2.60 (t, J = 7.2 Hz, 
2H, H-11), 1.76 (p, J = 7.4 Hz, 2H, H-link), 1.66 – 1.39 (m, 4H, H-link). 13C NMR (125 
MHz, CDCl3) δ 169.54, 168.66 (C=O), 138.25, 138.16, 138.14, 137.90, 137.53 (i-Ph), 
128.67, 128.62, 128.55, 128.51, 128.29, 128.19, 128.16, 128.10, 128.02, 128.00, 127.98, 
127.89, 127.76 (Ph), 100.65 (C-1B), 100.60 (C-1), 99.46 (C-1A), 81.78, 80.31, 75.39, 
74.98, 74.77, 74.53, 73.72, 73.52, 72.45, 71.99, 71.57, 71.22, 71.15, 69.64, 69.30, 68.99, 
68.97, 68.34, 67.29, 66.36, 65.78, 31.05 (C-11), 29.01 (O-Succ), 25.67 (C-link), 25.64 







Succinimidyl ester 157 (60 mg, 0.048 mmol) was dissolved in a 1:1 mixture of THF/EtOH 
(6 mL) and allowed to stir at room temperature. 10% Pd/C catalyst (60 mg) was added to 
the stirred solution and the atmosphere was removed and replaced with H2(g) three times. 
The reaction was left to stir overnight at room temperature. The mixture was then filtered 
through a bed of Celite®, which was subsequently washed with EtOH. The solvent was 
removed to give the crude product as a pale yellow oil, which was then dissolved in water 
and freeze dried to yield title compound 5 (34.18 mg, 100%) as an off white powder. 
1H NMR (500 MHz, DMSO-d6) δ inter alia 4.93 (d, J = 4.6 Hz, 1H, OH), 4.83 (d, J = 2.0 
Hz, 1H, H-1), 4.68 (d, J = 4.7 Hz, 2H, OH), 4.63 (d, J = 1.7 Hz, 1H, H-1B), 4.60 (s, 1H, 
OH), 4.56 (d, J = 1.6 Hz, 1H, H-1A), 4.43 (d, J = 37.4 Hz, 2H, OH), 3.82 (s, 1H), 3.75 (d, 
J = 3.7 Hz, 1H), 3.70 – 3.36 (m, 18H, ring protons), 2.81 (s, 4H, Succ), 2.66 (q, J = 8.5, 
7.9 Hz, 2H, H-11), 2.08 (d, J = 7.5 Hz, 1H), 1.70 – 1.61 (m, 2H, H-link), 1.59 – 1.49 (m, 
2H, H-link), 1.45 – 1.37 (m, 2H, H-link). 13C NMR (125 MHz, DMSO-d6) δ 170.27 
(C=Osucc), 168.93 (C=Olink), 102.43 (C-1), 99.99 (C-1A), 99.59 (C-1B), 79.38, 73.68, 
73.66, 73.58, 72.01, 70.97, 70.79, 70.40, 70.37, 70.30, 69.55, 69.52, 67.09, 66.92, 66.12, 
65.73, 65.68, 65.53, 65.50, 62.79, 61.28, 61.18, 61.04, 30.15 (C-11), 28.46 (C-link), 25.43 
(C-Succ), 24.77 (C-link), 24.02 (C-link). HRMS-ESI [M+Na+] calculated for 




2-Acetamino-2-deoxy-3,4,6-tri-O-acetyl-α-D-glucopyranosyl chloride (174) 150, 173 
and 2-acetamino-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose (178) 173 
 
Acetyl chloride (60 mL) was added to N-acetyl-D-glucosamine (10.0 g, 45.2 mmol) at 
room temperature and the solution was stirred for 2 days. The reaction was followed by 
TLC (CH2Cl2, 10% MeOH). The reaction was diluted with CH2Cl2 and poured into ice 
water. The organic layer was separated and the aqueous phase was extracted with CH2Cl2. 
The combined organic extracts were neutralised with the addition of sat. NaHCO3(aq). The 
organic layer was dried over MgSO4, filtered, and concentrated in vacuo. The crude 
material was columned (PE/EtOAc gradient) to give the product 174 (7.92 g, 48%) and 
178 (7.39 g, 42%), both as white solids. 
Data for 174: 1H NMR (400 MHz, CDCl3) δ 6.18 (d, J = 3.7 Hz, 1H, H-1), 5.86 (d, J = 
8.7 Hz, 1H, NH), 5.31 (dd, J = 10.7, 9.4 Hz, 1H, H-4), 5.24 – 5.15 (m, 1H, H-3), 4.53 
(ddd, J = 10.6, 8.7, 3.7 Hz, 1H, H-2), 4.31 – 4.22 (m, 2H, H-5, H-6), 4.17 – 4.08 (m, 1H, 
H-6), 2.10 (s, 3H, CH3), 2.05 (d, J = 1.0 Hz, 6H, CH3, CH3), 1.98 (s, 3H, CH3). 13C NMR 
(100 MHz, CDCl3) δ 171.62, 170.72, 170.28, 169.28 (C=O), 93.76 (C-1), 71.02 (C-5), 
70.27 (C-4), 67.09 (C-3), 61.28 (C-6), 53.62 (C-2), 23.20 (CH3), 20.81 (CH3), 20.67 
(CH3). HRMS-ESI [M+Na+] calculated for C14H20O8ClNNa+: 388.0770. Found: 
388.0793. 
Data for 178: 1H NMR (400 MHz, CDCl3) δ 6.17 (d, J = 3.6 Hz, 1H, NH), 5.53 (d, J = 
9.0 Hz, 1H, H-1), 5.28 – 5.17 (m, 2H, H-3, H-4), 4.48 (ddd, J = 10.5, 9.0, 3.5 Hz, 1H, H-
2), 4.25 (dd, J = 12.5, 4.1 Hz, 1H, H-6), 4.06 (dd, J = 12.5, 2.4 Hz, 1H, H-6), 3.99 (ddd, 
J = 9.6, 4.2, 2.6 Hz, 1H, H-5), 2.20 (s, 3H, CH3), 2.09 (s, 3H, CH3), 2.06 (s, 3H, CH3), 
2.04 (s, 3H, CH3), 1.94 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 171.91, 170.84, 
170.03, 169.22, 168.74 (C=O), 90.85 (C-1), 70.84 (C-3 or C-4), 69.87 (C-5), 67.59 (C-3 





glucopyranosyloxy]hexanoate (179) 174 
 
A mixture of AgOTf (1.56 g, 6.06 mmol), acceptor 25 (1.57 g, 11.80 mmol) and 4Å 
molecular sieves (1.0 g) in anhyd. CH2Cl2 (15 mL) was stirred under nitrogen for 1 hour 
at room temperature. The mixture was cooled to 0°C and glycosyl donor 174 (2.04 g, 5.60 
mmol) in anhyd. CH2Cl2 (5 mL) was slowly added via cannula. The reaction was allowed 
to warm to room temperature and then stirred for 17 hours. The mixture was filtered 
through Celite® and the filter cake washed with CH2Cl2. The organic filtrate was washed 
with water, sat. NaHCO3(aq) and brine, then dried over MgSO4. The solvent was removed 
and the residue columned (CH2Cl2/EtOAc 1:1 to EtOAc) to give the title compound 179 
(2.59 g, 97%) as a white foam. 
 1H NMR (500 MHz, CDCl3) δ 5.91 (dd, J = 8.8, 3.2 Hz, 1H, NH), 5.28 (t, J = 9.3 Hz, 
1H, H-3), 5.02 (t, J = 9.2, 1H, H-4), 4.66 (d, J = 8.3, 1H, H-1), 4.25 – 4.18 (m, 1H, H-6), 
4.12 – 4.05 (m, 1H, H-6), 3.88 – 3.73 (m, 2H, H-7, H-2), 3.68 (ddd, J = 10.1, 4.8, 2.4 Hz, 
1H, H-5), 3.63 (s, 3H, OCH3), 3.45 (dt, 1H, H-7), 2.27 (t, J = 7.5 Hz, 2H, H-11), 2.04 (s, 
3H, CH3), 1.99 (s, 3H, CH3), 1.98 (s, 3H, CH3), 1.90 (s, 3H, NHCOCH3), 1.65 – 1.47 (m, 
4H, H-link), 1.37 – 1.29 (m, 2H, H-link). 13C NMR (125 MHz, CDCl3) δ 174.30 
(C=Olinker), 170.89, 170.82, 170.37 (C=Oamide), 169.51 (C=O), 100.76 (C-1), 72.49 (C-3), 
71.79 (C-5), 69.51 (C-7), 68.86 (C-4), 62.28 (C-6), 54.85 (C-2), 51.58 (OCH3), 33.92 (C-
11), 29.01 (C-link), 25.43 (C-link), 24.50 (C-link), 23.30 (CH3), 20.82 (CH3), 20.77 







Methyl 6-[2-acetamino-2-deoxy-β-D-glucopyranosyloxy]hexanoate (183) 174 
 
Glycoside 179 (1.37 g, 3.05 mmol) was dissolved in a 2:1 mixture of MeOH/CH2Cl2 (3:1, 
50 mL) and left to stir slowly over IRA-400 (OH-) exchange resin (approx. 1 g) overnight. 
The reaction was monitored by TLC and after 12 hours no trace of the starting material 
remained and the reaction was filtered. The solvent was removed giving the crude product 
183 (1.06 g, 93%) as a white solid which was used without further purification.  
1H NMR (500 MHz, D2O) δ 4.51 (d, J = 8.5 Hz, 1H, H-1), 3.96 – 3.86 (m, 2H, H-6, H-
7), 3.78 – 3.72 (m, 1H, H-6), 3.71 (s, 3H, OCH3), 3.69 – 3.65 (m, 1H, H-2), 3.64 – 3.50 
(m, 2H, H-7, H-4), 3.47 – 3.43 (m, 2H, H-5, H-3), 2.41 (t, J = 7.5 Hz, 2H, H-11), 2.04 (s, 
3H, NHCOCH3), 1.67 – 1.52 (m, 4H, H-link), 1.41 – 1.27 (m, 2H, H-link). 13C NMR (125 
MHz, D2O) δ 180.16, 177.02 (C=O), 103.71 (C-1), 78.46 (C-3 or C-5), 76.45 (C-4), 72.80 
(C-7), 72.53 (C-3 or C-5), 63.36 (C-6), 58.20 (C-2), 54.68 (OCH3), 36.26 (C-11), 30.81 
(C-link), 27.27 (C-link), 26.51 (C-link), 24.73 (CH3). HRMS-ESI [M+Na+] calculated for 





Glycoside 183 (986 mg, 2.25 mmol) was dissolved in anhyd. DMF (12 mL) under an 
inert atmosphere. Benzaldehyde dimethyl acetal (0.85 mL, 5.65 mmol) and p-TSA (10 
mg) were added and the mixture was heated at 70°C for 3 hours. The solvent was removed 
by rotary evaporation and the residue was dissolved in CHCl3. The solution was washed 
with water then brine, and dried over MgSO4. The residue was suspended in Et2O and 
sonicated. The resulting solid was filtered to give the title compound 182 (976 mg, 80%) 
as a white solid. 
230 
1H NMR (500 MHz, CDCl3) δ 7.52 – 7.45 (m, 2H, Ph), 7.40 – 7.31 (m, 3H, Ph), 6.03 (d, 
J = 6.2 Hz, 1H, NH), 5.54 (s, 1H, PhCH), 4.70 (d, J = 8.3 Hz, 1H, H-1), 4.32 (dd, J = 
10.5, 4.9 Hz, 1H, H-6), 4.14 (t, J = 9.4 Hz, 1H, H-4), 3.88 (dt, J = 9.7, 6.1 Hz, 1H, H-7), 
3.77 (t, J = 10.2 Hz, 1H, H-6), 3.67 (s, 3H, OCH3), 3.58 – 3.51 (m, 1H, H-3), 3.47 (dtt, J 
= 13.1, 8.4, 4.9 Hz, 3H, H-2, H-5, H-7), 2.32 (t, J = 7.3 Hz, 2H, C-11), 2.03 (s, 3H, 
NHCOCH3), 1.70 – 1.53 (m, 4H, H-link), 1.50 – 1.28 (m, 2H, H-link). 13C NMR (125 
MHz, CDCl3) δ 174.40, 172.11 (C=O), 137.24 (i-Ph), 129.32, 128.41, 126.49 (Ph), 
102.03 (PhCH), 100.78 (C-1), 81.86 (C-3), 71.47 (C-4), 69.68 (C-7) 68.77 (C-6), 66.39 
(C-2 or C-5), 59.16 (C-2 or C-5), 51.72 (OCH3), 33.92 (C-11), 29.11 (C-link), 25.55 (C-
link), 24.49 (C-link), 23.66 (NHCOCH3). HRMS-ESI [M+Na+] calculated for 





TBAB and CuBr2 were dried under vacuum for 12 hours (CuBr2 was heated to 70°C 
during this time). Glycosyl donor 163 (360 mg, 0.823 mmol), glycosyl acceptor 182 (560 
mg, 1.17 mmol), TBAB (650 mg, 2.02 mmol), and 4Å molecular sieves (1 g) were 
combined and dried under high vacuum for 1 hour. The mixture was solvated with 
DMF/CH2Cl2 (1:4, 20 mL) and stirred for another hour under an inert atmosphere. CuBr2 
(445 mg, 1.99 mmol) was added and the reaction was left to stir at room temperature 
overnight. The molecular sieves were removed from the reaction mixture and the reaction 
was diluted with CH2Cl2. It was then washed with a mixture of sat. NH4Cl(aq) and 35% 
ammonia (9:1) until no blue colour remained in the organic layer. The aqueous layer was 
backwashed after each wash. The combined organic layers were then washed with brine, 
dried over MgSO4, and the solvent was removed. The crude product was purified by 
column chromatography (3:1 PE/EtOAc to 1:1 PE/EtOAc) giving the title compound 186 
(568 mg, 81%) as a white solid. 
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1H NMR (500 MHz, CDCl3) δ 7.49 – 7.20 (m, 20H, Ph), 5.73 (d, J = 7.3 Hz, 1H, NH), 
5.49 (s, 1H, PhCH), 5.06 (d, J = 3.7 Hz, 1H, α H-1A), 4.93 – 4.87 (m, 3H, PhCH2, β H-
1), 4.74 (s, 2H, PhCH2), 4.67 (d, J = 11.6 Hz, 1H, PhCH2), 4.58 (d, J = 11.4 Hz, 1H, 
PhCH2), 4.36 – 4.28 (m, 2H, H-3, H-6), 4.10 – 4.02 (m, 2H, H-2A, H-5A), 3.94 (dd, J = 
10.2, 2.7 Hz, 1H, H-3A), 3.82 (dt, J = 9.9, 6.2 Hz, 1H, H-7), 3.75 (t, J = 10.2 Hz, 1H, H-
6), 3.66 (s, 3H, OCH3), 3.61 – 3.54 (m, 2H, H-4A, H-4), 3.50 (dt, J = 9.5, 4.7 Hz, 1H, H-
5), 3.45 (dt, J = 9.9, 6.8 Hz, 1H, H-7), 3.34 (dt, J = 9.9, 7.6 Hz, 1H, H-2),  1.65 (s, 4H, 
NHCOCH3, H-link), 1.64 – 1.49 (m, 3H, H-link), 1.42 – 1.28 (m, 2H, H-link), 0.81 (d, J 
= 6.4 Hz, 3H, CH3 A). 13C NMR (125 MHz, CDCl3) δ 174.31 (C=Oester), 170.61 
(C=Oamide), 138.85, 138.79, 138.72, 137.48 (i-Ph), 129.15, 128.74, 128.54, 128.38, 
128.33, 128.31, 128.04, 127.68, 127.45, 126.37 (Ph), 101.74 (PhCH), 100.87 (β C-1), 
98.36 (α C-1A), 80.98 (C-4), 79.94 (C-3A), 77.79 (C-4A), 77.03 (C-2A or C-5A), 75.05 
(PhCH2), 74.83 (C-3), 74.18 (PhCH2), 72.70 (PhCH2), 69.91 (C-7), 69.01 (C-6), 66.97 
(C-2A or C-5A), 66.33 (C-5), 58.66 (C-2), 51.65 (OCH3), 34.06 (C-11), 29.14 (C-link), 
25.56 (C-link), 24.67 (C-link), 23.34 (NHCOCH3), 16.41 (CH3 A). HRMS-ESI [M+Na+] 





Diglycoside 186 (121.3 mg, 0.142 mmol) was dissolved in THF (15 mL) and 2 M 
NaOH(aq)  (2.5 mL) was added to the solution. The reaction was heated to 65°C and stirred 
overnight. The mixture was then allowed to cool to room temperature and was neutralised 
with H+ exchange resin, filtered, and the solvent was removed to give a white foam 
confirmed to be carboxylic acid 189 by HRMS. HRMS-ESI [M+Na+] calculated for 
C48H57O12NNa+: 862.3773. Found: 862.3787.   
The crude product 189 was in anhyd. CH2Cl2 under an inert atmosphere and EDCI.HCl 
(41 mg, 0.213 mmol) and NHS (25 mg, 0.213 mmol) were added to the stirred solution. 
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The reaction mixture was diluted with CH2Cl2 and the organic layer was washed with sat. 
NH4Cl(aq) and dried over MgSO4. The solvent was removed and the crude oil was purified 
by column chromatography (1:1 PE/EtOAc to 1:3 PE/EtOAc) to afford title compound 
187 (106 mg, 80% over two steps) as a white foam. 
k1H NMR (400 MHz, CDCl3) δ 7.49 – 7.22 (m, 20H, Ph), 5.94 (d, J = 7.4 Hz, 1H, NH), 
5.49 (s, 1H, PhCH), 5.11 (d, J = 3.6 Hz, 1H, α H-1A), 4.93 – 4.83 (m, 3H, β H-1, PhCH2), 
4.78 – 4.66 (m, 3H, PhCH2), 4.57 (d, J = 11.5 Hz, 1H, PhCH2), 4.40 – 4.30 (m, 2H, H-3, 
H-6), 4.13 – 4.00 (m, 2H, H-2A, H-5A), 3.94 (dd, J = 10.1, 2.6 Hz, 1H, H-3A), 3.87 (dt, J 
= 10.6, 5.9 Hz, 1H, H-7), 3.76 (t, J = 10.2 Hz, 1H, H-6), 3.62 – 3.54 (m, 2H, H-4A, H-4), 
3.54 – 3.36 (m, 3H, H-2, H-5, H-7), 2.75 (s, 4H, Succ), 2.60 (t, J = 7.2 Hz, 2H, H-11), 
1.76 (q, J = 7.4 Hz, 2H, H-link), 1.70 (s, 3H, NHCOCH3), 1.65 – 1.34 (m, 4H, H-link), 
0.81 (d, J = 6.4 Hz, 3H, CH3 A). 13C NMR (100 MHz, CDCl3) δ 170.68 (C=Oamide), 169.41 
(C=OSucc), 168.72 (C=Oester), 138.80, 138.78, 138.69, 137.47 (i-Ph), 129.12, 128.68, 
128.50, 128.37, 128.30, 128.27, 128.03, 127.99, 127.65, 127.63, 127.43, 126.32 (Ph), 
101.69 (PhCH), 100.84 (β C-1), 98.08 (α C-1A), 80.88 (C-4), 79.85 (C-3A), 77.69 (C-4A), 
76.78 (C-2A or C-5A), 75.00 (PhCH2), 74.37 (C-3), 73.83 (PhCH2), 72.73 (PhCH2), 69.65 
(C-7), 68.98 (C-6), 66.84 (C-2A or C-5A), 66.29 (C-5), 58.56 (C-2), 30.99 (C-11), 28.95 
(C-link), 25.65 (C Succ), 25.24 (C-link), 24.36 (C-link), 23.37 (NHCOCH3), 16.40 (CH3 





Trimannoside 187 (79.6 mg, 0.085 mmol) was dissolved in EtOH/THF (1:1, 6 mL) and 
10% Pd/C catalyst (80 mg) was added. The reaction was purged of atmosphere and H2 
gas was bubbled through (x3). The solution was allowed to stir under H2 gas overnight at 
room temperature. The reaction mixture was diluted with EtOH and filtered through 
Celite® and the solvent was removed. The resulting residue was re-dissolved in water and 
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subjected to freeze drying conditions to give the title compound 188 (49.1 mg, 100%) as 
an off-white powder.  
1H NMR (500 MHz, DMSO-d6) δ inter alia 7.85 (d, J = 8.5 Hz, 1H, NH), 4.79 (d, J = 5.6 
Hz, 1H, OH), 4.75 (s, 1H, H-1A), 4.62 – 4.52 (m, 2H, OH), 4.35 (d, J = 7.7 Hz, 3H, H-1, 
OH), 4.14 (q, J = 6.4 Hz, 1H), 3.76 – 3.63 (m, 3H), 3.49 (dt, J = 25.4, 9.6 Hz, 8H), 3.43 
– 3.34 (m, 1H), 3.25 – 3.11 (m, 4H, ring protons), 2.81 (s, 4H, Succ), 2.65 (t, J = 7.3 Hz, 
2H, H-11), 1.79 (s, 3H, NHCOCH3), 1.62 (p, J = 7.4 Hz, 2H, H-link), 1.55 – 1.41 (m, 2H, 
H-link), 1.41 – 1.21 (m, 2H, H-link), 1.03 (d, J = 6.5 Hz, 3H, CH3 A). 13C NMR (125 
MHz, DMSO-d6) δ inter alia 170.24, 169.87, 168.92 (C=O), 100.36 (C-1A), 99.86 (C-1), 
81.79, 76.65, 71.64, 69.78, 68.99, 68.17, 67.97, 66.48, 60.81, 54.58 (ring carbons and C-
7), 30.14 (C-11), 28.41 (C-link), 25.42 (Succ), 24.51 (C-link), 23.92 (C-link), 22.92 
(NHCOCH3), 16.37 (CH3 A). HRMS-ESI [M+Na+] calculated for C24H38O24N2Na+: 
601.2215. Found: 601.2231. 
 
Allyl 6-[2-acetamino-2-deoxy-3-O-allyl-4,6-O-benzylidene-β-D-
glucopyranosyloxy]hexanoate (199) and 6-[2-acetamino-2-deoxy-3-O-allyl-4,6-O-
benzylidene-β-D-glucopyranosyloxy]hexanoate (198) 
 
Method A: 60% sodium hydride in oil (105 mg, 2.74 mmol) was added to a solution of 
182 (799 mg, 1.83 mmol) in anhyd. DMF (10 mL) at 0°C. The mixture was stirred for 15 
min then allyl bromide (0.253 mL, 3.65 mmol) was slowly added. The mixture was 
allowed to warm to room temperature and the stirred under nitrogen for 20 hours. 
Methanol (2 mL) was carefully added and the reaction diluted with CH2Cl2. The reaction 
solution was washed with water. The water layer was back extracted with CH2Cl2. The 
combined organic extracts were washed with brine and dried over MgSO4. Removal of 
the solvent and purification of the resulting residue by column chromatography (EtOAc: 
CH2Cl2) gave two fractions. The first fraction was the title compound 199 (80 mg, 7%) 
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as a white solid. The lower Rf fraction was title compound 198 (569 mg, 65%) as a white 
solid. 
Data for 199: 1H NMR (500 MHz, CDCl3) δ 7.51 – 7.43 (m, 2H, Ph), 7.41 – 7.29 (m, 3H, 
Ph), 5.99 (d, J = 7.4 Hz, 1H, NH), 5.95 – 5.80 (m, 2H, H-2all), 5.52 (s, 1H, PhCH), 5.30 
(dq, J = 17.2, 1.7 Hz, 1H, H-3all), 5.26 – 5.19 (m, 2H, H-3all), 5.13 (dd, J = 10.5, 1.8 Hz, 
1H, H-3all), 5.04 (d, J = 8.3 Hz, 1H, H-1), 4.57 (dd, J = 5.8, 1.7 Hz, 2H, H-1all), 4.38 – 
4.30 (m, 2H, H-1all, H-6), 4.26 (t, J = 9.4 Hz, 1H, H-3), 4.13 (ddd, J = 12.7, 6.2, 1.6 Hz, 
1H, H-1all), 3.85 (dt, J = 9.7, 6.2 Hz, 1H, H-7), 3.75 (t, J = 10.2 Hz, 1H, H-6), 3.57 (t, J = 
9.1 Hz, 1H, H-4), 3.54 – 3.45 (m, 2H, H-5, H-7), 3.15 (dt, J = 10.1, 7.9 Hz, 1H, H-2), 
2.33 (t, J = 7.5 Hz, 2H, H-11) 1.98 (s, 3H, NHCOCH3), 1.70 – 1.53 (m, 4H, H-link), 1.38 
(p, J = 7.5 Hz, 2H, H-link). 13C NMR (125 MHz, CDCl3) δ 173.49, 170.65 (C=O), 137.51 
(i-Ph), 135.05, 135.03 (Call), 132.35, 132.33, 129.03, 128.32, 126.13 (Ph), 118.32, 117.23 
(Call), 101.25 (PhCH), 100.28 (C-1), 82.75 (C-4), 76.37 (C-3), 73.65 (Call), 69.91 (C-7), 
68.90 (C-6), 66.00 (C-5), 65.12 (Call), 58.52 (C-2), 34.16 (C-11), 29.12 (C-link), 25.59 
(C-link), 24.61 (C-link), 23.69 (NHCOCH3). HRMS-ESI [M+Na+] calculated for 
C27H37O8NNa+: 526.2411. Found: 526.2414. 
Data for 198: 1H NMR (500 MHz, CDCl3) δ 7.49 – 7.45 (m, 2H, Ph), 7.40 – 7.31 (m, 3H, 
Ph), 5.92 – 5.83 (m, 2H, H-2all, NH), 5.53 (s, 1H, PhCH), 5.24 (dq, J = 17.2, 1.6 Hz, 1H, 
H-3all, trans), 5.16 – 5.11 (m, 1H, H-3all, cis), 5.06 (d, J = 8.3 Hz, 1H, H-1), 4.37 – 4.31 (m, 
2H, H-1all, H-6), 4.28 (dd, J = 10.0, 8.8 Hz, 1H, H-3), 4.13 (ddt, J = 12.8, 6.2, 1.3 Hz, 1H, 
H-1all), 3.86 (dt, J = 9.7, 6.2 Hz, 1H, H-7), 3.76 (t, J = 10.2 Hz, 1H, H-6), 3.67 (s, 3H, 
OCH3), 3.57 (t, J = 9.1 Hz, 1H, H-4), 3.55 – 3.46 (m, 2H, H-5, H-7), 3.13 (dt, J = 10.2, 
7.9 Hz, 1H, H-2), 2.31 (t, J = 7.5 Hz, 2H, H-11), 1.99 (s, 3H, NHCOCH3), 1.73 – 1.50 
(m, 4H, H-link), 1.38 (p, J = 7.6 Hz, 2H, H-link). 13C NMR (125 MHz, CDCl3) δ 174.33 
(C=Oester), 170.66 (C=Oamide), 137.54 (i-Ph), 135.06 (Call), 129.07, 128.36, 126.16 (Ph), 
117.28 (Call), 101.30 (PhCH), 100.26 (C-1), 82.81 (C-4), 76.35 (C-3), 73.72 (Call), 69.98 
(C-7), 68.95 (C-6), 66.04 (C-5), 58.68 (C-2), 51.66 (OCH3), 34.03 (C-11), 29.15 (C-link), 
25.64 (C-link), 24.64 (C-link), 23.74 (NHCOCH3). HRMS-ESI [M+Na+] calculated for 
C25H35O8NNa+: 500.2255. Found: 500.2264. 
Method B: 60% sodium hydride in oil (117 mg, 2.91 mmol) was added to a solution of 
182 (850 mg, 1.94 mmol) in anhyd. DMF (10 mL) at 0°C. The mixture was stirred for 15 
min then allyl chloride (0.277 mL, 3.89 mmol) was slowly added. The mixture was 
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allowed to warm to room temperature and the stirred under nitrogen for 20 hours. 
Methanol (10 mL) was added and 60% sodium hydride (120 mg) was carefully added and 
the mixture stirred for 1 hour. Work up and purification by column chromatography as 
above gave the title compound 189 (824 mg, 89%) as a white solid. No trace of compound 





Benzylidene 198 (50 mg, 0.105 mmol) was dissolved in CH2Cl2 (5 mL) and stirred over 
4Å molecular sieves (500 mg) for 30 min. The reaction was cooled to -78°C then Et3SiH 
(84 μL, 0.524 mmol) and TMSOTf (94 μL, 0.5 mmol) were added slowly. The reaction 
was allowed to stir for 2 hours. Solid NaHCO3 was added and the reaction was filtered. 
The filtrate was washed with sat. NaHCO3(aq) and brine and the solvent was removed. The 
crude residue was purified using column chromatography (EtOAc) giving the title 
compound 195 (34 mg, 68%) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.27 (m, 5H, Ph), 5.99 – 5.80 (m, 2H, NH, H-3all), 
5.26 (dq, J = 17.2, 1.6 Hz, 1H, H-2all), 5.16 (dt, J = 10.3, 1.5 Hz, 1H, H-2all), 4.88 (d, J = 
8.2 Hz, 1H, H-1), 4.63 – 4.52 (m, 2H, PhCH2), 4.26 (ddt, J = 12.7, 5.8, 1.4 Hz, 1H, H-6), 
4.18 (ddt, J = 12.8, 6.0, 1.4 Hz, 1H, H-6), 3.95 (dd, J = 10.4, 8.2 Hz, 1H, H-3), 3.83 (dt, 
J = 9.8, 6.2 Hz, 1H, H-7), 3.74 (d, J = 4.6 Hz, 2H, H-1all), 3.65 (s, 3H, OCH3), 3.61 – 3.49 
(m, 2H, H-4, H-5), 3.45 (dt, J = 9.7, 6.7 Hz, 1H, H-7), 3.17 (dt, J = 10.3, 7.9 Hz, 1H, H-
2), 2.29 (t, J = 7.5 Hz, 2H, H-11), 1.97 (s, 3H, NHCOCH3), 1.68 – 1.46 (m, 4H, H-link), 
1.35 (p, J = 7.6 Hz, 2H, H-link). 13C NMR (125 MHz, CDCl3) δ 174.35 (C=Oester), 170.65 
(C=Oamide), 137.91 (i-Ph), 135.17 (Call), 128.59, 128.55, 127.89, 127.84 (Ph), 117.26 
(Call), 99.83 (C-1), 80.39 (C-3), 73.87 (C-4 or C-5), 73.78 (PhCH2), 73.39 (C-6), 73.17 
(C-4 or C-5), 70.73 (Call), 69.47 (C-7), 57.51 (C-2), 51.61 (OCH3), 34.02 (C-11), 29.13 
(C-link), 25.63 (C-link), 24.64 (C-link), 23.69 (NHCOCH3). HRMS-ESI [M+Na+] 
calculated for C25H37O8NNa+: 502.2411. Found: 502.2440. 
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2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide (210) 175-176 
 
D-galactose (10 g, 55.5 mmol) was dissolved in py (40 mL) and cooled to 0°C. Acetic 
anhydride (37 mL, 392 mmol) was added and the reaction was allowed to warm to room 
temperature and stirred overnight. The reaction was then cooled to 0°C and water was 
added. This mixture was diluted with EtOAc and the aqueous layer was extracted. The 
organic layer was washed with 1 M HCl(aq), water, 5% NaHCO3(aq), and water again, then 
dried over MgSO4 and the solvent was removed. The resulting clear colourless oil was 
then dissolved in anhyd. CH2Cl2 (60 mL) and HBr in acetic acid (33%, 65.5 mL, 334 
mmol) was added to the solution. The reaction was allowed to stir at room temperature 
overnight. The reaction mixture was diluted with CH2Cl2 and poured into ice water. The 
aqueous layer was extracted and the organic layer was washed with sat. NaHCO3(aq), 
brine, and dried over MgSO4. The solvent was removed and the title compound 210 
(22.65 g, 99% over two steps) as a clear yellow oil was used without further purification.   
1H NMR (400 MHz, CDCl3) δ 6.70 (d, J = 4.0 Hz, 1H, H-1), 5.52 (dd, J = 3.3, 1.3 Hz, 
1H, H-2), 5.41 (dd, J = 10.6, 3.3 Hz, 1H, H-4), 5.08 – 5.01 (m, 1H, H-3), 4.49 (tt, J = 6.4, 
1.1 Hz, 1H, H-5), 4.19 (dd, J = 11.4, 6.4 Hz, 1H, H-6), 4.11 (dd, J = 11.4, 6.8 Hz, 1H, H-
6), 2.15 (s, 3H, CH3), 2.12 (s, 3H, CH3), 2.06 (s, 3H, CH3), 2.01 (s, 3H, CH3). 13C NMR 
(100 MHz, CDCl3) δ 170.47, 170.21, 170.04, 169.91 (C=O), 88.24 (C-1), 71.18, 68.11, 
67.89, 67.09, 60.96 (ring carbons), 20.89, 20.78, 20.73, 20.70 (CH3). 
 
1,2-Di-O-acetyl-3,4,6-tri-O-benzyl-β-D-galactopyranose (214) 163, 177 
  
A solution of 210 (13.66 g, 33.2 mmol) in CHCl3:collidine (50 mL:7 mL) containing 
TBAB (1.07 g, 3.19 mmol) and methanol was stirred under reflux for approximately 24 
hours. The cooled reaction mixture was diluted with Et2O and the precipitate was 
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removed by filtration. The filtrate was washed with distilled water, saturated NaHCO3(aq), 
and brine. The organic layer was dried over MgSO4, filtered, and the solvent removed in 
vacuo to give an off-white solid which was dissolved in CH2Cl2 (10 mL) and MeOH (45 
mL) was added. The solution was stirred slowly over IRA-400 (1 g) overnight. The 
reaction was then filtered and the solvent removed. The resulting clear colourless oil was 
dissolved in anhyd. DMF (30 mL) and cooled to 0°C. NaH (60% in oil, 6.0 g, 151 mmol) 
was added to the solution followed by the dropwise addition of BnBr (16 mL, 136 mmol). 
The solution was left to warm to room temperature overnight. The reaction was then 
quenched with MeOH and the solvent removed. The residue was diluted with Et2O, 
washed with water then brine and dried over MgSO4. The solvent was removed and the 
residue was purified by column chromatography (PE/EtOAc) to give 213 (14.65 g, 87% 
over three steps) a pale yellow oil.  
Orthoester 213 (14.65, 33.22 mmol) was stirred for two days in glacial acetic acid at room 
temperature. The solvent was removed in vacuo to afford a clear, colourless oil, which 
was then dissolved in CH2Cl2 and washed with sat. NaHCO3(aq), water, and brine and dried 
over Mg2SO4. The solvent was removed and the crude was purified by column 
chromatography (PE/EtOAc gradient) to give product 214 (5.68, 32%) as a clear, 
colourless oil.  
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.24 (m, 15H, Ph), 5.58 (d, J = 8.2 Hz, 1H, H-1), 
5.47 (dd, J = 10.0, 8.2 Hz, 1H, H-2), 4.93 (d, J = 11.5 Hz, 1H, PhCH2), 4.67 (d, J = 12.2 
Hz, 1H, PhCH2), 4.60 (d, J = 11.5 Hz, 1H, PhCH2), 4.51 (d, J = 12.2 Hz, 1H, PhCH2), 
4.48 – 4.35 (m, 2H, PhCH2), 4.00 (dd, J = 2.9, 1.0 Hz, 1H, H-4), 3.71 (ddd, J = 7.2, 5.6, 
1.1 Hz, 1H, H-5), 3.67 – 3.52 (m, 3H, H-3, H-6), 2.06 (s, 3H, CH3), 2.00 (s, 3H, CH3). 
13C NMR (100 MHz, CDCl3) δ 169.67, 169.61 (C=O), 138.38, 137.84, 137.79, 128.61, 
128.39, 128.15, 128.04, 128.01, 127.80, 127.64 (Ph), 92.76 (C-1), 80.22 (C-3), 74.76 
(PhCH2), 74.49 (C-5), 73.71 (PhCH2), 72.33 (C-4), 72.23 (PhCH2), 70.47 (C-2), 68.00 
(C-6), 21.07 (CH3), 21.00 (CH3). HRMS-ESI [M+Na+] calculated for C31H34O8NNa+: 





2-Bromoethyl 2-O-acetyl-3,4,6-tri-O-benzyl-D-galactopyranoside (225) 
(4_213_p) 
2-bromoethanol (220 μL, 3.09 mmol) was added to a stirred solution of galactoside 214 
(710 mg, 1.328 mmol) and 4Å molecular sieves (approx. 1 g) in anhyd. CH2Cl2 (20 mL). 
The resulting mixture was allowed to stir at room temperature for 30 min. BF3OEt2 (990 
μL, 8.04 mmol) was added dropwise to the mixture and the reaction was allowed to stir 
for 3 days at room temperature. The reaction mixture was added to cold brine, the organic 
layer was extracted and again washed with brine, dried, and concentrated in vacuo. The 
crude oil was purified by column chromatography (PE/EtOAc gradient) to give title 
compound 225 (447 mg, 5:4 β/α, 56%) as a pale yellow oil. 
1H NMR (400 MHz, CDCl3) δ 7.40 – 7.21 (m, 30H, Ph), 5.40 (dd, J = 10.1, 7.9 Hz, 1H, 
β H-2), 5.31 (dd, J = 10.3, 3.8 Hz, 1H, α H-2), 5.18 (d, J = 3.8 Hz, 1H, α H-1), 4.95 (dd, 
J = 11.6, 2.9 Hz, 2H, PhCH2), 4.73 – 4.43 (m, 10H, PhCH2), 4.41 (d, J = 8.0 Hz, 1H, β 
H-1), 4.16 – 4.04 (m, 3H), 4.04 – 3.99 (m, 2H), 3.99 – 3.91 (m, 3H), 3.85 – 3.72 (m, 3H), 
3.65 – 3.54 (m, 6H), 3.54 – 3.47 (m, 3H), 3.46 – 3.41 (m, 3H), 2.10 (s, 3H, CH3), 2.07 (s, 
3H, CH3). 13C NMR (100 MHz, CDCl3) δ 170.62, 169.70 (C=O), 138.51, 138.46, 138.43, 
138.01, 137.99, 137.86, 128.57, 128.56, 128.52, 128.50, 128.49, 128.36, 128.35, 128.32, 
128.29, 128.02, 127.97, 127.88, 127.86, 127.85, 127.74, 127.72, 127.71, 127.68, 127.57, 
127.43 (Ph), 101.67 (β C-1), 96.73 (α C-1), 80.21, 74.85, 74.62, 74.56, 73.87, 73.68, 
73.59, 72.99, 72.58, 72.14, 71.32, 71.12, 69.87, 69.12, 68.93, 68.69, 68.26 (ring/linker C 
α/β), 30.60 (C-8), 30.41 (C-8), 21.18 (CH3), 21.15 (CH3). HRMS-ESI [M+Na+] 






2-Azidoethyl 3,4,6-tri-O-benzyl-α-D-galactopyranoside (227a) and 2-azidoethyl 3,4,6-
tri-O-benzyl-β-D-galactopyranoside (227b) 
  
Galactoside 225 (168.0 mg, 0.280 mmol) was dissolved in anhyd. DMF (9 mL) and NaN3 
(73 mg, 1.122 mmol) was added to the reaction. The mixture was heated to 60°C for 3 
hours and left to stir at room temperature overnight. The reaction was quenched with 
water and Et2O. The aqueous layer was extracted into CH2Cl2 and the combined organic 
layers were washed with water (x3). Dried over MgSO4 and solvent removed to give an 
oil (α/β mixture), the acetylated intermediate was confirmed by HRMS. HRMS-ESI 
[M+Na+] calculated for C31H35O7N3Na+: 584.2367. Found: 584.2354. 
The crude oil was dissolved in CH2Cl2 (1 mL) and MeOH was added (8 mL). The solution 
was stirred slowly over IRA-400 (OH-) exchange resin (500 mg) overnight. The reaction 
was then filtered and the solvent removed. The crude oil was purified by column 
chromatography (3:1 – 1:1 PE/EtOAc) which allowed for the α- (bottom spot) and β- (top 
spot) products to be separated. Title compound 227b was a clear colourless oil (107 mg, 
73%) as was anomer 227a (26 mg, 18%), giving an overall reaction yield of 91% over 
two steps. 
α-product 227a: 1H NMR (500 MHz, CDCl3) δ 7.40 – 7.26 (m, 15H, Ph), 4.98 (d, J = 3.9 
Hz, 1H, H-1), 4.90 (d, J = 11.4 Hz, 1H, PhCH2 ), 4.76 – 4.68 (m, 2H, PhCH2), 4.56 (d, J 
= 11.4 Hz, 1H, PhCH2), 4.51 (d, J = 11.8 Hz, 1H, PhCH2), 4.44 (d, J = 11.8 Hz, 1H, 
PhCH2), 4.20 (ddd, J = 10.1, 7.9, 3.9 Hz, 1H, H-2), 4.00 – 3.95 (m, 2H, H-4, H-5), 3.91 
(ddd, J = 10.6, 6.9, 3.5 Hz, 1H, H-6), 3.74 (dd, J = 10.1, 2.7 Hz, 1H, H-3), 3.67 (ddd, J = 
10.8, 6.3, 3.5 Hz, 1H, H-6), 3.60 – 3.55 (m, 2H, H-7), 3.48 (ddd, J = 13.3, 6.9, 3.5 Hz, 
1H, H-8), 3.40 (ddd, J = 13.2, 6.3, 3.5 Hz, 1H, H-8). 13C NMR (125 MHz, CDCl3) δ 
138.58, 138.31, 138.05, 128.64, 128.57, 128.56, 128.42, 128.34, 127.95, 127.92, 127.86, 
127.81 (Ph), 99.28 (C-1), 79.55 (C-3), 74.86 (PhCH2), 74.23 (C-4 or C-5), 73.66 (PhCH2), 
72.75 (PhCH2), 70.27 (C-4 or C-5), 69.11 (C-2), 69.09 (C-7), 67.35 (C-6), 50.84 (C-8). 
HRMS-ESI [M+Na+] calculated for C29H33O6N3Na+: 542.2262. Found: 542.2236. 
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β-product 227b: 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.24 (m, 15H, Ph), 4.91 (d, J = 
11.6 Hz, 1H, PhCH2), 4.79 – 4.68 (m, 2H, PhCH2), 4.62 (d, J = 11.6 Hz, 1H, PhCH2), 
4.53 – 4.39 (m, 2H, PhCH2), 4.31 (d, J = 7.6 Hz, 1H, H-1), 4.06 (ddd, J = 10.6, 5.0, 3.9 
Hz, 1H, H-6), 4.00 (dd, J = 9.8, 7.6 Hz, 1H, H-4), 3.93 (d, J = 2.9 Hz, 1H, H-2), 3.71 
(ddd, J = 10.6, 8.1, 3.8 Hz, 1H, H-6), 3.65 – 3.58 (m, 3H, H-7, H-5), 3.53 (ddd, J = 13.1, 
8.1, 3.9 Hz, 1H, H-8), 3.46 (dd, J = 9.8, 2.9 Hz, 1H, H-3), 3.33 (ddd, J = 13.2, 5.0, 3.8 
Hz, 1H, H-8). 13C NMR (100 MHz, CDCl3) δ 138.51, 138.18, 137.87, 128.59, 128.55, 
128.37, 128.31, 128.30, 127.99, 127.94, 127.92, 127.88, 127.74, 127.71 (Ph), 103.51 (C-
1), 81.80 (C-3), 74.64 (PhCH2), 73.92 (C-5), 73.65 (PhCH2), 73.03 (C-2), 72.66 (PhCH2), 
71.43 (C-4), 68.79 (C-6), 68.51 (C-7), 50.75 (C-8). HRMS-ESI [M+Na+] calculated for 





TBAB was dried under high vacuum for 5 hours. CuBr2 was heated to 70°C and dried 
under high vacuum for 5 hours. L-fucoside donor 163 (114 mg, 0.238 mmol), D-
galactoside acceptor 227b (95.0 mg, 0.183 mmol), TBAB (147.4 mg, 0.457 mmol), and 
4Å molecular sieves (250 mg) were combined and dried under high vacuum for 1 hour. 
The reaction vessel was placed under an inert N2 atmosphere solvated with CH2Cl2 (4 
mL) and DMF (1 mL). After stirring for 1 hour, CuBr2 (102 mg, 0.457 mmol) was added 
and the reaction was left to stir at room temperature overnight. The molecular sieves were 
removed from the reaction mixture and the reaction was diluted with CH2Cl2. It was then 
washed with sat. NH4Cl and 35% ammonia (9:1) until no blue colour remained in the 
organic layer. The aqueous layer was backwashed after each wash. The combined organic 















The crude oil was purified by column chromatography (PE/EtOAc gradient) giving the 
title compound 228 (92.5 mg, 54%) as a pale yellow oil. 
 1H NMR (500 MHz, CDCl3) δ 7.40 – 7.26 (m, 15H, Ph), 7.26 – 7.20 (m, 5H, Ph), 7.19 – 
7.01 (m, 5H), 5.70 (d, J = 3.1 Hz, 1H, H-1A), 4.96 (d, J = 11.5 Hz, 1H, PhCH2), 4.83 (dd, 
J = 11.6, 2.7 Hz, 2H, PhCH2), 4.79 – 4.72 (m, 2H, PhCH2), 4.63 (dd, J = 11.8, 3.8 Hz, 
2H, PhCH2), 4.58 (d, J = 12.0 Hz, 1H, PhCH2), 4.56 – 4.52 (m, 2H, PhCH2), 4.52 – 4.49 
(m, 1H, H-1), 4.48 – 4.40 (m, 3H, PhCH2, ring proton), 4.01 (dt, J = 10.7, 4.3 Hz, 1H), 
3.95 (d, J = 2.7 Hz, 1H), 3.75 (dd, J = 9.7, 2.7 Hz, 1H, H-3), 3.74 – 3.72 (m, 1H), 3.64 – 
3.53 (m, 4H), 3.47 (ddd, J = 13.2, 4.8, 3.8 Hz, 1H, H-8), 3.39 (ddd, J = 12.8, 8.4, 4.0 Hz, 
1H, H-8), 1.15 (d, J = 6.4 Hz, 3H, CH3 A). 13C NMR (125 MHz, CDCl3) δ 139.11, 138.96, 
138.43, 138.39, 138.07, 137.89 (i-Ph), 128.59, 128.55, 128.45, 128.43, 128.39, 128.38, 
128.29, 128.23, 128.22, 128.14, 128.12, 128.07, 128.05, 128.00, 127.92, 127.71, 127.52, 
127.47, 127.37, 126.47, 126.46 (Ph), 102.09 (C-1A), 97.40 (C-1), 84.38, 79.75, 78.18, 
75.73, 74.92, 74.51, 73.76, 73.61, 73.01, 72.87, 72.09, 72.07, 71.52, 68.93, 67.00, 66.47, 
50.96 (C-8), 29.82, 16.61 (CH3 A). HRMS-ESI [M+Na+] calculated for C56H61O10N3Na+: 
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